<SEC-DOCUMENT>0001047469-17-002384.txt : 20170406
<SEC-HEADER>0001047469-17-002384.hdr.sgml : 20170406
<ACCEPTANCE-DATETIME>20170406160908
ACCESSION NUMBER:		0001047469-17-002384
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170523
FILED AS OF DATE:		20170406
DATE AS OF CHANGE:		20170406
EFFECTIVENESS DATE:		20170406

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gemphire Therapeutics Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		17746062

	BUSINESS ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
		BUSINESS PHONE:		248-980-6538

	MAIL ADDRESS:	
		STREET 1:		17199 N. LAUREL PARK DRIVE
		STREET 2:		SUITE 401
		CITY:			LIVONIA
		STATE:			MI
		ZIP:			48152
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231618zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg46001_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Gemphire Therapeutics Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=773965,FOLIO='blank',FILE='DISK125:[17ZBE1.17ZBE46001]BA46001A.;3',USER='CHE108068',CD='31-MAR-2017;21:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g342833.jpg" ALT="GRAPHIC" WIDTH="180" HEIGHT="103">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;6, 2017 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dear
Stockholder: </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the 2017 Annual Meeting of Stockholders of Gemphire Therapeutics&nbsp;Inc. to be held at our headquarters, 17199 N. Laurel Park Drive, Livonia,
Michigan 48152 on Tuesday, May&nbsp;23, 2017 at 8:00&nbsp;a.m. local time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
enclosed Notice of 2017 Annual Meeting of Stockholders and the Proxy Statement contain details of the business to be conducted at the Annual Meeting and information you should
consider when you vote your shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, the agenda includes: (1)&nbsp;to elect two Class&nbsp;I directors, each to serve three-year terms until the 2020 annual meeting of stockholders and until the
election and qualification of his successor, or his earlier death, resignation, or removal, and (2)&nbsp;to ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered
public accounting firm for the fiscal year ending December&nbsp;31, 2017. The Board of Directors unanimously recommends that you vote FOR the election of each director nominee and FOR the
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP. </FONT><FONT SIZE=2><B>Your vote is important.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether
or not you attend the Annual Meeting, it is important that your shares be represented and voted at the meeting. Therefore, I urge you to promptly vote by submitting your proxy
via the Internet at the address listed on the proxy card or by signing, dating, and returning the enclosed proxy card in the enclosed envelope. If you decide to attend the Annual Meeting, you will be
able to vote in person, even if you have previously submitted your proxy. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Sincerely,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g241589.jpg" ALT="GRAPHIC" WIDTH="198" HEIGHT="76">
 </B></FONT><FONT SIZE=2><BR>
<BR>
Mina Sooch<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=329475,FOLIO='blank',FILE='DISK125:[17ZBE1.17ZBE46001]BC46001A.;13',USER='C902264',CD=';5-APR-2017;15:51' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="be46001_gemphire_therapeutics_inc._171__gem02599"> </A>
<A NAME="toc_be46001_1"> </A>
<BR></FONT><FONT SIZE=4><B>GEMPHIRE THERAPEUTICS&nbsp;INC.  <BR>    <BR>    </B></FONT><FONT SIZE=2><B>17199 N. Laurel Park Drive, Suite&nbsp;401<BR>  Livonia, Michigan 48152    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="be46001_notice_of_2017_annual_meeting___not02123"> </A>
<A NAME="toc_be46001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE OF&nbsp;2017 ANNUAL MEETING OF STOCKHOLDERS<BR>  To Be Held May&nbsp;23, 2017    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To
Our Stockholders: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOTICE
IS HEREBY GIVEN that the 2017 Annual Meeting of Stockholders of Gemphire Therapeutics&nbsp;Inc. will be held at our headquarters, 17199 N. Laurel Park Drive, Livonia,
Michigan&nbsp;48152 on Tuesday, May&nbsp;23, 2017 at 8:00&nbsp;a.m. local time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are holding the meeting for the following purposes, which are more fully described in the accompanying proxy statement: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
elect two Class&nbsp;I directors, each to serve three-year terms until the 2020 annual meeting of stockholders and until the election and qualification of his
successor, or his earlier death, resignation, or removal.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>To
ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2017. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, stockholders may be asked to consider and vote upon such other business as may properly come before the meeting or any adjournment or postponement thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
stockholders of record at the close of business on March&nbsp;27, 2017 are entitled to notice of, and to vote at, the meeting and any adjournments thereof. For ten days prior to
the meeting, a complete list of the stockholders entitled to vote at the meeting will be available for examination by any stockholder for any purpose relating to the meeting during ordinary business
hours at our headquarters. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote as a Gemphire Therapeutics&nbsp;Inc. stockholder is very important. Each share of stock that you own represents one vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
questions regarding your stock ownership, you may contact our Chief Financial Officer at (734)&nbsp;245-1700 or jmathiesen@gemphire.com or, if you are a registered holder, our
transfer agent, Computershare,&nbsp;Inc. by email through their website at https://www-us.computershare.com/Investor/Contact or by phone at (800)&nbsp;736-3001. Whether or not you expect to attend
the meeting, we encourage you to read the proxy statement and vote through the Internet, or request, sign and return your proxy card as soon as possible, so that your shares may be represented at the
meeting. For specific instructions on how to vote your shares, please refer to the section entitled "General Information About the Meeting" in the proxy statement. If you attend the Annual Meeting,
you may vote in person even if you have previously voted via the Internet or by returning your proxy card. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sincerely,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g241589.jpg" ALT="GRAPHIC" WIDTH="198" HEIGHT="76">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Mina Sooch</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><I> President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Livonia,
Michigan<BR>
April&nbsp;6, 2017 </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=11793,FOLIO='blank',FILE='DISK125:[17ZBE1.17ZBE46001]BE46001A.;9',USER='C902264',CD=';5-APR-2017;15:53' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_bg46001_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<A NAME="bg46001_table_of_contents"> </A>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG46001A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg46001_gemphire_therapeutics_inc._pro__gem03838"> </A>
<BR></FONT><FONT SIZE=2><B>  GEMPHIRE THERAPEUTICS&nbsp;INC.<BR>  <BR>    PROXY STATEMENT FOR 2017 ANNUAL MEETING OF STOCKHOLDERS<BR>  <BR>    TABLE OF CONTENTS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG46001_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#AA1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>GENERAL INFORMATION ABOUT THE MEETING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#AA1"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da46001_general_proxy_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>GENERAL PROXY INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da46001_general_proxy_information"><FONT SIZE=2><BR>
1</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da46001_corporate_governance_s__da402278"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CORPORATE GOVERNANCE STANDARDS AND DIRECTOR INDEPENDENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da46001_corporate_governance_s__da402278"><FONT SIZE=2><BR>
4</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc46001_proposal_no._1_election_of_class_i_directors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 1 ELECTION OF CLASS I DIRECTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc46001_proposal_no._1_election_of_class_i_directors"><FONT SIZE=2><BR>
9</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc46001_proposal_no._2_ratification_of__pro02974"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROPOSAL NO. 2 RATIFICATION OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc46001_proposal_no._2_ratification_of__pro02974"><FONT SIZE=2><BR>
14</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de46001_report_of_the_audit_committee"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>REPORT OF THE AUDIT COMMITTEE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de46001_report_of_the_audit_committee"><FONT SIZE=2><BR>
16</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de46001_security_ownership_of_certain___sec02460"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de46001_security_ownership_of_certain___sec02460"><FONT SIZE=2><BR>
17</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de46001_executive_officers"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE OFFICERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de46001_executive_officers"><FONT SIZE=2><BR>
20</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg46001_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXECUTIVE COMPENSATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg46001_executive_compensation"><FONT SIZE=2><BR>
21</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk46001_certain_relationships_and_related-party_transactions"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CERTAIN RELATIONSHIPS AND RELATED-PARTY
TRANSACTIONS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk46001_certain_relationships_and_related-party_transactions"><FONT SIZE=2><BR>
34</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk46001_additional_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ADDITIONAL INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk46001_additional_information"><FONT SIZE=2><BR>
42</FONT></A></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk46001_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OTHER MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk46001_other_matters"><FONT SIZE=2><BR>
43</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=62496,FOLIO='i',FILE='DISK125:[17ZBE1.17ZBE46001]BG46001A.;8',USER='CHE108068',CD='31-MAR-2017;21:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da46001_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>GEMPHIRE THERAPEUTICS&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>17199 N. Laurel Park Drive, Suite&nbsp;401<BR>
Livonia, Michigan 48152  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE 2017 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>May&nbsp;23, 2017  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="AA1"></A>GENERAL INFORMATION ABOUT THE MEETING</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors (the "Board") solicits your proxy on our behalf for the 2017 Annual Meeting of Stockholders (the "Annual Meeting") and at any postponement or adjournment of the
Annual Meeting for the purposes set forth in this Proxy Statement and the accompanying Notice of 2017 Annual Meeting of Stockholders (the "Notice"). The Annual Meeting will be held at our
headquarters, 17199 N. Laurel Park Drive, Livonia, Michigan 48152 on Tuesday, May&nbsp;23, 2017 at 8:00&nbsp;a.m. local time. This Proxy Statement is first being sent to stockholders on or about
April&nbsp;11, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References
in this Proxy Statement to "we," "us," "the Company" and "our" refer to Gemphire Therapeutics&nbsp;Inc. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the meeting, stockholders will act upon the proposals described in this proxy statement. In addition, we will consider any other matters that
are properly presented for a vote at the meeting. We are not aware of any other matters to be submitted for consideration at the meeting. If any other matters are properly presented for a vote at the
meeting, the persons named in the proxy, who are officers of the company, have the authority in their discretion to vote the shares represented by the proxy. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Record Date; Quorum  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only holders of record of common stock at the close of business on March&nbsp;27, 2017, the record date, will be entitled to vote at the
Annual Meeting. At the close of business on March&nbsp;27, 2017, 10,596,838 shares of common stock were outstanding and entitled to vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of a majority of the outstanding shares of stock entitled to vote at the meeting as of the record date must be present, in person, by remote communication, if applicable, or
by proxy duly authorized at the meeting in order to hold the meeting and conduct business. This presence is called a quorum. Your shares are counted as present at the meeting if you are present and
vote in person at the meeting or if you have properly submitted a proxy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da46001_general_proxy_information"> </A>
<A NAME="toc_da46001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  GENERAL PROXY INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights; Required Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of shares of common stock is entitled to one vote for each share of common stock held as of the close of business on
March&nbsp;27, 2017, the record date. You may vote all shares owned by you at such date, including (1)&nbsp;shares held directly in your name as the stockholder of record and (2)&nbsp;shares
held for you as the beneficial owner in street name through a broker, bank, trustee or other nominee. Dissenters' rights are not applicable to any of the matters being voted on. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=674737,FOLIO='1',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record: Shares Registered in Your Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If on March&nbsp;27, 2017, your shares were registered directly in your name with
our
transfer agent, Computershare,&nbsp;Inc., then you are considered the stockholder of record with respect to those shares. As a stockholder of record, you may vote at the meeting, or vote in advance
through the Internet or by mail. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner: Shares Registered in the Name of a Broker or Nominee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If on March&nbsp;27, 2017, your shares were held in an account
with a
brokerage firm, bank or other nominee, then you are the beneficial owner of the shares held in street name. As a beneficial owner, you have the right to direct your broker on how to vote the shares
held in your account, and your broker has enclosed or provided voting instructions for you to use in directing it on how to vote your shares. Because the brokerage firm, bank or other nominee that
holds your shares is the stockholder of record, if you wish to attend the meeting and vote your shares you must obtain a valid proxy from the firm that holds your shares giving you the right to vote
the shares at the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes Required to Adopt Proposals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each director will be elected by a plurality of the votes of shares present in person or represented
by proxy at
the meeting and entitled to vote on the election of directors. This means that the two individuals nominated for election to the Board at the Annual Meeting receiving the highest number of "FOR" votes
will be elected. You may either vote "FOR" one or both of the nominees or "WITHHOLD" your vote with respect to one or both of the nominees. You may not cumulate votes in the election of directors.
Approval of the ratification of the appointment of our independent registered public accounting firm will be obtained if the holders of a majority of the shares present in person or represented by
proxy at the Annual Meeting and entitled to vote at the Annual Meeting vote "FOR" the proposal. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
proxy submitted by a stockholder may indicate that the shares represented by the proxy are not being voted (stockholder withholding) with respect to a particular matter. In addition, a
broker may not be permitted to vote on shares held in street name on a particular matter in the absence of instructions from the beneficial owner of the stock (broker non-vote). The shares subject to
a proxy which are not being voted on a particular matter because of either stockholder withholding or broker non-votes will count for purposes of determining the presence of a quorum. Abstentions will
have no effect on the election of directors, but will count as a vote "against" the ratification of the appointment of Ernst &amp; Young&nbsp;LLP (Ernst&nbsp;&amp; Young) and are counted in the
determination of a quorum. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendations of the Board on Each of the Proposals Scheduled to be Voted on at the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors recommends that you vote </FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election of each of the Class&nbsp;I
directors named in this proxy statement (Proposal 1)&nbsp;and </FONT><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the ratification of the
appointment of Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2017 (Proposal 2). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Instructions; Voting of Proxies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Vote in person&#151;we will provide a ballot to stockholders who attend the Annual Meeting and wish to vote in person. Submitting a
proxy will not prevent a stockholder from attending the Annual Meeting, revoking their earlier-submitted proxy, and voting in person. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Vote through the Internet&#151;you may vote through the Internet. To vote by Internet, you will need to use a control number provided to
you in the materials with this proxy statement and follow the additional steps when prompted. The steps have been designed to authenticate your identity, allow you to give voting instructions, and
confirm that those instructions have been recorded properly. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=81151,FOLIO='2',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Vote by mail&#151;complete, sign and date the accompanying proxy card and return it as soon as possible before the Annual Meeting in the
envelope provided. If the postage-paid envelope is missing, please mail your completed proxy card to the attention of our Secretary, Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive,
Suite&nbsp;401, Livonia, Michigan 48152. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes
submitted through the Internet must be received by 11:59&nbsp;p.m., Eastern Time, on May&nbsp;22, 2017. Submitting your proxy, whether through the Internet or by mail, will not
prevent a stockholder from attending the Annual Meeting, revoking their earlier-submitted proxy, and voting in person. If you are not the stockholder of record, please refer to the voting instructions
provided by your nominee to direct it on how to vote your shares. You may either vote "FOR" all of the nominees to the Board, or you may withhold your vote from any nominee you specify. For Proposal
2, you may vote "FOR" or "AGAINST" or "ABSTAIN" from voting. Your vote is important. Whether or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure that your vote is
counted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
proxies will be voted in accordance with the instructions specified on the proxy card. If you sign a physical proxy card and return it without instructions as to how your shares
should be voted on a particular proposal at the Annual Meeting, your shares will be voted in accordance with the recommendations of our Board stated above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you do not vote and you hold your shares in street name, and your broker does not have discretionary power to vote your shares, your shares may constitute "broker non-votes" (as
described above). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. To make certain all of your shares are voted, please
complete, sign and return each proxy card to ensure that all of your shares are voted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of Soliciting Proxies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay the expenses associated with soliciting proxies. Following the original distribution and mailing of the solicitation materials, we
or our agents may solicit proxies by mail, electronic mail, telephone, facsimile, by other similar means, or in person. Our directors, officers and other employees, without additional compensation,
may solicit proxies personally or in writing, by telephone, e-mail or otherwise. Following the original distribution and mailing of the solicitation materials, we will request brokers, custodians,
nominees and other record holders to forward copies of those materials to persons for whom they hold shares and to request authority for the exercise of proxies. In such cases, we, upon the request of
the record holders, will reimburse such holders for their reasonable expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revocability of Proxies  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder of record who has given a proxy may revoke it at any time before the closing of the polls by the inspector of elections at the
meeting by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> delivering to our Secretary (by any means, including facsimile) a written notice stating that the proxy is revoked; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> signing and delivering a proxy bearing a later date; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting again through the Internet or by telephone; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attending and voting at the Annual Meeting (although attendance at the meeting will not, by itself, revoke a proxy). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
note, however, that if your shares are held of record by a brokerage firm, bank or other nominee and you wish to revoke a proxy, you must contact that firm to revoke or change any
prior voting instructions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>

<!-- ZEQ.=3,SEQ=7,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=863486,FOLIO='3',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting results will be tabulated and certified by the inspector of elections appointed for the Annual Meeting. The preliminary voting results
will be announced at the Annual Meeting and posted on our website at http://ir.gemphire.com. The final results will be tallied by the inspector of elections and filed with the Securities and Exchange
Commission (the "SEC") in a current report on Form&nbsp;8-K within four business days of the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of Being an "Emerging Growth Company"  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply
with certain reduced public company reporting requirements. These reduced reporting requirements include reduced disclosure about the company's executive compensation arrangements and no requirement
to have non-binding advisory votes on executive compensation. We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2021, (2)&nbsp;the last day of the fiscal
year (a)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (b)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our
common stock that is held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th, and (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
non-convertible debt during the prior three-year period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da46001_corporate_governance_s__da402278"> </A>
<A NAME="toc_da46001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE STANDARDS AND DIRECTOR INDEPENDENCE    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are committed to good corporate governance practices. These practices provide an important framework within which our Board and management
pursue our strategic objectives for the benefit of our stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Guidelines  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has adopted Corporate Governance Guidelines that set forth expectations for directors, director independence standards, Board
committee structure and functions and other policies for the governance of the Company. Our Corporate Governance Guidelines are available without charge on the investor relations section of our
website at http://ir.gemphire.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board is currently chaired by our Chief Scientific Officer, Dr.&nbsp;Bisgaier, who has authority, among other things, to call and preside
over meetings of our Board, to set meeting agendas and to determine materials to be distributed to the Board and, accordingly, has substantial ability to shape the work of the Board. The positions of
our chairman of the Board and Chief Executive Officer are presently separated. Separating these positions allows our Chief Executive Officer, Ms.&nbsp;Sooch, to focus on our day-to-day business,
while allowing Dr.&nbsp;Bisgaier, our co-founder who was also instrumental in the discovery and development of gemcabene, to lead the Board. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of the Board in Risk Oversight  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One of the key functions of our Board is informed oversight of our risk management process. Our Board does not have a standing risk management
committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of our Board that address risks inherent in their
respective areas of oversight. This risk management process allows our Board to play an active role in understanding and overseeing the management of risks that our Company faces and ensures that
management has the framework and processes in place to effectively and adequately monitor and manage these risks. In particular, our Board is responsible for monitoring and assessing strategic risk
exposure and our audit committee has the responsibility to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=115199,FOLIO='4',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>consider
and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which
risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and corporate governance committee monitors the
effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our compensation committee assesses and
monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the NASDAQ Global Market ("NASDAQ"). Under the rules of NASDAQ, independent directors must comprise a majority of
a listed company's Board. In addition, the rules of NASDAQ require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and corporate governance
committees be independent. Under the rules of NASDAQ, a director will only qualify as an "independent director" if, in the opinion of that company's board of directors, that person does not have a
relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Additionally, compensation committee members must not have a
relationship with us that is material to the director's ability to be independent from management in connection with the duties of a compensation committee member. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit
committee members must also satisfy the independence criteria set forth in Rule&nbsp;10A-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In order to
be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board
of directors or any other board of directors committee: (i)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its
subsidiaries; or (ii)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has undertaken a review of the independence of each director and considered whether each director has a material relationship with us that could compromise his or her ability
to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our Board determined that all of our directors, except Ms.&nbsp;Sooch and
Dr.&nbsp;Bisgaier, are "independent directors" as defined under the applicable rules and regulations of the SEC and the listing requirements and rules of NASDAQ. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of Our Board  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which has
the composition and responsibilities described below. Members serve on these committees until their resignation or until otherwise determined by our Board. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Copies
of the charters for each committee are available without charge on the investor relations section of our website at http://ir.gemphire.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our audit committee is comprised of Mr.&nbsp;Kousky, Mr.&nbsp;Lichtinger and Mr.&nbsp;Sassine, and Mr.&nbsp;Sassine is currently the
chairman. Each member of our audit committee meets the requirements for independence under the current NASDAQ and SEC rules and regulations and is financially literate. In addition, our Board has
determined that Mr.&nbsp;Sassine is an "audit committee financial expert" as defined in Item&nbsp;407(d)(5)(ii) of Regulation&nbsp;S-K promulgated under the Securities Act of 1933, as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=9,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=322001,FOLIO='5',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>amended
(the "Securities Act"). This designation does not impose on him any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our
Board. Our audit committee is directly responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our accounting and financial reporting processes, including our financial statement audits and the integrity of our financial statements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our compliance with legal and regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the qualifications, independence and performance of our independent auditors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the preparation of the audit committee report to be included in our annual proxy statement. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our compensation committee is currently comprised of Mr.&nbsp;Hawryluk, Mr.&nbsp;Lichtinger and Dr.&nbsp;Gullans, and Mr.&nbsp;Hawryluk
is currently the chairman. Each member of our compensation committee meets the requirements for independence under the current NASDAQ and SEC rules and regulations, is an outside director, as defined
pursuant to Section&nbsp;162(m) of the Internal Revenue Code of 1984, as amended, or the Code, and is a non-employee director as defined in Rule&nbsp;16b-3 promulgated under the Exchange. Our
compensation committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> evaluating, recommending, approving and reviewing executive officer and director compensation arrangements, plans, policies and programs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> administering our cash-based and equity-based compensation plans; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> making recommendations to our Board regarding any other Board responsibilities relating to executive compensation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
executive officer compensation program is substantially based on decisions made by the compensation committee, in consultation with certain members of management, including our Chief
Executive Officer. Compensation determinations for the executive officers are made based on historical practice, Company and individual performance and benchmarking compensation of similar positions
at peer group companies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee may form and delegate its authority to subcommittees as appropriate. The responsibilities and activities of the compensation committee are described further in
its charter. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is comprised of Mr.&nbsp;Hawryluk, Dr.&nbsp;Gullans and Mr.&nbsp;Sassine, and
Dr.&nbsp;Gullans is currently the chairman. Each member of our nominating and corporate governance committee meets the requirements for independence under the current NASDAQ and SEC rules and
regulations. Our nominating and corporate governance committee is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying, considering and recommending candidates for membership on our Board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the process of evaluating the performance of our Board; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> advising our Board on other corporate governance matters. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including our Chief
Executive Officer, Chief Financial Officer and other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=10,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=780375,FOLIO='6',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_7"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>executive
officers. We intend to disclose future amendments to certain provisions of our code of business conduct and ethics, or waivers of these provisions, on our website or in public filings. The
full text of our code of conduct is posted on the investor relations section of our website at http://ir.gemphire.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our current executive officers has served as a member of the Board, or as a member of the compensation or similar committee, of any
entity that has one or more executive officers who served on our Board or compensation committee during the fiscal year ended December&nbsp;31, 2016. None of the members of the compensation
committee is or has been an officer or an employee of the Company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board and Committee Meetings and Attendance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board and its committees meet regularly throughout the year and also hold special meetings and act by written consent from time to time.
During 2016, the Board held 15 meetings; the audit committee held 4 meetings; the compensation committee held 6 meetings; and the nominating and corporate governance committee held no meetings, in
each case, including telephonic
meetings. During 2016, none of the directors attended fewer than 75% of the aggregate of the total number of meetings held by the Board during his or her tenure and the total number of meetings held
by all committees of the Board on which such director served during his or her tenure. The independent members of the Board also meet separately without management directors on a regular basis to
discuss such matters as the independent directors consider appropriate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Attendance at Annual Stockholders' Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors are expected to attend the Annual Meeting, either in person or telephonically. Our 2017 Annual Meeting will be our first annual
meeting of stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communication with Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders and interested parties who wish to communicate with our Board, non-management members of our Board as a group, a committee of the
Board or a specific member of our Board (including our Chairman) may do so by letters addressed to the attention of our Secretary, Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive,
Suite&nbsp;401, Livonia, Michigan 48152. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
communications by letter addressed to the attention of our Secretary will be reviewed by the Secretary and provided to the members of the Board unless such communications are
unsolicited items, sales materials and other routine items and items unrelated to the duties and responsibilities of the Board. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Considerations in Evaluating Director Nominees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee reviews and makes recommendations to the Board, from time to time, regarding the appropriate
skills and characteristics required of Board members in the context of the current make-up of the Board, the operations of the Company and the long-term interests of stockholders. See "Proposal
No.&nbsp;1, Election of Class&nbsp;I Directors". The committee does not have a specific diversity policy underlying its nomination process,
although it seeks to ensure the Board includes directors with diverse backgrounds, qualifications, skills and experience relevant to the Company's business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the case of an incumbent director whose term of office is set to expire, the nominating and corporate governance committee reviews such director's overall service to the Company
during his or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=11,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=435167,FOLIO='7',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_da46001_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>her
term, including the number of meetings attended, level of participation, quality of performance, and any other relationships and transactions that might impair such director's independence.
Generally, the committee will re-nominate incumbent directors who continue to satisfy the committee's criteria for membership on the Board, continue to make important contributions to the Board and
consent to continue their service on the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a vacancy on the Board occurs or the Board increases in size, the nominating and corporate governance committee will actively seek individuals that satisfy the committee's criteria
for membership on the Board, and the committee may rely on multiple sources for identifying and evaluating potential nominees, including referrals from our current directors and management. In 2016,
the committee did not employ a search firm or pay fees to other third parties in connection with identifying or evaluating Board nominee candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee will consider recommendations of director nominees by stockholders so long as such recommendations are sent on a timely basis and are
otherwise in accordance with our Third Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and applicable law. See "Additional Information&#151;Stockholder
Proposals to be Presented at Next Annual Meeting" for additional information. The committee will evaluate nominees recommended by stockholders against the same criteria that it uses to evaluate other
nominees. We did not receive any nominations of directors by stockholders for the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Recommendations for Nominations to the Board of Directors  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee will consider properly submitted stockholder recommendations for candidates for our Board who
meet the minimum qualifications as described above. A stockholder of record can nominate a candidate for election to the
Board by complying with the procedures in Article&nbsp;III, Section&nbsp;5 of our Amended and Restated Bylaws and applicable law. Any eligible stockholder who wishes to submit a nomination should
review the requirements in the Amended and Restated Bylaws on nominations by stockholders. Any nomination should be sent in writing to our Secretary, Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel
Park Drive, Suite&nbsp;401, Livonia, Michigan 48152. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
proposals of stockholders that are intended to be presented by such stockholder at an annual meeting of stockholders must be in writing and notice must be delivered to the Secretary
at our principal executive offices not later than the close of business on the 90th&nbsp;day nor earlier than the close of business on the 120th&nbsp;day prior to the first anniversary of the
preceding year's annual meeting, except in the case of our first annual meeting after our initial public offering, for which notice must be received no earlier than January&nbsp;23, 2017, the
120<SUP>th</SUP>&nbsp;day prior to such annual meeting and not later than March&nbsp;27, 2017, the 10th&nbsp;day following the day on which public announcement is first made of the date of
the annual meeting. Stockholders are also advised to review our Amended and Restated Bylaws, which contain additional requirements with respect to advance notice of stockholder proposals and director
nominations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=12,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=815127,FOLIO='8',FILE='DISK125:[17ZBE1.17ZBE46001]DA46001A.;12',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc46001_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc46001_proposal_no._1_election_of_class_i_directors"> </A>
<A NAME="toc_dc46001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1<BR>  ELECTION OF CLASS I DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is divided into three classes. Members of each class serve staggered three-year terms. Directors in Class&nbsp;I will
stand for election at this meeting. The terms of office of directors in Class&nbsp;II and Class&nbsp;III do not expire until the annual meetings of stockholders to be held in 2018 and 2019,
respectively. Based on the recommendation of the nominating and corporate governance committee of our Board, our Board has nominated Dr.&nbsp;Charles Bisgaier and Kenneth Kousky for election as
Class&nbsp;I directors to serve for three-year terms ending at the 2020 annual meeting or until their successors are elected and qualified. Each of the nominees is a current member of our Board and
has consented to serve if elected. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
director will be elected by a plurality of the votes present in person or represented by proxy at the meeting and entitled to vote. This means that the two individuals nominated for
election to the Board at the Annual Meeting receiving the highest number of "FOR" votes will be elected. You may
either vote "FOR" one or both of the nominees or "WITHHOLD" your vote with respect to one or both of the nominees. You may not cumulate votes in the election of directors. Shares represented by
proxies will be voted "FOR" the election of each of the Class&nbsp;I nominees, unless the proxy is marked to withhold authority to so vote. If any nominee is unable or unwilling to serve at the time
of the Annual Meeting, the persons named as proxies may vote for a substitute nominee chosen by the present Board. In the alternative, the proxies may vote only for the remaining nominees, leaving a
vacancy on the Board. The Board may fill such vacancy at a later date or reduce the size of the Board. We have no reason to believe that any of the nominees will be unwilling or unable to serve if
elected as a director. Additional information regarding the directors and director nominees of the Company is set forth below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees to the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominees of the Company are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="141pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="41pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>AGE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>TITLE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>CLASS </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Charles Bisgaier</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer and Chairman of the Board</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;I</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;I</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the audit committee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Dr.&nbsp;Charles Bisgaier</B></FONT><FONT SIZE=2>, one of our co-founders, has served as our Chief Scientific Officer and Chairman of our Board since November
2014. He also currently serves as an Adjunct Associate Professor of Pharmacology at the University of Michigan. Prior to our founding, he served from September 2008 to November 2014 as the Chief
Executive Manager for our predecessor, Michigan Life Therapeutics,&nbsp;LLC. In addition, he co-founded Michigan Life Ventures,&nbsp;LLC, a venture capital firm investing primarily in
Michigan-based life sciences companies, where since 2008 he has served as the Chief Executive Manager. He also served as the Interim President and Chief Executive Officer of ProNAi
Therapeutics,&nbsp;Inc., a clinical-stage oncology company, from September 2010 to April 2012, and as a member of its board of directors from 2009 to March 2014. In 1998, Dr.&nbsp;Bisgaier
co-founded the original Esperion, which was acquired by Pfizer in 2003. After the acquisition, he served as the Senior Director of Pharmacology for the Esperion Division of Pfizer Global Research and
Development from 2004 to 2006. From 2006 to 2008, Dr.&nbsp;Bisgaier also served as a director, board member and president of Pipex Pharmaceuticals,&nbsp;Inc., currently known as Synthetic
Biologics,&nbsp;Inc., a specialty pharmaceutical company. From 1990 to 1998, Dr.&nbsp;Bisgaier was an Associate Research Fellow in the Department of Cardiovascular Diseases in the Parke-Davis
division of Warner-Lambert&nbsp;Co. Currently he is a board
member at Hygieia,&nbsp;Inc., a privately held health service company, and at BioSavita&nbsp;Inc., a privately held life sciences company. He received a B.A. in biology from the State University
of New York at </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=445381,FOLIO='9',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Oneonta
and an M.S. and Ph.D. in biochemistry from George Washington University. After receiving his Ph.D., he studied lipoprotein metabolism within the Specialized Center of Research for
atherosclerosis at Columbia University College of Physicians and Surgeons. Our Board believes Dr.&nbsp;Bisgaier should serve as a director based on his depth of experience in founding and developing
biopharmaceutical companies as well as his knowledge of our product candidate gemcabene. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Kenneth Kousky</B></FONT><FONT SIZE=2> has served as a member of our Board since March 2015. Mr.&nbsp;Kousky has also served as the Chief Executive Officer of
the Mid-Michigan Innovation Center, a privately funded, non-profit business incubator, since 2010. He has also served as the President and Chief Executive Officer of IP3,&nbsp;Inc., an information
security consulting firm, since 2002. Also, Mr.&nbsp;Kousky is a founding member and has served as Executive Director of the Blue Water Angels Investment Network, a Michigan-based funding network
that assists in private equity investments in early-stage tech startups, since 2008. In 1988, Mr.&nbsp;Kousky founded an IT services company, Wave Technologies International&nbsp;Inc., which he
led through an initial public offering in 1994. In 1989, he established Washington University's graduate program in Telecommunication Management, and he has lectured at Saginaw Valley State
University, Washington University and at the Wharton School of Business at the University of Pennsylvania. Mr.&nbsp;Kousky is a member of several corporate boards, including Michigan Sugar
Corporation, RetroSense Therapeutics&nbsp;LLC and Foodjunky&nbsp;LLC. Mr.&nbsp;Kousky holds a B.A. in economics and urban studies from Washington University, and an M.S. in economics from
University of Pennsylvania. Our Board believes Mr.&nbsp;Kousky should serve as a director based on his extensive financial and strategic business planning experience. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Continuing Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The directors who are serving for terms that end following the 2017 annual meeting are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="328pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>AGE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>TITLE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>CLASS </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Steve Gullans(1)(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;II</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk(1)(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>48</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Class&nbsp;II</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger(1)(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;III</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine(2)(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;III</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer, Treasurer and Director</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Class&nbsp;III</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the compensation committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the audit committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Member
of the nominating and corporate governance committee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Dr.&nbsp;Steve Gullans</B></FONT><FONT SIZE=2> has served as a member of our Board since April 2016. He is currently Managing Director at Excel Venture
Management,&nbsp;LLC (Excel), a Boston-based venture capital firm which he co-founded and where he has been employed since February 2008. At Excel, he focuses on investing in life science technology
companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr.&nbsp;Gullans co-founded RxGen,&nbsp;Inc., a pharmaceutical services company
where he served as chief executive officer from January 2004 to February 2008. Dr.&nbsp;Gullans is currently a director at Molecular Templates,&nbsp;Inc., a private biotechnology company,
Cleveland HeartLab,&nbsp;Inc., a private cardiovascular testing company, and N-of-One,&nbsp;Inc., an oncology diagnostics company. He was previously a board member of Activate
Networks,&nbsp;Inc. which was acquired by Decision Resource Group, BioTrove,&nbsp;Inc. which was acquired by Life Technologies Corporation, Biocius Life Sciences,&nbsp;Inc. which was acquired by
Agilent Technologies&nbsp;Inc., nanoMR&nbsp;Inc. which was acquired by DNA Electronics&nbsp;Ltd and Tetraphase Pharmaceuticals,&nbsp;Inc. which went public in 2013. Dr.&nbsp;Gullans was a
faculty member at Harvard Medical School and Brigham and Women's Hospital for almost 20&nbsp;years. Dr.&nbsp;Gullans holds a B.S. from Union College and a Ph.D. from Duke University. Our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=818648,FOLIO='10',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Board
believes Dr.&nbsp;Gullans should serve as a director based on his extensive experience in the life sciences industry and his board experience. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>P. Kent Hawryluk</B></FONT><FONT SIZE=2> has served as a member of our Board since February 2015. He is the Co-Founder and has served as the Chief Business
Officer of Avidity NanoMedicines&nbsp;LLC, a precision nanomedicines company, since January 2013. He was also Co-Founder and served as the Chief Executive Officer of MB2&nbsp;LLC, a clinical-stage
company focused on diabetes and obesity, from May 2014 to March 2016. MB2 was acquired by Novo Nordisk in October 2015. Previously, in January 2006, Mr.&nbsp;Hawryluk co-founded Marcadia
Biotech&nbsp;Inc., which was acquired by Roche Holding&nbsp;Ltd., where he served as Chief Business Officer and Vice President, Business Development from January 2006 to April 2011. He
currently serves as partner of Twilight Venture Partners,&nbsp;LLC, a private seed and early-stage life science venture capital fund. He was a founding partner of JEGI Capital,&nbsp;LLC, a venture
capital fund co-sponsored by GE Capital Corp. that launched in 2000. Mr.&nbsp;Hawryluk holds a B.A. from Princeton University, an M.B.A. from Kellogg School of Management at Northwestern University,
and an M.S. degree in biology from Indiana University-Purdue University Indianapolis. Our Board believes Mr.&nbsp;Hawryluk should serve as a director based on his experience founding and developing
biopharmaceutical companies and his knowledge of the biopharmaceutical industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Pedro Lichtinger</B></FONT><FONT SIZE=2> has served as a member of our Board since December 2015. He was the President and Chief Executive Officer of Asterias
Biotherapeutics,&nbsp;Inc., a publicly traded company with a focus on neurology and oncology from June 2014 to February 2016. Mr.&nbsp;Lichtinger served as President, Chief Executive Officer, and
a director of Optimer Pharmaceuticals,&nbsp;Inc., from May 2010 to February 2013. Mr.&nbsp;Lichtinger previously served as an executive of Pfizer,&nbsp;Inc. from 1995 to 2009, including as
President of Pfizer's Global Primary Care Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global Animal Health from 1999 to 2006, and Regional President Europe Animal
Health from 1995 to 1999. Before joining Pfizer, Mr.&nbsp;Lichtinger was an executive of Smith Kline Beecham&nbsp;Plc, last serving as Senior Vice-President Europe Animal Health from 1987 to 1995.
Mr.&nbsp;Lichtinger serves as a director of Sanfer de Mexico, a leading Mexican pharmaceutical company. Mr.&nbsp;Lichtinger previously served as a director of BioTime,&nbsp;Inc. and Optimer
Pharmaceuticals,&nbsp;Inc. Mr.&nbsp;Lichtinger holds an MBA degree from the Wharton School of Business and an engineering degree from the National University of Mexico. Our Board believes
Mr.&nbsp;Lichtinger should serve as director based on his extensive pharmaceutical industry and public company leadership experience. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Andrew Sassine</B></FONT><FONT SIZE=2> has served as a member of our Board since May 2015. Mr.&nbsp;Sassine served in various positions at Fidelity Investments
from 1999 to 2012, including as a Portfolio Manager for various funds from 2005 to December 2011. Mr.&nbsp;Sassine has also served on several boards of life science companies. Mr.&nbsp;Sassine
currently serves on the board of directors of iCAD,&nbsp;Inc., a public cancer detection and radiation therapy solutions company and previously served on the boards of directors of FluoroPharma
Medical,&nbsp;Inc., a public biopharmaceutical company, Acorn Energy,&nbsp;Inc., a public holding company focused on technology solutions for energy infrastructure asset management and CNS
Response, Inc., a public psychiatric clinical decision support company. Mr.&nbsp;Sassine also serves on the board of directors of Freedom Meditech,&nbsp;Inc., a private medical device company, and
Comhear&nbsp;Inc., a private digital audio software and device company, where he is also the chairman of the board of directors. Mr.&nbsp;Sassine serves on the Strategic Advisory Board of MD
Revolution&nbsp;Inc., a private digital health service company. Mr.&nbsp;Sassine has been a member of the Henry B. Tippie College of Business, University of Iowa Board of Advisors since 2009 and
served on the board of trustees at the Clarke Schools for Hearing and Speech from 2009 through 2014. Mr.&nbsp;Sassine holds a B.A. from the University of Iowa and an M.B.A. from the Wharton School
at the University of Pennsylvania. Our Board believes Mr.&nbsp;Sassine should serve as a director based on his extensive experience in the public markets as well as his financial expertise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=135658,FOLIO='11',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Mina Sooch</B></FONT><FONT SIZE=2> has served as our President and Chief Executive Officer and as a member of our Board since November 2014. Prior to joining us,
she served from July 2012 to May 2014 as the President and Chief Executive Officer of ProNAi Therapeutics,&nbsp;Inc., a public clinical-stage oncology company that she co-founded and as a member of
the board of directors from its founding in 2004 through May 2014 as well as a business development advisor from December 2010 to June 2012. In addition, Ms.&nbsp;Sooch founded Apjohn Ventures Fund,
a venture capital firm that invests primarily in early-stage life sciences companies, and has served as its Managing Partner since its founding in 2003. She also serves as Manager of Tara Ventures
I,&nbsp;LLC, an angel fund organized in 2002, for life sciences investments. Ms.&nbsp;Sooch also served as an entrepreneur in residence at North Coast Technology Investors&nbsp;LP from 2001 to
2002. Ms.&nbsp;Sooch co-founded three life sciences start-ups: ProNAi Therapeutics,&nbsp;Inc., Afmedica,&nbsp;Inc. and CytoPherx&nbsp;Inc. (formerly known as Nephrion&nbsp;Inc.).
Ms.&nbsp;Sooch has served on over 10 private, public and non-profit venture capital boards including ProNAi Therapeutics,&nbsp;Inc., ZyStor Therapeutics,&nbsp;Inc., Asterand&nbsp;Inc.,
CytoPherx&nbsp;Inc., Svelte Medical Systems,&nbsp;Inc., Wolverine Venture Fund and Michigan Venture Capital Association. From 1993 to 2000, she last served as global account manager at Monitor
Deloitte (formerly known as Monitor Company Group), a global strategy consulting firm based in Boston. Ms.&nbsp;Sooch received an M.B.A. from Harvard Business School and a B.S. in chemical
engineering from Wayne State University. Our Board believes Ms.&nbsp;Sooch should serve as a director based on her extensive experience founding and developing biopharmaceutical companies and
managing and negotiating venture capital investments and strategic transactions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no familial relationships among any of our directors and executive officers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Director Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our non-employee directors receive a mix of cash and share-based compensation which is intended to encourage non-employee directors to continue
to serve on our board of directors, further align the interests of the directors and stockholders, and attract new non-employee directors with outstanding qualifications. Directors who are employees
or officers of the Company do not receive any additional compensation for Board service. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
non-employee director compensation policy became effective following the completion of our initial public offering in August 2016. Pursuant to this policy, each of our non-employee
directors receives an annual retainer of $50,000. Additionally, the Chairmen of our Audit, Compensation and Nominating and Corporate Governance Committees receive an additional annual payment of
$15,000, $7,500 and $5,000, respectively; and the members of each of our committees receive an additional annual payment of $5,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the date of each non-employee director's initial election to the Board, each such director will be automatically granted a stock option for 60,000 shares, which will vest in a series
of 48 equal monthly installments, subject to the director's continued service, and will vest in full upon a change in control (as defined in the Amended and Restated 2015 Equity Incentive Plan). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=953983,FOLIO='12',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_13"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table provides compensation information for the fiscal year ended December&nbsp;31, 2016 for each non-employee member of our Board. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned<BR>
or Paid in<BR>
Cash(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steven Gullans</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,831</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>379,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>402,893</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,788</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>379,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>404,850</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,356</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>379,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>402,418</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>379,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>403,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>379,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>407,282</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Reflects
cash retainers.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts reflect the aggregate grant date fair value of the options granted to our non-employee directors during the fiscal year ended December&nbsp;31, 2016,
as computed in accordance with FASB Accounting Standards Codification Topic 718 (ASC 718). Assumptions used in the calculation of these amounts are included in Note&nbsp;9 to the financial
statements included in our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures
related to service-based vesting conditions.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2016, Mr.&nbsp;Hawryluk had 4,008 shares of restricted stock outstanding and each of the following non-employee directors had shares underlying outstanding
stock options as follows: Dr.&nbsp;Gullans, 60,000; Mr.&nbsp;Hawryluk, 60,000; Mr.&nbsp;Kousky, 68,016; Mr.&nbsp;Lichtinger, 92,062; and Mr.&nbsp;Sassine, 92,062. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE </B></FONT><FONT SIZE=2><B><I>"FOR"</I></B></FONT><FONT SIZE=2><B> THE ELECTION OF EACH OF THE NOMINATED CLASS I DIRECTORS.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=455291,FOLIO='13',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc46001_proposal_no._2_ratification_of__pro02974"> </A>
<A NAME="toc_dc46001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2<BR>  RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young audited our financial statements for the fiscal years ended December&nbsp;31, 2016, 2015 and 2014. We expect that
representatives of Ernst&nbsp;&amp; Young will be present at
the annual meeting, will be able to make a statement if they so desire and will be available to respond to appropriate questions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the annual meeting, the stockholders are being asked to ratify the appointment of Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2017. Our audit committee is submitting the selection of Ernst&nbsp;&amp; Young to our stockholders because we value our stockholders' views on our independent registered public
accounting firm and as a matter of good corporate governance. If this proposal does not receive the affirmative approval of a majority of the votes cast on the proposal, the audit committee would
reconsider the appointment. Notwithstanding its selection and even if our stockholders ratify the selection, our audit committee, in its discretion, may appoint another independent registered public
accounting firm at any time during the year if the audit committee believes that such a change would be in our best interests and the interests of our stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents fees for professional audit services rendered by Ernst&nbsp;&amp; Young for the audit of our annual financial statements for the years ended
December&nbsp;31, 2016 and 2015. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Service Fees Paid to the Independent Registered Public Accounting Firms  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the fiscal years ended December&nbsp;31, 2016 and 2015, we retained Ernst&nbsp;&amp; Young to provide services in the following categories
and amounts. The Audit Committee has considered the scope and fee arrangements for all services provided by Ernst&nbsp;&amp; Young, taking into account whether the provision of non-audit-related
services is compatible with maintaining Ernst&nbsp;&amp; Young's independence. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>FEE CATEGORY

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>451,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>457,215</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-related fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,103</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>39,196</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All other fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>476,703</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>496,411</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
fees include fees for professional services provided by Ernst&nbsp;&amp; Young in connection with the annual audit of our financial statements, review of our
quarterly financial statements, and related services that are typically provided in connection with registration statements, including our initial public offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
fees include fees billed for assurance and related services reasonably related to the performance of the audit of our financial statements. There were
no audit related fees billed by Ernst&nbsp;&amp; Young in 2016 or 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
fees relate to permissible services for technical tax advice related to federal and state income tax matters.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>There
were no other fees billed by Ernst&nbsp;&amp; Young for any other services in 2016 or 2015.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=603941,FOLIO='14',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<A NAME="page_dc46001_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent
Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our audit committee generally pre-approves all audit and permitted non-audit and tax services provided by the independent registered public
accounting firm. Pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent registered public accounting firm and
management are required to periodically report to the Audit Committee regarding the extent of services provided by the independent registered public accounting firm in accordance with this
pre-approval, and the fees for the services performed to date. Our Audit Committee may also pre-approve particular services on a case-by-case basis. All of the services relating to the fees described
in the table above were approved by our audit committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS RECOMMENDS A VOTE </B></FONT><FONT SIZE=2><B><I>"FOR"</I></B></FONT><FONT SIZE=2><B> APPROVAL OF PROPOSAL NO. 2.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=63214,FOLIO='15',FILE='DISK125:[17ZBE1.17ZBE46001]DC46001A.;15',USER='C902264',CD=';5-APR-2017;16:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de46001_1_16"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de46001_report_of_the_audit_committee"> </A>
<A NAME="toc_de46001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the following report of the audit committee is not considered to be "soliciting material," "filed" or incorporated
by reference in any past or future filing by us under the Exchange Act or the Securities Act unless and only to the extent that we specifically incorporate it by reference. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee has reviewed and discussed with our management and Ernst&nbsp;&amp; Young&nbsp;our audited financial statements as of and for the year ended December&nbsp;31, 2016.
The audit committee has also discussed with Ernst&nbsp;&amp; Young&nbsp;the matters required to be discussed by Auditing Standard No.&nbsp;16 adopted by the Public Company Accounting Oversight Board
(United States) regarding "</FONT><FONT SIZE=2><I>Communication with Audit Committees</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee has received and reviewed the written disclosures and the letter from Ernst&nbsp;&amp; Young&nbsp;required by applicable requirements of the Public Company Accounting
Oversight Board regarding the independent accountant's communications with the audit committee concerning independence, and has discussed with Ernst&nbsp;&amp; Young&nbsp;its independence. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the review and discussions referred to above, the audit committee recommended to our Board that the audited financial statements as of and for the year ended December&nbsp;31,
2016 be included in our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 for filing with the Securities and Exchange Commission. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Audit Committee</B></FONT><FONT SIZE=2><BR>
Andrew Sassine (Chair)<BR>
Pedro Lichtinger<BR>
Kenneth Kousky </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=564457,FOLIO='16',FILE='DISK125:[17ZBE1.17ZBE46001]DE46001A.;18',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_de46001_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de46001_security_ownership_of_certain___sec02460"> </A>
<A NAME="toc_de46001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT(1)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding beneficial ownership of our capital stock as of March&nbsp;27, 2017,
by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our named executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current executive officers and directors as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table lists applicable percentage ownership based on 10,596,838 shares of common stock outstanding as of March&nbsp;27, 2017. In addition, the rules include shares of our common
stock issuable pursuant to the exercise of stock options that are either immediately exercisable or exercisable within 60&nbsp;days of March&nbsp;27, 2017. These shares are deemed to be
outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of
computing the percentage ownership of any other person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared
voting power or investment power with respect to those securities. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to
all shares shown as beneficially owned by them, subject to applicable community property laws. Except as otherwise noted below, the address for each person or entity listed in the table is c/o
Gemphire Therapeutics&nbsp;Inc., 17199 N. Laurel Park Drive, Suite&nbsp;401, Livonia, Michigan 48152. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SHARES<BR>
BENEFICIALLY<BR>
OWNED </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME AND ADDRESS OF BENEFICIAL OWNER

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>NUMBER </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>PERCENT </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% stockholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cormorant Asset Management,&nbsp;LLC(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>992,397</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Excel Ventures II&nbsp;GP,&nbsp;LLC(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>898,422</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Lowenschuss(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>808,574</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>675,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>850,883</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles L. Bisgaier, Ph.D.(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,378,487</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>77,227</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steve Gullans, Ph.D.(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>909,672</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>143,951</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Kousky(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,201</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger(11)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101,714</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andy Sassine(12)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>194,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (10&nbsp;persons)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,779,226</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than one percent.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(i)&nbsp;900,000 shares of common stock beneficially owned by Cormorant Asset Management,&nbsp;LLC ("Cormorant") and certain of its affiliates as
reported on the </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=491932,FOLIO='17',FILE='DISK125:[17ZBE1.17ZBE46001]DE46001A.;18',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_de46001_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>Schedule&nbsp;13G
filed with the SEC on August&nbsp;15, 2016, (ii)&nbsp;52,798 shares of common stock purchased by Cormorant and an affiliate in the March 2017 private placement and
(iii)&nbsp;warrants to purchase 39,599 shares of common stock exercisable within 60&nbsp;days of March&nbsp;27, 2017, purchased by Cormorant and an affiliate in the March 2017 private placement.
The address for Cormorant is 200 Clarendon Street, 52nd&nbsp;Floor, Boston, MA&nbsp;02116.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(i)&nbsp;806,025 shares of common stock beneficially owned by Excel Ventures&nbsp;II&nbsp;GP,&nbsp;LLC ("Excel") and certain of its affiliates as
reported on the Schedule&nbsp;13G filed with the SEC on February&nbsp;8, 2017, (ii)&nbsp;52,798 shares of common stock purchased by an affiliate of Excel in the March 2017 private placement and
(iii)&nbsp;warrants to purchase 39,599 shares of common stock exercisable within 60&nbsp;days of March&nbsp;27, 2017, purchased by an affiliate of Excel in the March 2017 private placement. The
address for Excel is 800&nbsp;Boylston Street Suite&nbsp;2825, Boston, MA&nbsp;02199.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(i)&nbsp;806,247 shares of common stock beneficially owned by David Lowenschuss as reported on the Schedule&nbsp;13G filed with the SEC on
February&nbsp;14, 2017 and (ii)&nbsp;2,327 shares of common stock purchased through the exercise of options in 2017. The address for Mr.&nbsp;Lowenschuss is 2020 Shadford Road, Ann Arbor, MI
48104. Pursuant to the Schedule&nbsp;13G filed with the SEC on February&nbsp;10, 2017, Exchange Capital Management,&nbsp;Inc. ("Exchange") has shared voting and investment power over these
shares. The address for Exchange is 303 Detroit Street, Suite&nbsp;203, Ann Arbor, MI 48104.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Pursuant
to Schedule&nbsp;13G filed with the SEC on February&nbsp;13, 2017. Represents 675,250 shares of common stock beneficially owned by Pfizer&nbsp;Inc.
("Pfizer"). The address for Pfizer is 235 East 42nd&nbsp;St., New York, New York 10017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;668,732 shares of common stock held by Ms.&nbsp;Sooch, (b)&nbsp;117,720 shares underlying options to purchase common stock that are
exercisable within 60&nbsp;days of March&nbsp;27, 2017, (c)&nbsp;39,431 shares of common stock held by the Arvinder S. Sooch Trust dated September&nbsp;20, 2006, of which Ms.&nbsp;Sooch's
spouse is the trustee and (d)&nbsp;25,000 shares of common stock held in a grantor retained annuity trust.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;1,244,440 shares of common stock held by Dr.&nbsp;Bisgaier, (b)&nbsp;32,599 shares underlying options to purchase common stock that are
exercisable within 60&nbsp;days of March&nbsp;27, 2017, (c)&nbsp;82,220 shares of common stock held by The Charles L. Bisgaier Trust dated November&nbsp;8, 2000, of which Dr.&nbsp;Bisgaier
is the trustee, and (d)&nbsp;19,228 shares of common stock held by Bisgaier Family,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;7,927 shares of common stock and (b)&nbsp;69,300 shares underlying options to purchase common stock that are exercisable within
60&nbsp;days of March&nbsp;27, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;11,250 shares underlying options to purchase common stock that are exercisable within 60&nbsp;days of March&nbsp;27, 2017 and
(b)&nbsp;898,422 shares of common stock or shares underlying warrants as described in note&nbsp;(2) above beneficially owned by Excel, of which Dr.&nbsp;Gullans is the Manager.
Dr.&nbsp;Gullans may be deemed to have voting and investment power over the shares owned by Excel.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;32,062 shares of common stock held by P. Kent Hawryluk, (b)&nbsp;11,250 shares underlying options to purchase common stock that are
exercisable within 60&nbsp;days of March&nbsp;27, 2017, (c)&nbsp;81,889 shares of common stock held by the P. Kent Hawryluk Revocable Trust, of which Mr.&nbsp;Hawryluk is the trustee and
(d)&nbsp;18,750 shares underlying warrants to purchase common stock that are exercisable within 60&nbsp;days of March&nbsp;27, 2017 held by the P. Kent Hawryluk Revocable Trust, of which
Mr.&nbsp;Hawryluk is the trustee. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=453675,FOLIO='18',FILE='DISK125:[17ZBE1.17ZBE46001]DE46001A.;18',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_de46001_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;1,000 shares of common stock held by Mr.&nbsp;Kousky, (b)&nbsp;19,266 shares underlying options to purchase common stock exercisable
within 60&nbsp;days of March&nbsp;27, 2017 and (c)&nbsp;10,935 shares of common stock held by BWA Gemphire Investment Group,&nbsp;LLC or BWA Gemphire Investment Group II,&nbsp;LLC, of which
Mr.&nbsp;Kousky is a Manager. Mr.&nbsp;Kousky may be deemed to have voting and investment power over the shares owned by BWA Gemphire Investment Group,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;59,833 shares of common stock held by Mr.&nbsp;Lichtinger, (b)&nbsp;33,961 shares underlying options to purchase common stock that are
exercisable within 60&nbsp;days of March&nbsp;27, 2017 and (c)&nbsp;7,920 shares underlying warrants to purchase common stock that are exercisable within 60&nbsp;days of March&nbsp;27, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
(a)&nbsp;136,264 shares of common stock held by Mr.&nbsp;Sassine, (b)&nbsp;41,976 shares underlying options to purchase common stock that are
exercisable within 60&nbsp;days of March&nbsp;27, 2017 and (c)&nbsp;15,840 shares underlying warrants to purchase common stock that are exercisable within 60&nbsp;days of March&nbsp;27,
2017.  </FONT></DD></DL>
 </DIV>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=23,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=969411,FOLIO='19',FILE='DISK125:[17ZBE1.17ZBE46001]DE46001A.;18',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<A NAME="page_de46001_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de46001_executive_officers"> </A>
<A NAME="toc_de46001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding our executive officers as of April&nbsp;6, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="328pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>AGE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>POSITION(S) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Financial Officer and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Charles L. Bisgaier</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer and Chairman of the Board</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Lee Golden</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Seth Reno</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Commercial Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
"Proposal No.&nbsp;1-Election of Class&nbsp;I Directors" for biographical and other information regarding Mina Sooch and Dr.&nbsp;Charles L. Bisgaier. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Jeffrey S. Mathiesen</B></FONT><FONT SIZE=2> has served as our Chief Financial Officer since September 2015 and as a consultant to us from August 2015 until
September 2015. Prior to joining us, Mr.&nbsp;Mathiesen served as Chief Financial Officer of Sunshine Heart,&nbsp;Inc., a publicly traded medical device company, from March 2011 to January 2015.
From December 2005 to April 2010, Mr.&nbsp;Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems,&nbsp;Inc., a manufacturer and marketer of medical products, perimeter
fencing and security systems, which was purchased by Woodstream Corporation in April 2010. Mr.&nbsp;Mathiesen has held executive positions with publicly traded companies dating back to 1993,
including vice president and chief financial officer positions. Mr.&nbsp;Mathiesen also serves as a director and audit committee chairman of Sun BioPharma,&nbsp;Inc., a publicly traded
biopharmaceutical company that develops therapies for pancreatic diseases. Mr.&nbsp;Mathiesen received a B.S. in Accounting from the University of South Dakota and is also a Certified Public
Accountant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Dr.&nbsp;Lee Golden</B></FONT><FONT SIZE=2> joined Gemphire in October 2016 as the Chief Medical Officer. In this role he oversees all clinical development,
clinical operations and clinical regulatory activities of the Company. Prior to joining us from July 2011 to October 2016, Dr.&nbsp;Golden was the Therapeutic Area Head for CV, Pulmonary and CNS at
Mesoblast,&nbsp;Ltd., a global regenerative medicine company. He also served as Therapeutic Area Head for Cardiovascular and Blood Disorders at Eisai&nbsp;Inc., a global pharmaceutical company
from November 2009 to July 2011. From January, 2005 to March, 2008 he served as the Senior Director, US Medical at Actelion Pharmaceuticals US,&nbsp;Inc., a global biotech company, and from October
2001 to January 2005 he was a Medical Director and Team Leader in the US Cardiovascular and Metabolic Group at Pfizer. He received a B.S. in Physiological Psychology from University of Michigan, Ann
Arbor, MI and earned his M.D. degree from New York University School of Medicine. After his Internal Medicine Residency at New York University Medical Center, he completed fellowships in cardiology at
University of Miami Health Center and interventional cardiology at George Washington University Hospital. While at George Washington University Hospital, Dr.&nbsp;Golden also served as an Adjunct
Instructor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Seth Reno</B></FONT><FONT SIZE=2> has served as our Chief Commercial Officer since August 2015. Prior to joining us, he served in several commercial roles
including Head of Commercial Operations for Medimmune,&nbsp;LLC, a biologics company, from June 2010 to April 2015. From April 2001 to June 2010, Mr.&nbsp;Reno worked at AstraZeneca, a public
biopharmaceutical company, in a number of roles, including in the sales, commercial operations, managed markets and brand team spaces. Prior to joining AstraZeneca in 2001, Mr.&nbsp;Reno spent
11&nbsp;years at Wyeth Pharmaceuticals,&nbsp;Inc., a pharmaceutical company, in commercial operations and sales account management. Mr.&nbsp;Reno holds a B.S. in human resources from the
University of Delaware and an M.B.A. from Strayer University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=24,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=109485,FOLIO='20',FILE='DISK125:[17ZBE1.17ZBE46001]DE46001A.;18',USER='ABEAULI',CD=';6-APR-2017;13:31' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg46001_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg46001_executive_compensation"> </A>
<A NAME="toc_dg46001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officer Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables and accompanying narrative disclosure discuss the compensation awarded to, earned by, or paid
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mina Sooch, our President, Chief Executive Officer and Director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Charles L. Bisgaier, Ph.D., our Chief Scientific Officer and Chairman of our Board of Directors; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Jeffrey S. Mathiesen, our Chief Financial Officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
refer to these three executive officers as the "named executive officers." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table for 2016  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents summary information regarding the total compensation for services rendered in all capacities that was earned by our
named executive officers during the fiscal years ended December&nbsp;31, 2016 and 2015. Our named executive officers in 2016 and 2015 were Mina Sooch, Charles L. Bisgaier, Ph.D. and Jeffrey S.
Mathiesen. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="100pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="88pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME AND PRINCIPAL<BR>
POSITION

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>YEAR </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>SALARY<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>BONUS<BR>
($)(1)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OPTION<BR>
AWARDS(3)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>NON-EQUITY<BR>
INCENTIVE<BR>
PLAN<BR>
COMPENSATION(1)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>ALL OTHER<BR>
COMPENSATION(5) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>TOTAL<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Mina Sooch</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>380,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>102,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,790,624</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>159,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>226</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,433,370</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>President and Chief Executive Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>315,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>319,009</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Charles L. Bisgaier, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>300,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>54,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>947,656</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,391,753</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>270,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,436</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>273,436</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jeffrey S. Mathiesen(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>280,645</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,326,718</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>97</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,719,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>104,833</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,965</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>220,798</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>We
did not pay any bonus or non-equity incentive plan compensation to any of our executive officers during the year ended December&nbsp;31, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Reflects
discretionary bonus payments following the closing of the Company's initial public offering in August 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts reported do not reflect the amounts actually received by our named executive officers. Instead, these amounts reflect the aggregate grant date fair value
of the stock options granted to our named executive officers during the fiscal year ended December&nbsp;31, 2015 and 2016, as computed in accordance with FASB Accounting Standards Codification Topic
718 (ASC 718). Assumptions used in the calculation of these amounts are included in Note&nbsp;9 to the financial statements included in our annual report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2016. As required by SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amounts
reflect cash bonuses awarded pursuant to the achievement of our 2016 corporate objectives. See "&#151;Non-Equity Incentive Plan Compensation" below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amounts
reflect the dollar value of group life insurance premiums paid during 2016 with respect to life insurance for the named executive officer.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amount
excludes $35,000 in salary foregone by Ms.&nbsp;Sooch in exchange for a stock option award for 5,220 shares granted on June&nbsp;29, 2015 as described in
the table below under "&#151;Outstanding Equity Awards at Fiscal Year-End."
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amount
excludes $30,000 in salary foregone by Dr.&nbsp;Bisgaier in exchange for a stock option award for 4,474 shares granted on June&nbsp;29, 2015 as described
in the table below under "&#151;Outstanding Equity Awards at Fiscal Year-End."
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Mr.&nbsp;Mathiesen
provided consulting services to us during August and September 2015. He began serving as our Chief Financial Officer in September 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amount
includes $34,000 paid to The Mathiesen Group,&nbsp;Inc. for consulting services provided by Mr.&nbsp;Mathiesen.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Amount
includes $6,867 of aggregate grant date fair value of stock options granted to Mr.&nbsp;Mathiesen in connection with the consulting agreement, computed as
described in note&nbsp;(3) above. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=361707,FOLIO='21',FILE='DISK125:[17ZBE1.17ZBE46001]DG46001A.;15',USER='C902265',CD=';5-APR-2017;17:00' -->
<A NAME="page_dg46001_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Agreements with Our Named Executive Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered into written employment agreements with each of our named executive officers, as described below. For a discussion of the
severance pay and other benefits to be provided in connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see
"&#151;Potential Payments Upon Termination or Change in Control" below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of our named executive officers has also executed our standard form of confidential information and invention assignment agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreement with Mina Sooch  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We initially entered into an employment agreement with Ms.&nbsp;Sooch in November 2014 that, as amended, governed the terms of her employment
with us prior to the closing of our initial public offering. Under the terms of this agreement, Ms.&nbsp;Sooch was entitled to an annual base salary of $350,000 beginning on January&nbsp;1, 2015.
Ms.&nbsp;Sooch agreed to defer 20% of her salary until June&nbsp;30, 2015, to be paid in cash or stock at Ms.&nbsp;Sooch's election. In June 2015, we granted her a fully-vested stock option
exercisable for 5,220 shares of our common stock, at an exercise price equal to $1.34 per share, in satisfaction of our obligations under such deferral arrangement. Effective February&nbsp;29, 2016,
Ms.&nbsp;Sooch agreed to defer 25% of her base salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an arms-length equity financing (including a public financing);
(ii)&nbsp;a change of control of the Company; or (iii)&nbsp;June&nbsp;30, 2016. Pursuant to the employee agreement, Ms.&nbsp;Sooch was granted 641,232 shares of common stock, with 320,616
shares vesting immediately and the other 320,616 shares vesting in 24 equal monthly installments at the end of each month beginning in November 2014, subject to continued service. In August 2016, the
shares that remained subject to vesting at such time became fully-vested upon the closing of our initial public offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreement with Charles L. Bisgaier, Ph.D.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We initially entered into an employment agreement with Dr.&nbsp;Bisgaier in November 2014 that, as amended, governed the terms of his
employment with us prior to the closing of our initial public offering. Under the terms of this agreement, Dr.&nbsp;Bisgaier was entitled to an annual base salary of $300,000 beginning on
January&nbsp;1, 2015. Dr.&nbsp;Bisgaier agreed to defer 20% of his salary from January&nbsp;1, 2015 until June&nbsp;30, 2015, to be paid in cash or stock at Dr.&nbsp;Bisgaier's election. In
June 2015, we granted him a fully-vested stock option exercisable for 4,474 shares of our common stock, with an exercise price equal to $1.34 per share, in satisfaction of our obligations under such
deferral arrangement. Effective February&nbsp;29, 2016, Dr.&nbsp;Bisgaier agreed to defer 25% of his base salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an
arms-length equity financing (including a public financing); (ii)&nbsp;a change of control of the Company; or (iii)&nbsp;June&nbsp;30, 2016. In connection with the merger with Michigan Life
Therapeutics, LLC (our predecessor company) we agreed to issue to Dr.&nbsp;Bisgaier 1,192,690 shares of our common stock, of which 238,538 shares vest in 18 equal monthly installments at the end of
each month beginning in November 2014, subject to continued service. In August 2016, the shares that remained subject to vesting at such time became fully-vested upon the closing of our initial public
offering. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreement with Jeffrey S. Mathiesen  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We initially entered into a letter agreement with Mr.&nbsp;Mathiesen in September 2015 that governed the terms of his employment with us prior
to the closing of our initial public offering. Under the terms of this agreement, as amended, Mr.&nbsp;Mathiesen was entitled to an annual base salary of $250,000. Effective February&nbsp;29,
2016, Mr.&nbsp;Mathiesen agreed to defer 25% of his base salary from March&nbsp;1, 2016 through the earlier of (i)&nbsp;the closing of an arms-length equity financing (including a public
financing); </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=400277,FOLIO='22',FILE='DISK125:[17ZBE1.17ZBE46001]DG46001A.;15',USER='C902265',CD=';5-APR-2017;17:00' -->
<A NAME="page_dg46001_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>(ii)&nbsp;a
change of control of the Company; or (iii)&nbsp;June&nbsp;30, 2016. Pursuant to the agreement, Mr.&nbsp;Mathiesen was granted an option exercisable for 48,093 shares of our common
stock, vesting in 36 equal monthly installments at the end of each month. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amended Employment Agreements with Named Executive Officers  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into new employment agreements with Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen effective on the closing of our
initial public offering that supersede the prior agreements and govern the terms of their employment with us (the Amended Employment Agreements). The initial term (the Initial Term) of each Amended
Employment Agreement is from the effective date, August&nbsp;8, 2016, through the third anniversary of the effective date and automatically renews for an additional one year period at the end of the
Initial Term and each anniversary thereafter, provided that at least 90&nbsp;days prior to the expiration of the Initial Term or any renewal term the board does not notify such officer of its
intention not to renew the employment period. Under the terms of the Amended Employment Agreement, Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen are entitled to initial annual base
salaries of $425,000, $300,000 and $325,000, respectively, each reviewed at least annually. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Amended Employment Agreement also entitles such officer to, among other benefits, the following compensation: (i)&nbsp;eligibility to receive an annual cash bonus of up to a
percentage of such officer's annual base salary as specified in his or her individual Amended Employment Agreement at the sole discretion of the board and as determined by the Compensation Committee
commensurate with the policies and practices applicable to other senior executive officers of the Company; (ii)&nbsp;an opportunity to participate in any stock option, performance share, performance
unit or other equity
based long-term incentive compensation plan commensurate with the terms and conditions applicable to other senior executive officers (the Plans); and (iii)&nbsp;participation in welfare benefit
plans, practices, policies and programs provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life,
accidental death and travel accident insurance plans and programs) to the extent available to our other senior executive officers. Each such officer is entitled to retain all shares of our common
stock and stock options he or she held as of the effective date (the Officer's Equity), and to the extent such officer remains employed as of the closing date of a change in control, the Officer's
Equity will fully vest, effective as of the closing date of the change in control. Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen are additionally entitled to certain severance
benefits pursuant to their employment agreements, the terms of which are described below under "&#151;Potential Payments Upon Termination or Change in Control." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;25, 2016, our Compensation Committee approved the award of options to purchase 600,000, 150,000 and 210,000 shares of our common stock to Ms.&nbsp;Sooch,
Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen, respectively, with a per share exercise price equal to the initial public offering price, which were granted in connection with our initial public
offering. For Ms.&nbsp;Sooch, 240,000 shares underlying her award were subject to performance conditions, with 120,000 shares to be earned upon the initiation of our first clinical trial and 120,000
shares to be earned upon the initiation of our second clinical trial. The first and second clinical trials were initiated in 2016, and all 240,000 shares underlying Ms.&nbsp;Sooch's award have been
earned, subject to time vesting conditions. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Equity Incentive Plan Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonequity incentive plan compensation is based on the achievement of corporate performance objectives, and then subject to adjustment following
an evaluation of corporate performance. In 2016, each of the Company's named executive officers had a target bonus, set forth as a percentage of annual base salary. The earned bonus was based on the
achievement of corporate performance objectives defined and weighted by the compensation committee, in consultation with our Chief Executive Officer, and primarily related to the Company's clinical
trials, financing activities and manufacturing initiatives. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=666948,FOLIO='23',FILE='DISK125:[17ZBE1.17ZBE46001]DG46001A.;15',USER='C902265',CD=';5-APR-2017;17:00' -->
<A NAME="page_dg46001_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
compensation committee assessed the Company's achievement of those objectives at year end, and calculated a total weighted average performance to objectives of 75% for 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth target and earned non-equity incentive plan compensation for 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Earned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% of<BR>
Base Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>212,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles L. Bisgaier, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>130,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments Upon Termination or Change in Control  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Amended Employment Agreements, regardless of the manner in which a named executive officer's service terminates, the named
executive officer is entitled to receive amounts earned during his or her term of service, including salary and other benefits. In addition, each of our named executive officers is eligible to receive
certain benefits pursuant to his or her agreement with us described above under "&#151;Agreements with our Named Executive Officers." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is permitted to terminate the employment of Ms.&nbsp;Sooch, Dr.&nbsp;Bisgaier and Mr.&nbsp;Mathiesen for the following reasons: (1)&nbsp;death or disability,
(2)&nbsp;Termination for Cause (as defined below) or (3)&nbsp;for any other reason or no reason. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
such officer is permitted Termination for Good Reason (as defined below) of such officer's employment. In addition, each such officer may terminate his or her employment upon
written notice to the Company 30&nbsp;days prior to the effective date of such termination. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of such officer's death during the employment period or a termination due to such officer's disability, such officer or his or her beneficiaries or legal representatives
shall be provided the sum of (a)&nbsp;any annual base salary earned, but unpaid, for services rendered to the Company on or prior to the date on which the employment period ends and (b)&nbsp;the
bonus that would have been payable to such officer subject to any performance conditions and (c)&nbsp;certain other benefits provided for in the employment agreement (the Unconditional
Entitlements). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of such officer's Termination for Cause by the Company or the termination of such officer's employment as a result of such officer's resignation other than a Termination for
Good Reason, such officer shall be provided the Unconditional Entitlements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a Termination for Good Reason by such officer or the exercise by the Company of its termination rights to terminate such officer other than by Termination for Cause,
death or disability, such officer shall be provided the Unconditional Entitlements and, subject to such officer signing and delivering to the Company and not revoking a general release of claims in
favor of the Company and certain related parties, the Company shall provide such officer a severance amount equal to (i)&nbsp;0.5-1.0 (which ratio varies based on the negotiated terms in the
agreement of such officer) times such officer's annual base salary as of the termination date less the Non-Compete Amount (if applicable) (as defined in his or her employment agreement) and
(ii)&nbsp;a prorated cash bonus for the year as well as continued medical coverage for 12&nbsp;months following such termination, immediate vesting of all stock options, which become immediately
exercisable in accordance with the stock option award documents, subject to the same conditions that would be applicable to such officer if he or she remained employed through the end of the
employment period and continued vesting of equity awards in accordance with the terms of the award agreements (the Conditional Benefits). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=220142,FOLIO='24',FILE='DISK125:[17ZBE1.17ZBE46001]DG46001A.;15',USER='C902265',CD=';5-APR-2017;17:00' -->
<A NAME="page_dg46001_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a change in control during the employment period or within two years after a change in control, if the Company terminates such officer other than due to such officer's
death or disability or a Termination for Cause, or such officer effects a Termination for Good Reason, the Company will pay to such officer, in a lump sum in cash within 30&nbsp;days after the
termination date, the aggregate of: (i)&nbsp;the
Unconditional Entitlements; and (ii)&nbsp;the amount equal to the product of 1.0-1.5 (which ratio varies based on the negotiated terms in the agreement of such officer) times the sum of
(y)&nbsp;such officer's annual base salary, and (z)&nbsp;the greater of the target bonus for the then current fiscal year under the Plans or any successor annual bonus plan and the average annual
bonus paid to or for the benefit of such officer for the prior three full years (or any shorter period during which such officer had been employed by the Company). In addition, the Company shall
provide such officer the Conditional Benefits minus such officer's severance amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the employment agreements, "Termination for Cause" means a termination of the officer's employment by the Company due to (A)&nbsp;an intentional act or acts of dishonesty
undertaken by the officer and intended to result in substantial gain or personal enrichment to the officer at the expense of the Company, (B)&nbsp;unlawful conduct or gross misconduct that is
willful and deliberate on the officer's part and that, in either event, is materially injurious to the Company, (C)&nbsp;the conviction of the officer of, or the officer's entry of a no contest or
nolo contendre plea to, a felony, (D)&nbsp;material breach by the officer of the officer's fiduciary obligations as an officer or director of the Company, (E)&nbsp;a persistent failure by the
officer to perform the duties and responsibilities of the officer's employment hereunder, which failure is willful and deliberate on the officer's part and is not remedied by the officer within
30&nbsp;days after the officer's receipt of written notice from the Company of such failure; or (F)&nbsp;material breach of any terms and conditions of the respective employment agreement by the
officer, which breach has not been cured by the officer within ten days after written notice thereof to the officer from the Company. No act or failure to act on the officer's part shall be considered
"dishonest," "willful" or "deliberate" unless intentionally done or omitted to be done by the officer in bad faith and without reasonable belief that the officer's action or omission was in the best
interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board shall be conclusively presumed to be done, or omitted to be done, by
the officer in good faith and in the best interests of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the employment agreements, "Termination for Good Reason" means a termination of the officer's employment by such officer within 30&nbsp;days of the Company's failure to cure, in
accordance with the procedures set forth below, any of the following events: (A)&nbsp;a reduction in the officer's annual base salary as in effect immediately prior to such reduction by more than
10% without the officer's written consent, unless such reduction is made pursuant to an across the board reduction applicable to all senior executives of the Company; (B)&nbsp;the removal of the
officer by the Company from the executive officer position held; (C)&nbsp;a material reduction in the officer's duties and responsibilities as in effect immediately prior to such reduction; or
(D)&nbsp;a material breach of any material provision of the employment agreement by the Company to which the officer shall have delivered a written notice to the board within 45&nbsp;days of the
officer's having actual knowledge of the occurrence of one of such events stating that the officer intends to terminate the officer's employment by Termination for Good Reason and specifying the
factual basis for such termination, and such event, if capable of being cured, shall not have been cured within 21&nbsp;days of the receipt of such notice. Notwithstanding the foregoing, a
termination shall not be treated as a Termination for Good Reason if the officer shall have consented in writing to the occurrence of the event giving rise to the claim of Termination for Good Reason. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=389348,FOLIO='25',FILE='DISK125:[17ZBE1.17ZBE46001]DG46001A.;15',USER='C902265',CD=';5-APR-2017;17:00' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di46001_1_26"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Fiscal Year-End 2016  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding restricted stock awards and outstanding stock options held by our named executive officers
as of December&nbsp;31, 2016: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="87pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="82pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=10 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OPTION AWARDS(1) </B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>NAME

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>GRANT<BR>
DATE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>VESTING<BR>
COMMENCEMENT<BR>
DATE </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>NUMBER OF<BR>
SECURITIES<BR>
UNDERLYING<BR>
UNEXERCISED<BR>
OPTIONS<BR>
EXERCISABLE<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>NUMBER OF<BR>
SECURITIES<BR>
UNDERLYING<BR>
UNEXERCISED<BR>
OPTIONS<BR>
UNEXERCISABLE<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OPTION<BR>
EXERCISE<BR>
PRICE<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>OPTION<BR>
EXPIRATION<BR>
DATE </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Mina Sooch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>June&nbsp;29, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>June&nbsp;29, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>June&nbsp;28, 2025</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>550,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;3, 2026</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Charles L. Bisgaier, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>June&nbsp;29, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>June&nbsp;29, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,474</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1.34</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>June&nbsp;28, 2025</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>137,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;3, 2026</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jeffrey S. Mathiesen</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;24, 2025</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;25, 2015</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>21,376</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>26,717</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>September&nbsp;24, 2025</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;4, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>17,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>192,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>August&nbsp;3, 2026</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>All
of the outstanding stock option awards were granted under our 2015 Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>Options
fully vested upon grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
shares underlying the option vest monthly in equal increments over a 36&nbsp;month period beginning on September&nbsp;30, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
shares underlying the option vest monthly in equal increments over a 48&nbsp;month period beginning on August&nbsp;4, 2016. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Benefit and Stock Plans  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amended and Restated 2015 Equity Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors initially adopted the 2015 Plan in April 2015, and our stockholders approved the 2015 Plan in April 2015. In April 2016,
our board of directors and stockholders approved the amendment and restatement of the 2015 Plan in order to increase the share reserve under the 2015 Plan, include an "evergreen" provision, allow
limited delegation of award authority to an executive officer and include certain annual limits on equity awards, which amendments became effective on August&nbsp;4, 2016. We refer to such amended
and restated plan as the 2015 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan provides for the grant of incentive stock options (ISOs), nonstatutory stock options (NSOs), stock
appreciation rights,
restricted stock awards, restricted stock unit awards (RSUs), performance-based stock awards, and other forms of equity compensation, or collectively, stock awards, all of which may be granted to
employees, including officers, non-employee directors and consultants of us and our affiliates. Additionally, the 2015 Plan provides for the grant of performance cash awards. ISOs may be granted only
to employees. All other awards may be granted to employees, including officers, and to non-employee directors and consultants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Reserve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;When initially adopted, the aggregate number of shares of our common stock that may be issued pursuant to stock awards
under the 2015
Plan was 1,000,000 shares. In addition, the maximum number of shares of our common stock that were issuable upon the exercise of ISOs under our 2015 Plan is 1,000,000 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
aggregate number of shares of our common stock initially reserved to be issued pursuant to stock awards under the 2015 Plan is 2,400,000 shares plus the number of shares that are
Returning Shares (as
defined in the 2015 Plan). The number of shares that remain available for issuance as of December&nbsp;31, 2016 are 355,200. Additionally, the number of shares of our common stock reserved for
issuance under our 2015 Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2017 and continuing through and including January&nbsp;1, 2026, to an amount
equal to 20% of the fully diluted shares as of December&nbsp;31 of the preceding calendar year, or a lesser number of shares </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=375234,FOLIO='26',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>determined
by our board of directors. The maximum number of shares of our common stock that may be issued upon the exercise of ISOs under our 2015 Plan is 4,800,000 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
person may be granted stock awards covering more than 1,000,000 shares of our common stock under our 2015 Plan during any calendar year pursuant to stock options, stock appreciation
rights and other stock awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value on the date the stock award is granted.
Additionally, no person may be granted in a calendar year a performance stock award covering more than 1,000,000 shares of our common stock or a performance cash award having a maximum value in excess
of $1,000,000. Such limitations are designed to help ensure that any deductions to which we would otherwise be entitled with respect to such awards will not be subject to the $1,000,000 limitation on
the income tax deductibility of compensation paid to any covered executive officer imposed by Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stock award granted under the 2015 Plan expires or otherwise terminates without being exercised in full, or is settled in cash, the shares of our common stock not acquired pursuant
to the stock award again will become available for subsequent issuance under the 2015 Plan. In addition, the following types of shares of our common stock under the 2015 Plan may become available for
the grant of new stock awards under the 2015 Plan: (1)&nbsp;shares that are forfeited to or repurchased by us prior to becoming fully vested; (2)&nbsp;shares withheld to satisfy income or
employment withholding taxes; or (3)&nbsp;shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2015 Plan may be previously unissued shares or reacquired shares
bought by us on the open market. As December&nbsp;31, 2016, 2,130,978 awards have been granted and 2,436 shares of our common stock have been issued under the 2015 Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors, or a duly authorized committee thereof, has the authority to administer the 2015 Plan. Our board
of directors
may also delegate to one or more of our officers the authority to (1)&nbsp;designate employees (other than other officers) to be recipients of certain stock awards, and (2)&nbsp;determine the
number of shares of common stock to be subject to such stock awards. Subject to the terms of the 2015 Plan, our board of directors or the authorized committee, referred to herein as the plan
administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted and the terms and conditions of the stock awards, including the period of their exercisability
and vesting schedule applicable to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike price or purchase price of awards
granted and the types of consideration to be paid for the award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
plan administrator has the authority to modify outstanding awards under our 2015 Plan. Subject to the terms of our 2015 Plan, the plan administrator has the authority to reduce the
exercise, purchase or strike price of any outstanding stock award, cancel any outstanding stock award in exchange for new stock awards, cash or other consideration, or take any other action that is
treated as a repricing under generally accepted accounting principles, with the consent of any adversely affected participant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator
determines the
exercise price for a stock option, within the terms and conditions of the 2015 Plan, provided that the exercise price of a stock option generally cannot be less than 100% of the fair market value of
our common stock on the date of grant. Options granted under the 2015 Plan vest at the rate specified by the plan administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
plan administrator determines the term of stock options granted under the 2015 Plan, up to a maximum of ten years. Unless the terms of an optionholder's stock option agreement
provide otherwise, if an optionholder's service relationship with us, or any of our affiliates, ceases for any reason other than disability, death or cause, the optionholder may generally exercise any
vested options for a period of three months following the cessation of service. The option term may be extended in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=331850,FOLIO='27',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
event that exercise of the option following such a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder's service relationship with
us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise
any vested options for a period of 12&nbsp;months in the event of disability and 18&nbsp;months in the event of death. In the event of a termination for cause, options generally terminate
immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration of its term. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acceptable
consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1)&nbsp;cash, check,
bank draft or money order, (2)&nbsp;a broker-assisted cashless exercise, (3)&nbsp;the tender of shares of our common stock previously owned by the optionholder, (4)&nbsp;a net exercise of the
option if it is an NSO, and (5)&nbsp;other legal consideration approved by the plan administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the plan administrator provides otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic relations order.
An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder's death. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Limitations On Incentive Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined at the time of grant, of our common stock with
respect to
ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will
generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of
any of our affiliates unless (1)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant, and (2)&nbsp;the term of the ISO
does not exceed five years from the date of grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are granted pursuant to restricted stock award agreements adopted by the plan
administrator.
Restricted stock awards may be granted in consideration for (1)&nbsp;cash, check, bank draft or money order, (2)&nbsp;services rendered to us or our affiliates, or (3)&nbsp;any other form of
legal consideration. Common stock acquired under a restricted stock award may, but need not, be subject to a share repurchase option in our favor in accordance with a vesting schedule to be determined
by the plan administrator. A restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. Except as otherwise provided in the applicable award
agreement, restricted stock awards that have not vested may be forfeited or repurchased by us upon the participant's cessation of continuous service for any reason. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock Unit Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the
plan
administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled by cash, delivery of stock, a combination
of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may
be credited in respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited
upon the participant's cessation of continuous service for any reason. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan
administrator.
The plan administrator determines the strike price for a stock appreciation right, which generally cannot be less than 100% of the fair market value of our common stock on the date of grant. Upon the
exercise of a stock appreciation right, we will pay the
participant an amount equal to the product of (1)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over the strike price, multiplied by (2)&nbsp;the
number of shares of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=276505,FOLIO='28',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>common
stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2015 Plan vests at the rate specified in the stock appreciation right
agreement as determined by the plan administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
plan administrator determines the term of stock appreciation rights granted under the 2015 Plan, up to a maximum of ten years. Unless the terms of a participant's stock appreciation
right agreement provides otherwise, if a participant's service relationship with us or any of our affiliates ceases for any reason other than cause, disability or death, the participant may generally
exercise any vested stock appreciation right for a period of three months following the cessation of service. The stock appreciation right term may be further extended in the event that exercise of
the stock appreciation right following such a termination of service is prohibited by applicable securities laws. If a participant's service relationship with us, or any of our affiliates, ceases due
to disability or death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation right for a
period of 12&nbsp;months in the event of disability and 18&nbsp;months in the event of death. In the event of a termination for cause, stock appreciation rights generally terminate immediately
upon the occurrence of the event giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the expiration of its term. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan permits the grant of performance-based stock and cash awards that may qualify as performance-based
compensation
that is not subject to the $1,000,000 limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section&nbsp;162(m) of the Code. To help assure that
the compensation attributable to performance-based awards will so qualify, our compensation committee can structure such awards so that stock or cash will be issued or paid pursuant to such award only
after the achievement of certain pre-established performance goals during a designated performance period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
performance goals that may be selected include one or more of the following: (1)&nbsp;earnings (including earnings per share and net earnings); (2)&nbsp;earnings before interest,
taxes and depreciation; (3)&nbsp;earnings before interest, taxes, depreciation and amortization; (4)&nbsp;earnings before interest, taxes, depreciation, amortization and legal settlements;
(5)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements and other income (expense); (6)&nbsp;earnings before interest, taxes, depreciation, amortization, legal
settlements, other income (expense) and stock-based compensation; (7)&nbsp;earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based
compensation and changes in deferred revenue; (8)&nbsp;total stockholder return; (9)&nbsp;return on
equity or average stockholder's equity; (10)&nbsp;return on assets, investment or capital employed; (11)&nbsp;stock price; (12)&nbsp;margin (including gross margin); (13)&nbsp;income (before
or after taxes); (14)&nbsp;operating income; (15)&nbsp;operating income after taxes; (16)&nbsp;pre-tax profit; (17)&nbsp;operating cash flow; (18)&nbsp;sales or revenue targets;
(19)&nbsp;increases in revenue or product revenue; (20)&nbsp;expenses and cost reduction goals; (21)&nbsp;improvement in or attainment of working capital levels; (22)&nbsp;economic value added
(or an equivalent metric); (23)&nbsp;market share; (24)&nbsp;cash flow; (25)&nbsp;cash flow per share; (26)&nbsp;share price performance; (27)&nbsp;debt reduction; (28)&nbsp;implementation
or completion of projects or processes (including, without limitation, clinical trial initiation, clinical trial enrollment, clinical trial results, new and supplemental indications for existing
products, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory approvals and product supply); (29)&nbsp;stockholders' equity;
(30)&nbsp;capital expenditures; (31)&nbsp;debt levels; (32)&nbsp;operating profit or net operating profit; (33)&nbsp;workforce diversity; (34)&nbsp;growth of net income or operating income;
(35)&nbsp;billings; (36)&nbsp;bookings; (37)&nbsp;employee retention; (38)&nbsp;initiation of phases of clinical trials and/or studies by specific dates; (39)&nbsp;patient enrollment rates;
(40)&nbsp;budget management; (41)&nbsp;submission to, or approval by, a regulatory body (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing or a product
candidate; (42)&nbsp;regulatory milestones; (43)&nbsp;progress of internal research or clinical programs; (44)&nbsp;progress of partnered programs; (45)&nbsp;partner satisfaction;
(46)&nbsp;timely </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=103427,FOLIO='29',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>completion
of clinical trials; (47)&nbsp;submission of INDs and new drug applications and other regulatory achievements; (48)&nbsp;research progress, including the development of programs;
(49)&nbsp;strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property); and (50)&nbsp;to the extent that an award is not intended to comply with
Section&nbsp;162(m) of the Code, other measures of performance selected by our board of directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
performance goals may be based on a company-wide basis, with respect to one or more business units, divisions, affiliates, or business segments, and in either absolute terms or
relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise (i)&nbsp;in the award agreement at the time the award
is granted or (ii)&nbsp;in such other document setting forth the performance goals at the time the goals are established, we will appropriately make adjustments in the method of calculating the
attainment of performance goals as follows: (1)&nbsp;to exclude restructuring and/or other nonrecurring charges; (2)&nbsp;to exclude exchange rate effects; (3)&nbsp;to exclude the effects of
changes to generally accepted accounting principles; (4)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (5)&nbsp;to exclude the effects of any "extraordinary
items" as determined under generally accepted accounting principles; (6)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (7)&nbsp;to assume that any business divested by us
achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (8)&nbsp;to exclude the effect of any change in the outstanding shares of
our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off, combination or exchange of shares or other similar
corporate change, or any distributions to common stockholders other than regular cash dividends; (9)&nbsp;to exclude the effects of stock-based compensation and the award of bonuses under our bonus
plans; (10)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; (11)&nbsp;to
exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles;
(12)&nbsp;to exclude the effect of any other unusual, non-recurring gain or loss or other extraordinary item; and (13)&nbsp;to exclude the effects of the timing of acceptance for review and/or
approval of submissions to the FDA or any other regulatory body. In addition, we retain the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of the
performance goals and to define the manner of calculating the performance criteria we select to use for such performance period. The performance goals may differ from participant to participant and
from award to award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may grant other awards based in whole or in part by reference to our common stock. The plan
administrator
will set the number of shares under the stock award and all other terms and conditions of such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes to Capital Structure.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there is a specified type of change in our capital structure, such as a stock split or
recapitalization, appropriate adjustments will be made to (1)&nbsp;the class and maximum number of shares reserved for issuance under the 2015 Plan, (2)&nbsp;the class and maximum number of shares
by which the share reserve may increase automatically each year, (3)&nbsp;the class and maximum number of shares that may be issued upon the exercise of ISOs, (4)&nbsp;the class and maximum number
of shares subject to stock awards that can be granted in a calendar year (as established under the 2015 Plan pursuant to Section&nbsp;162(m) of the Code) and (5)&nbsp;the class and number of
shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Transactions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain specified significant corporate transactions, the plan administrator has the discretion
to take any
of the following actions with respect to stock awards:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring entity or parent company; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=34,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=427747,FOLIO='30',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving or acquiring entity or parent company; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> accelerate the vesting of the stock award and provide for its termination prior to the effective time of the corporate transaction; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> arrange for the lapse of any reacquisition or repurchase right held by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cancel or arrange for the cancellation of the stock award in exchange for such cash consideration, if any, as our board of directors may deem
appropriate; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> make a payment equal to the excess of (1)&nbsp;the value of the property the participant would have received upon exercise of the stock award
over (2)&nbsp;the exercise price otherwise payable in connection with the stock award. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
plan administrator is not obligated to treat all stock awards, even those that are of the same type, in the same manner. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2015 Plan, a corporate transaction is generally the consummation of (1)&nbsp;a sale or other disposition of all or substantially all of our assets, (2)&nbsp;a sale or other
disposition of at least 90% of our outstanding securities, (3)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation, or (4)&nbsp;a merger,
consolidation or similar transaction following which we are the surviving corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged
into other property by virtue of the transaction. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator may provide, in an individual award agreement or in any other written agreement between a
participant and
us that the stock award will be subject to additional
acceleration of vesting and exercisability in the event of a change of control. For example, certain of our employees may receive an award agreement that provides for vesting acceleration upon the
individual's termination without cause or resignation for good reason (including a material reduction in the individual's base salary, duties, responsibilities or authority, or a material relocation
of the individual's principal place of employment with us) in connection with a change of control. Under the 2015 Plan, a change of control is generally (1)&nbsp;the acquisition by a person or
entity of more than 50% of our combined voting power other than by merger, consolidation or similar transaction; (2)&nbsp;a consummated merger, consolidation or similar transaction immediately after
which our stockholders cease to own more than 50% of the combined voting power of the surviving entity; (3)&nbsp;a consummated sale, lease or exclusive license or other disposition of all or
substantially of our assets; or (4)&nbsp;the replacement of a majority of the directors who were on the board of directors at the time the 2015 Plan became effective, or the Incumbent Board, by
directors who were not elected to the board by a majority of the directors who were sitting on the Incumbent Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendment and Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2015 Plan, provided that such
action does not
materially impair the existing rights of any participant without such participant's written consent. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our
2015 Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2016, our board of directors and stockholders approved the 2016 Employee Stock Purchase Plan (ESPP), in order to enable eligible
employees to purchase shares of our common stock at a discount following the date of our initial public offering. The ESPP became effective on August&nbsp;4, 2016. The purpose of the ESPP is to
retain the services of new employees and secure the services of new and existing employees while providing incentives for such individuals to exert maximum efforts toward our success and that of our
affiliates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=35,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=893642,FOLIO='31',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share Reserve.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The ESPP authorizes the issuance of 150,000 shares of our common stock pursuant to purchase rights granted to our
employees or to
employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1 of each calendar year, from
January&nbsp;1, 2017 (assuming the ESPP becomes effective before such date)
through January&nbsp;1, 2026 by the least of (1)&nbsp;1.0% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year and (2)&nbsp;75,000
shares. The ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section&nbsp;423 of the Code. As of the date hereof, no shares of our common stock have been
purchased under the ESPP. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has delegated its authority to administer the ESPP to our compensation committee. The ESPP is
implemented
through a series of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with durations of not more than 27&nbsp;months, and may specify shorter purchase
periods within each offering. Each offering will have one or more purchase dates on which shares of our common stock will be purchased for employees participating in the offering. An offering may be
terminated under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payroll Deductions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers, employed by us or by any of our designated
affiliates, may
participate in the ESPP and may contribute, normally through payroll deductions, up to an amount determined by the board of directors, but not exceeding 15% of their earnings for the purchase of our
common stock under the ESPP. Unless otherwise determined by our board of directors, common stock will be purchased for accounts of employees participating in the ESPP at a price per share equal to the
lower of (1)&nbsp;85% of the fair market value of a share of our common stock on the first date of an offering or (2)&nbsp;85% of the fair market value of a share of our common stock on the date
of purchase. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in the ESPP, as
determined by our
board of directors: (1)&nbsp;customarily employed for more than 20&nbsp;hours per week, (2)&nbsp;customarily employed for more than five months per calendar year or (3)&nbsp;continuous
employment with us or one of our affiliates for a period of time, not to exceed two years. No employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock based
on the fair market value per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any
purchase rights under the ESPP if immediately after such rights are granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value pursuant to
Section&nbsp;424(d) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes to Capital Structure.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there occurs a change in our capital structure through such actions as a stock split,
merger,
consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares,
exchange of shares, change in corporate structure or similar transaction, the board of directors will make appropriate adjustments to (1)&nbsp;the number of shares reserved under the ESPP,
(2)&nbsp;the maximum number of shares by which the share reserve may increase
automatically each year and (3)&nbsp;the number of shares and purchase price of all outstanding purchase rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate Transactions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain significant corporate transactions, including the consummation of: (1)&nbsp;a sale of
all our
assets, (2)&nbsp;the sale or disposition of 90% of our outstanding securities, (3)&nbsp;a merger or consolidation where we do not survive the transaction and (4)&nbsp;a merger or consolidation
where we do survive the transaction but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction,
any then-outstanding rights to purchase our stock under the ESPP may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=36,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=160936,FOLIO='32',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<A NAME="page_di46001_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>surviving
or acquiring entity (or its parent company) elects not to assume, continue or substitute for such purchase rights, then the participants' accumulated payroll contributions will be used to
purchase shares of our common stock within ten business days prior to such corporate transaction, and such purchase rights will terminate immediately. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Amendments, Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend or terminate our ESPP, provided that except in certain
circumstances
any such amendment or termination may not materially impair any outstanding purchase rights without the holder's consent. We will obtain stockholder approval of any amendment to our ESPP as required
by applicable law or listing requirements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=37,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=606691,FOLIO='33',FILE='DISK125:[17ZBE1.17ZBE46001]DI46001A.;10',USER='C902265',CD=';5-APR-2017;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk46001_1_34"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk46001_certain_relationships_and_related-party_transactions"> </A>
<A NAME="toc_dk46001_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following includes a summary of transactions since January&nbsp;1, 2016 to which we have been a party, in which the amount involved in the
transaction exceeded $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family
of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change of control and other arrangements, which are
described under "Executive Officer and Director Compensation." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lease with Michigan Life Ventures,&nbsp;LLC  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2016, we entered into sublease agreement with Michigan Life Ventures&nbsp;LLC ("MLV"). Pursuant to the lease we currently have
limited use office space in the facility in Northville, Michigan for a fixed rental fee of $1. The current cancelable lease expires in September 2017. Dr.&nbsp;Bisgaier, our Chief Scientific
Officer, Chairman of our board of directors and co-founder, and Mr.&nbsp;Lowenschuss, our former Chief Legal Officer and Secretary and co-founder, are members of MLV. Dr.&nbsp;Bisgaier and
Mr.&nbsp;Lowenschuss are also both beneficial owners of more than 5% of our capital stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pfizer&nbsp;Inc. License Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2011, we entered into the Pfizer Agreement for a worldwide exclusive license to certain patent rights to make, use, sell, offer for
sale and import the clinical product candidate gemcabene. In exchange for this license, we agreed to issue shares of our common stock to Pfizer representing 15% of our fully diluted capital at the
close of our first arms-length Series&nbsp;A financing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
agreed to make milestone payments totaling up to $37&nbsp;million upon the achievement of certain milestones, including the first regulatory submission in any country, regulatory
approval in each of the United States, Europe and Japan, the first anniversary of the first regulatory approval in any country, and upon achieving certain aggregate sales levels of gemcabene or any
product containing gemcabene. Future milestone payments under the Pfizer Agreement, if any, are not expected to begin for at least several years and extend over a number of subsequent years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also agreed to pay Pfizer tiered royalties on a country-by-country basis based upon the annual amount of net sales as specified in the Pfizer Agreement until expiration of the
last valid claim of the licensed patent rights, including any patent term extensions or supplemental protection certificates. The royalty rates range from the high single digits to the low teens
depending on the level of net sales. Under the Pfizer Agreement we are obligated to use commercially reasonable efforts to develop and commercialize gemcabene. In addition, Pfizer has a non-exclusive,
sub licensable, royalty-free right and license for non-commercial research or development purposes to intellectual property rights relating to gemcabene that are developed by us after the effective
date of the license with Pfizer. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2015, upon the closing of our Series&nbsp;A preferred stock financing, we issued 675,250 shares of our common stock to Pfizer in connection with the first equity payment,
pursuant to which Pfizer became the owner of more than 5% of our capital stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Pfizer Agreement will expire upon expiration of the last royalty term. Either party may terminate the Pfizer Agreement for the other party's uncured material breach and specified
bankruptcy events. Pfizer may terminate the Pfizer Agreement if we or any of our sublicensees challenge the validity, enforceability or ownership of the licensed patents. Furthermore, upon termination
of the license agreement for cause by Pfizer, we must grant Pfizer a non-exclusive license to use any intellectual property rights arising from the development or commercialization of gemcabene.
Additionally, Pfizer may revoke the license if we are unable to adequately commercialize gemcabene by April 2021. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=665534,FOLIO='34',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Promissory Notes, Convertible Note Financings and Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From March 2009 to October 2014, we borrowed an aggregate of $318,200 from, and issued promissory notes to, Dr.&nbsp;Bisgaier and our former
Chief Operating Officer, Ms.&nbsp;McShane. These promissory notes were refinanced in connection with the convertible note financing discussed below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November&nbsp;1, 2014, we entered into a convertible note financing pursuant to which we issued 8% convertible notes in an aggregate principal amount of $2.7&nbsp;million to
various investors from November&nbsp;1, 2014 to February&nbsp;18, 2015. On March&nbsp;31, 2015, we also entered into a stock purchase agreement pursuant to which we agreed to issue and sell to
various investors shares of our Series&nbsp;A convertible preferred stock at a per share price of $6.70585 (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our
stock, which became effective April&nbsp;27, 2016). In connection with the stock purchase agreement, 125% of the unpaid principal plus any unpaid accrued interest on the notes was converted into
shares of our Series&nbsp;A convertible preferred stock. Each share of Series&nbsp;A convertible preferred stock converted into one share of our common stock upon the closing of our initial public
offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the principal amount of convertible notes and shares of Series&nbsp;A convertible preferred stock purchased or received upon conversion by members of our
board of directors, executive officers or related parties. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Noteholder

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
Convertible<BR>
Note ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Received<BR>
Upon<BR>
Conversion<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Shares of<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Received<BR>
Upon<BR>
Conversion of<BR>
Principal<BR>
and Interest<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Investment<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Series&nbsp;A<BR>
Convertible<BR>
Preferred<BR>
Stock<BR>
Investment<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Charles L. Bisgaier Trust Dated November&nbsp;8, 2000(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>311,517</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>59,561</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>399,406</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Margaret M. McShane Revocable Trust(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>47,532</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,088</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Arvinder S. Sooch Trust Dated September 2006(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,567</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,743</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,511</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,544</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Lowenschuss(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,708</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,574</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>18,641</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michelle Johnson(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,693</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31,467</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk Revocable Trust(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,457</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>400,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>75,080</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>503,473</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BWA Gemphire Investment Group,&nbsp;LLC(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>95,439</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>640,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Bisgaier,
our Chief Scientific Officer and Chairman of our Board and a beneficial owner of more than 5% of our capital stock, is the trustee of The
Charles L. Bisgaier Trust Dated November&nbsp;8, 2000.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;McShane,
our former Chief Operating Officer is the trustee of The Margaret M. McShane Revocable Trust.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
spouse of Ms.&nbsp;Sooch, our Chief Executive Officer and a member of our Board and a beneficial owner of more than 5% of our capital stock, is the trustee of
the Arvinder S. Sooch Trust Dated September 2006. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=39,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=517669,FOLIO='35',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Edward
Lowenschuss is the brother of Mr.&nbsp;Lowenschuss, our former Chief Legal Officer and Secretary and a beneficial owner of more than 5% of our capital
stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Michelle
Johnson is the sister-in-law of Dr.&nbsp;Bisgaier, our Chief Scientific Officer and Chairman of our Board and a beneficial owner of more than 5% of our
capital stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Hawryluk
is a member of our Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Sassine
is a member of our Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Kenneth
Kousky, a member of our Board, is the manager of BWA Gemphire Investment Group,&nbsp;LLC.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
July&nbsp;31, 2015, December&nbsp;11, 2015, February&nbsp;25, 2016 and April&nbsp;14, 2016, we entered into convertible note financings in which we issued 8% convertible notes
in an aggregate principal amount of $10.6&nbsp;million to various investors. Under the terms of the convertible notes, the outstanding principal, plus accrued interest, under such notes converted
into shares of our common stock at a conversion price of $6.70585 per share (which was adjusted from $2.15 in connection with the 1-for-3.119 reverse split of our stock, which became effective on
April&nbsp;27, 2016) immediately prior to the closing of our initial public offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the principal amount of convertible notes purchased by members of our board of directors, executive officers or related parties. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Noteholder

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Principal<BR>
Amount of<BR>
Convertible<BR>
Note($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Charles L. Bisgaier Trust Dated November&nbsp;8, 2000(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Margaret M. McShane Revocable Trust(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Arvinder S. Sooch Trust Dated September 2006(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Edward Lowenschuss(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michelle Johnson(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk Revocable Trust(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Beverly Selnick Revocable Living Trust(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bisgaier Family,&nbsp;LLC(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BWA Gemphire Investment Group II,&nbsp;LLC(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>746,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dena Marie Bisgaier(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stanley Bisgaier(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Excel Venture Fund II,&nbsp;L.P.(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Bisgaier,
our Chief Scientific Officer and Chairman of our Board and a beneficial owner of more than 5% of our capital stock, is the trustee of The
Charles L. Bisgaier Trust Dated November&nbsp;8, 2000.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;McShane,
our former Chief Operating Officer is the trustee of The Margaret M. McShane Revocable Trust.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
spouse of Ms.&nbsp;Sooch, our Chief Executive Officer, a member of our Board and a beneficial owner of more than 5% of our capital stock, is the trustee of the
Arvinder S. Sooch Trust Dated September 2006. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=40,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=1033192,FOLIO='36',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Edward
Lowenschuss is the brother of Mr.&nbsp;Lowenschuss, our former Chief Legal Officer and Secretary and a beneficial owner of more than 5% of our capital
stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Michelle
Johnson is the sister-in-law of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our Board and a beneficial owner of more than 5% of our
capital stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Hawryluk
is a member of our Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Sassine
is a member of our Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;Selnick,
the mother of Mr.&nbsp;Lowenschuss, our former Chief Legal Officer and Secretary and a beneficial owner of more than 5% of our capital stock,
is the trustee of The Beverly Selnick Revocable Living Trust.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Bisgaier,
our Chief Scientific Officer, Chairman of our Board and a beneficial owner of more than 5% of our capital stock, is the manager of the Bisgaier
Family,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Mathiesen,
our Chief Financial Officer, held these notes jointly with his spouse.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Kenneth
Kousky, a member of our Board, is the manager of BWA Gemphire Investment Group II,&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Lichtinger
is a member of our Board.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ms.&nbsp;Bisgaier
is the daughter of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our Board and a beneficial owner of more than 5% of our
capital stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Bisgaier
is the son of Dr.&nbsp;Bisgaier, our Chief Scientific Officer, Chairman of our Board and a beneficial owner of more than 5% of our capital
stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Gullans,
a member of our Board, is the Manager of Excel Venture Fund II,&nbsp;L.P.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Investor Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November&nbsp;1, 2014, we entered into a shareholders agreement with the Charles L. Bisgaier Trust dated November&nbsp;8, 2000, as
amended, of which Dr.&nbsp;Bisgaier is the Trustee, Mr.&nbsp;Lowenschuss, Ms.&nbsp;McShane, Dr.&nbsp;Oniciu and Ms.&nbsp;Sooch. The agreement contains rights of first offer, drag-along
rights and tag-along rights. Those rights terminated upon the closing of our initial public offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November&nbsp;1, 2014, we entered into a voting agreement with the Charles L. Bisgaier Trust dated November&nbsp;8, 2000, as amended, of which Dr.&nbsp;Bisgaier is the Trustee,
Mr.&nbsp;Lowenschuss, Ms.&nbsp;McShane, Dr.&nbsp;Oniciu and Ms.&nbsp;Sooch (collectively, the "Voting Agreement Shareholders"). The agreement obligates the Voting Agreement Shareholders to
vote all of their shares of capital stock so as to elect three members of the Board as designated by the Voting Agreement Shareholders. Those rights terminated upon the closing of our initial public
offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our Series&nbsp;A convertible preferred stock financing, we entered into an investor rights agreement and right of first refusal and co-sale agreement containing
voting rights, information rights, rights of first refusal and co-sale and registration rights, among other things, with each of the holders of our Series&nbsp;A convertible preferred stock. On
April&nbsp;14, 2016, we amended the investor rights agreement to provide registration rights to certain holders of our convertible notes. As detailed above, certain members of our board of
directors, executive officers and related parties were holders of our Series&nbsp;A convertible preferred stock prior to the closing of our initial public offering. These rights terminated upon the
closing of our initial public offering, except for the registration rights described below. These registration rights will terminate as to a given holder of registrable securities upon the earlier of
(i)&nbsp;five years following the closing of our initial public offering, (ii)&nbsp;after the consummation of a liquidation event and (iii)&nbsp;when freely tradeable under Rule&nbsp;144 of
the Securities Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=41,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=839458,FOLIO='37',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_38"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At any time beginning six months after our initial public offering date, upon the written request of certain of the holders of the registrable
securities then outstanding that we file&nbsp;a registration statement under the Securities Act covering the registration of the registrable securities having an aggregate offering price to the
public of not less than $5&nbsp;million, we will be obligated to notify all holders of registrable securities of such request and to use our reasonable best efforts to register the sale of all
registrable securities that holders may request to be registered. We are not required to effect more than two registration statements which are declared or ordered effective. We may postpone the
filing or effectiveness of a registration statement for up to 90&nbsp;days once in any twelve month period if our Board determines in its good faith judgment that such registration and offering
would materially and adversely affect us. As of March&nbsp;27, 2017, the holders of 1,436,161 shares were entitled to these demand registration rights. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Piggyback" Registration Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we register any securities for public sale, holders of registration rights will have the right to include their shares in the registration
statement. These piggyback registration rights are subject to specified conditions and limitations, including the right of the underwriters of any underwritten offering to limit the number of shares
having registration rights to be included in the registration statement, but not below 30% of the total number of shares included in the registration statement. As of March&nbsp;27, 2017, the
holders of 1,436,161 shares were entitled to these piggyback registration rights. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-3 Registration Rights  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, holders of at least 20% of the outstanding registrable securities
will have the right to demand that we file&nbsp;a registration statement on Form&nbsp;S-3 so long as the aggregate price to the public of the securities to be sold under the registration statement
on Form&nbsp;S-3 is at least $5&nbsp;million. We are not required to effect more than two registrations on Form&nbsp;S-3 in any 12-month period. The right to have such shares registered on
Form&nbsp;S-3 is further subject to other specified conditions and limitations. Upon such a request, we will be required to use our reasonable best efforts to file the registration as soon as
practicable. As of March&nbsp;27, 2017, the holders of 1,436,161 shares were entitled to these Form&nbsp;S-3 registration rights. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have entered, and intend to continue to enter, into separate indemnification agreements with our directors and executive officers, in
addition to the indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require us to indemnify our
directors and officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of their
services as one of our directors or officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and indemnification agreements
are necessary to attract and retain qualified persons as directors and officers. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation and amended and restated bylaws limit our directors' liability to the fullest extent permitted under Delaware corporate law.
Delaware corporate law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for
liability:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any transaction from which the director derives an improper personal benefit; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=42,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=604223,FOLIO='38',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> under Section&nbsp;174 of the Delaware General Corporation Law (unlawful payment of dividends or redemption of shares); or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any breach of a director's duty of loyalty to the corporation or its stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors
shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware
law and our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and
officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to payment or
reimbursement of reasonable expenses (including attorneys' fees and disbursements) in advance of the final disposition of the proceeding. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Insider Participation in Initial Public Offering  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our principal stockholders and their affiliated entities, including stockholders affiliated with our officers and directors,
purchased an aggregate of 659,370 shares of our common stock in our initial public offering at $10.00 per share, which is the same public offering price at which shares were sold to all investors in
the initial public offering. The following table summarizes common stock purchased in our initial public offering by our executive officers, members of our board of directors and entities who held
more than 5% of our outstanding capital stock at the time of the purchase. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% stockholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Excel Ventures II&nbsp;GP,&nbsp;LLC(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Lowenschuss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,120</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>111,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Executive Officers</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mina Sooch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>525,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Charles Bisgaier</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>517,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jeffrey S. Mathiesen</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Seth Reno</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Steven R. Gullans, Ph.D.(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>500,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth W. Kousky</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our
director, Dr.&nbsp;Gullans, is a Manager of Excel.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
25,000 shares of common stock purchased by the P. Kent Hawryluk Revocable Trust, of which Mr.&nbsp;Hawryluk is the trustee.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=43,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=108096,FOLIO='39',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Insider Participation in March Private Placement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain of our directors and 5% holders participated in our March 2017 private placement wherein we issued and sold units at a price of $9.47
per unit, with each unit consisting of one share of our common stock and a warrant to purchase 0.75 shares of common stock. The warrants have an exercise price of $10.40 per share and are exercisable
for a period of five years from the date of issuance. The following table summarizes units purchased in the private placement by our directors and entities who held more than 5% of our outstanding
capital stock at the time of the purchase. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Units<BR>
Purchased </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Purchase<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Greater than 5% stockholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cormorant Asset Management,&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,798</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>499,997.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Excel Venture Fund II,&nbsp;LLC(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,798</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>499,997.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pedro Lichtinger</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,559</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>99,993.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Sassine</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,119</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>199,996.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>P. Kent Hawryluk(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>236,750.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our
director, Dr.&nbsp;Gullans, is a Manager of Excel.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Purchased
by the P. Kent Hawryluk Revocable Trust, of which Mr.&nbsp;Hawryluk is the trustee.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Private Placement Registration Rights Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;10, 2017, the Company entered into a Securities Purchase Agreement with certain accredited investors (the "Purchasers") pursuant
to which the Company, in a private placement (the "Private Placement"), agreed to issue and sell to the Purchasers units, each of which consisted of one share of the Company's common stock, par value
$0.001 per share (the "Common Stock"), and a warrant to purchase 0.75 shares of Common Stock (the "Warrants"). In connection with the Private Placement, the Company entered into a Registration Rights
Agreement with the Purchasers, dated as of March&nbsp;10, 2017 (the "Registration Rights Agreement"), pursuant to which the Company has agreed to file&nbsp;a registration statement with the SEC
covering the resale of the shares of Common Stock sold in the Private Placement and the shares of Common Stock issuable upon exercise of the Warrants. The Company has agreed to file such registration
statement within 30&nbsp;days of the closing of the Private Placement. The Registration Rights Agreement includes customary indemnification rights in connection with the registration statement. As
of March&nbsp;27, 2017, the holders of 2,317,460 shares were party to the Registration Rights Agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Transactions with Related Parties  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To assist the Company in complying with its disclosure obligations and to enhance the Company's disclosure controls, the Board approved a formal
policy in June 2016 regarding related person transactions. A "related person" is a director, officer, nominee for director or a more than 5% stockholder (of any class of the Company's voting stock)
since the beginning of the Company's last completed fiscal year, and their immediate family members. A related person transaction is any
transaction or any series of transactions in which the Company was or is to be a participant, the amount involved exceeds $120,000, and in which any related person had or will have a direct or
indirect material interest. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=44,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=52776,FOLIO='40',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the policy establishes a process for identifying related persons and procedures for reviewing and approving such related person transactions. In addition, directors and
executive officers are required to complete an annual questionnaire in connection with the Company's proxy statement for its annual meeting of stockholders, which includes questions regarding related
person transactions, and such persons also are required to provide written notice to the Company or outside legal counsel of any updates to such information prior to the annual meeting. Further, the
Company's legal, financial and other departments have established additional procedures to assist the Company in identifying existing and potential related person transactions and other potential
conflict of interest transactions, including policies and procedures designed to comply with Auditing Standard No.&nbsp;18 issued by the Public Company Accounting Oversight Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee and/or the independent directors of the Board review such proposed business transactions to ensure that the Company's involvement in such transactions is on terms
comparable to those that could be obtained in arm's length dealings with an unrelated third party and is in the best interests of the Company and its stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, under the Code of Business Conduct and Ethics, the Company's employees, officers and directors are discouraged from entering into any transaction that may cause a conflict
of interest for the Company. In addition, they must report any potential conflict of interest, including related person transactions, to their supervisor or the compliance officer, as defined in the
Code of Business Conduct and Ethics. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=45,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=692358,FOLIO='41',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk46001_additional_information"> </A>
<A NAME="toc_dk46001_2"> </A>
<BR></FONT><FONT SIZE=2><B>  ADDITIONAL INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Proposals to be Presented at Next Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requirements for Stockholder Proposals to be Brought Before an Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Amended and Restated Bylaws provide that for
stockholder
nominations to our Board or other proposals to be considered at an annual meeting, the stockholder must give timely notice thereof in writing to the Secretary at Gemphire Therapeutics&nbsp;Inc.,
17199 N. Laurel Park Drive, Suite&nbsp;401, Livonia, Michigan&nbsp;48152. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
be timely for our company's 2018 Annual Meeting of Stockholders, a stockholder's notice must be delivered to or mailed and received by our Secretary at our principal executive offices
not earlier than the close of business on January&nbsp;23, 2018 and not later than the close of business on February&nbsp;22, 2018. A stockholder's notice to the Secretary must set forth as to
each matter the stockholder proposes to bring before the annual meeting the information required by applicable law and our bylaws. In no event will the public announcement of an adjournment or a
postponement of our annual meeting commence a new time period for the giving of a stockholder's notice as provided above. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requirements for Stockholder Proposals to be Considered for Inclusion in our Proxy Materials.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stockholder proposals submitted pursuant
to
Rule&nbsp;14a-8 under the Exchange Act and intended to be presented at our 2018 annual meeting of stockholders must be received by us not later than Tuesday, December&nbsp;12, 2017 in order to be
considered for inclusion in our proxy materials for that meeting. A stockholder's notice to the Secretary must set forth as to each matter the stockholder proposes to bring before the annual meeting
the information required by applicable law and our bylaws. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Section&nbsp;16(a) Beneficial Ownership Reporting Compliance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16 of the Exchange Act requires our directors, executive officers and any persons who own more than 10% of our common stock, to
file initial reports of ownership and reports of changes in ownership with the SEC. Such persons are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) forms that they
file. Based solely on our review of the copies of such forms furnished to us and written representations from the directors and executive officers, we believe that all Section&nbsp;16(a) filing
requirements were timely met in 2016. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Available Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will mail without charge, upon written request, a copy of our annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016,
including the financial statements and list of exhibits, and any exhibit specifically requested. Requests should be sent to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk46001_gemphire_therapeutics_inc._171__gem03599"> </A>
<A NAME="toc_dk46001_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Gemphire Therapeutics&nbsp;Inc.<BR>  17199 N. Laurel Park Drive, Suite&nbsp;401, Livonia, Michigan 48152<BR>  Attn: Director of Finance    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The annual report on Form&nbsp;10-K is also available at http://ir.gemphire.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Householding"&#151;Stockholders Sharing the Same Address  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC has adopted rules that permit companies and intermediaries (such as brokers) to implement a delivery procedure called "householding."
Under this procedure, multiple stockholders who reside at the same address may receive a single copy of our annual report on Form&nbsp;10-K and proxy materials unless the affected stockholder has
provided other instructions. This procedure reduces printing costs and postage fees, and helps protect the environment as well. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=46,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=633994,FOLIO='42',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<A NAME="page_dk46001_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg46001a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that a number of brokers with account holders who are our stockholders will be "householding" our annual report on Form&nbsp;10-K and proxy materials. A single set of an
annual report on Form&nbsp;10-K and other proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from one or more of the
affected stockholders. Once you have received notice from your broker that it will be "householding" communications to your address, "householding" will continue until you are notified otherwise or
until you revoke your consent. Stockholders may revoke their consent at any time by contacting your broker. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
written or oral request, we will undertake to promptly deliver a separate copy of the annual report on Form&nbsp;10-K and other proxy materials to any stockholder at a shared
address to which a single copy of any of those documents was delivered. To receive a separate copy of the annual report on Form&nbsp;10-K and other proxy materials, you may write our Director of
Finance at 17199 N. Laurel Park Drive, Suite&nbsp;401, Livonia, Michigan 48152, Attn: Director of Finance, or arabourn@gemphire.com, or call (734)&nbsp;245-1700. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
stockholders who share the same address and currently receive multiple copies of our annual report on Form&nbsp;10-K and other proxy materials who wish to receive only one copy in
the future can contact their bank, broker or other holder of record to request information about "householding" or our Director of Finance at the address or telephone number listed above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk46001_other_matters"> </A>
<A NAME="toc_dk46001_4"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board does not presently intend to bring any other business before the meeting and, so far as is known to the Board, no matters are to be
brought before the meeting except as specified in the notice of the meeting. As to any business that may arise and properly come before the meeting, however, it is intended that proxies, in the form
enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting such proxies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=47,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=186095,FOLIO='43',FILE='DISK125:[17ZBE1.17ZBE46001]DK46001A.;11',USER='ABEAULI',CD=';6-APR-2017;13:32' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">MMMMMMMMMMMM .   MMMMMMMMMMMMMMM C123456789 000004 000000000.000000 ext 000000000.000000 ext   000000000.000000 ext 000000000.000000 ext 000000000.000000 ext   000000000.000000 ext ENDORSEMENT_LINE______________ SACKPACK_____________   Electronic Voting Instructions Available 24 hours a day, 7 days a week!   Instead of mailing your proxy, you may choose one of the voting methods   outlined below to vote your proxy. VALIDATION DETAILS ARE LOCATED BELOW IN   THE TITLE BAR. Proxies submitted by the Internet or telephone must be   received by 11:59 PM Eastern Time May 22, 2017. MR A SAMPLE DESIGNATION (IF   ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 Vote by Internet &#149; Go to   www.envisionreports.com/GEMP &#149; Or scan the QR code with your smartphone &#149;   Follow the steps outlined on the secure website Vote by telephone &#149; Call toll   free 1-800-652-VOTE (8683) within the USA, US territories &amp; Canada on a   touch tone telephone &#149; Follow the instructions provided by the recorded   message Using a black ink pen, mark your votes with an X as shown in this   example. Please do not write outside the designated areas. q IF YOU HAVE NOT   VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND   RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Proposals &#151; The Board   of Directors recommends a vote FOR all nominees and FOR Proposal 2. 1.   Election of Directors: + For Withhold For Withhold 01 - Charles L. Bisgaier,   Ph.D. 02 - Kenneth Kousky ForAgainst Abstain 2. Proposal to ratify the   appointment of Ernst &amp; Young LLP as our independent registered public   accounting firm for the fiscal year ending December 31, 2017. Non-Voting   Items Change of Address &#151; Please print your new address below. Comments &#151;   Please print your comments below. Meeting Attendance Mark the box to the   right if you plan to attend the Annual Meeting. Authorized Signatures &#151; This   section must be completed for your vote to be counted. &#151; Date and Sign Below   Please sign exactly as name(s) appears hereon. Joint owners should each sign.   When signing as attorney, executor, administrator, corporate officer,   trustee, guardian, or custodian, please give full title. Date (mm/dd/yyyy) &#151;   Please print date below. Signature 1 &#151; Please keep signature within the box.   Signature 2 &#151; Please keep signature within the box. MMMMMMMC 1234567890 J N T   MR A SAMPLE (THIS AREA IS SET UP TO ACCOMMODATE 140 CHARACTERS) MR A SAMPLE   AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND MR A   SAMPLE AND MR A SAMPLE AND MR A SAMPLE AND + 2 1 D V3 2 8 4 0 3 1 02KTAB   MMMMMMMMM C B A Annual Meeting Proxy Card1234 5678 9012 345 X IMPORTANT   ANNUAL MEETING INFORMATION </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1209" src="g101602bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=48,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=901300,FOLIO='',FILE="DISK126:[17ZBE2.17ZBE46002]10160-2-BG_ZBE46002.CHC",USER="CMATTI",CD='Apr  4 19:09 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">. q IF YOU HAVE   NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION, DETACH   AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. q Proxy &#151; Gemphire   Therapeutics Inc. Notice of 2017 Annual Meeting of Shareholders 17199 N.   Laurel Park Drive, Liviona, MI 48152 Proxy Solicited by Board of Directors   for Annual Meeting &#151; 8 a.m. Eastern Time &#151; May 23rd, 2017 Mina Sooch and   Jeffrey Mathiesen, or any of them, each with the power of substitution, are   hereby authorized to represent and vote the shares of the undersigned, with   all the powers which the undersigned would possess if personally present, at   the Annual Meeting of Stockholders of Gemphire Therapeutics Inc. to be held   on May 23rd, 2017 or at any postponement or adjournment thereof. Shares   represented by this proxy will be voted by the stockholder. If no such   directions are indicated, the Proxies will have authority to vote FOR 1 and   FOR 2. In their discretion, the Proxies are authorized to vote upon such   other business as may properly come before the meeting. (Items to be voted   appear on reverse side.) </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1209" src="g101602bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=49,EFW="2231618",CP="GEMPHIRE THERAPEUTICS INC.",DN="1",CHK=513725,FOLIO='',FILE="DISK126:[17ZBE2.17ZBE46002]10160-2-BG_ZBE46002.CHC",USER="CMATTI",CD='Apr  4 19:09 2017' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g342833.jpg
<DESCRIPTION>G342833.JPG
<TEXT>
begin 644 g342833.jpg
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M-TW(:0B6F^C1NHWUD^"&Q_W*>WB_!%A%I*_X[]6B#2 0B#Q>7R*&M; Z7F)
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MU#ZK+QZHDG62LSZ8C P-TGQ-37+6#8:M"#.5CG]8'[*G)L>Z9(29(&/J.Q;
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8CCCQX\>../'CQXXX\>/'CCCQX\>..?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g241589.jpg
<DESCRIPTION>G241589.JPG
<TEXT>
begin 644 g241589.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ _35),3%]'4D%02$E#4SI;1T5-4$A)
M4D5?5$A%4D%0155424-37TE.0UU-24Y!7U-/3T-(7TM?4TE'+D504__; $,
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MV,_CJ'2H&%*RJ,"X!^YC D94ZTH\%V7Z5H_./@/D1^ ^1  $?C[B ?@!'\_
M?(_'^_.L/[N>F"93V=Q>T/%DL]CP3!NG^I>=,KD&)9-GNW=%OL&2\<<=TR+B
ME5/T2,K2+KO-BO[]5-$5:Y#(.;29PV0BECC MIZ,W/#O6_I'&GIR%YT]K_,^
M)ZG<NOO8# L)>SYM'] R\?/:KMC/%YMFPFC="]8:MH\]97\/7J<YM=<Q)K*P
M[N]3)I&)85I.0^&,(U3J;D[%>).<V&D\X^MBCTV-1ZEZZFHVT9MT9[&].L:#
M6P;7!81'V6.KFD9]C.BW*5L8ZCTE<(N-NUZB5TZ#E#!E$L92R^6Z]A6%&V.S
M<*^G##<-D*GQ]<Y*'USK>4J-1>5S(Z7R!S!8(&=KV!1LXS;,XIM-[AJS2H5I
MU%0,JI;&-782<G(,5(^PNI=*<?;_ !D!5N>.8I>T-BU[EG(.Y.0]$ZD3B8U8
MM2JW.F46UY96<A98.#8N50S6GZM"X[*69JSC5(^)K<2H^D4VL!&/W+:I>+]'
MXSVGW_L7<>V+263\F^N+G;+'?,4CT6D;(8)Q8>J&U_L.@]JOZE>OX67IT19<
MRI];SS%9B_-HB:4J,E:IMK7HR0L[0C>N'>VG]!^S')(+IK/:E;Z_ZD^7M[YP
MVNSTV0SVR.]2]CN59MNU#G]MTIIFJ_\ '62,YBR/-HVQW_.ZM,0+FS[O,UT]
MH0KQ(Z/J:!=G[K[AO6'1X" FU.WN>[NZMYXY*ETK&[_%[MJMX>SBQ6\+&4O(
ML9/>]-M$K*O548]G&1%5<.A?K)LEDT7'RF71]B[*_9-'I$73<CMLW=%0>ME6
M;Q$KA$BP(NVBY2+M7*0'!-PW6*55!8IT5"E.0P!B?T+K_L%@_9D\PS"=JQ:-
MI]@Y$KW0&$X3NV4&1S[;K+G6DS=!Z6SL^]4YXTTS.[E#1%IQBWP-DCX/5(B
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MLZA:NZ P0UYZ"GX)8T/K_0B+%!9XV<RF;Y02NY6:3&\7V   /@ ^ #[  ?@
M_MX\>/'CQX\>/'CQX\>/.   $1   1_(@'W'_?\ ?SGQX\>/'D/36$9A8]II
MF_V& <3NG9U4+'2\^DYB<G9&#HT=;W"2MLF*C3G4BK4*_=K*P11K<U?XV$;W
;9]3BJ4U2>_XN[>Q+F8?'CQX\>/'CQX\>//_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g101602bgi001.gif
<DESCRIPTION>G101602BGI001.GIF
<TEXT>
begin 644 g101602bgi001.gif
M1TE&.#=AIP.Y!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M%P(&QX#"(4"#JA(="?OE.#YM,'$:(Y6I8H6F]01N6Y1CE=? =XL%5&];Y+.
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MLJ=ON%,!+U9,<>8L^,<NV@0P?<-P!(9CC@=QCQ8R(_0O<E4I=Z-7VM2 R_2
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ME2@ HL\8E[P) (A)"0*P08A)!,<*E:-JFVTJ$#_@!2(9B\RJJU[)JMPZ%3W
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M[A2?(M/Q ZUHXB1!D5(^$$?KGOX8C:#-M#PPR/[H"2R0M8A0#V=9#UFK"A&
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M=D#S)+0W3)7^RU+""DWL4<92<SYY!?BT3.GJ4+GT4>PODY2!2JF.U3=$%:C
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MD<C;A];T" &R2VP)4 :0C @P28X  8TX@ %@4 95' 7-!OLY.=/$*XF@10"
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M"# '(F@$2)" *2"%2;@!";AI&DB'H[Z!"*"%(5@!-< !![#I(9#E$5"#H5Z
M=$@#' @!A$Z# , !%BB"K;X"DEX#*4X$(_"$)U@"MEX!*;A;2HCD#- !%' #
MI(;J8K@!2G8#)O""*AB"I-Z(*?CJ5#B%H9: $<#J5'CKF+D""E@!(F #7U"#
M(.@#,TB#)UCKS.X#K^X"'T"##/"$+D@$!S#M1NCE0QB#NKZ")2 "'R@$6E"#
M(:#KPC:#_\7. @T8@35 YX^0@MCU8#J0E(WPX0,>:'A^82=8;HL;:.AV9Q-^
M81((8>G>B!WNX7[6V(+V;M?UA'4@8DZD!2+H@Q'8/2WX@%-( IH>@2=@XJ8.
M!@]X@D30B: FAA'0 2"0B)O.@:NV8P!8;T0@@D!P '-0@P 0!#20AQ/88@!_
MY%- !#?0 M7V! 5' TE@@AS(@ 07!!88!"98@2?PZ8T>@C1>[S6@<!; ZPK_
MB XGZQ(8A)>V@R<@!C<Q!T30@E.":C8P[!%H$B+@!T$H!$D( ALH AW7B720
M@E[>"+Q.!--6\$+P #9X8T0(;@#( $KP 5F: AWP@4.@A$30 /^HQNI0&&M!
M: ,LV.LLD/$)]P$1D(C?!H((R( E@ ,TCW, N(0T"/,T:($3T 1:8 +#]@@>
M<-\WL6>+C&[J9O0#)N&5G&='7TE]=FY^]F<R> 8(YN[O]G3:'=Z/L.E)P 1)
M> *J'H$9*H,,)P)B" 4L: 0XV(9.$ &=N 0=P %)B'7*=H,3$ %XR(-/0(/^
M#@)5.(4/-W5/Z(0?.'8'P-!M*(,MY@B;9H,P.'862/92L'9!L(=LW_9!P&H)
MV&U?[W%C)_*HEN6.L&E$4 ,?> $=4'8[( )$8 ,4N (;\  WJ'=[WV)X& 0V
M>'!):!)/\(0@H( \4/-!"&D"4((?4 +_!T!D=/< 2O"$4CCX$ZCMP#YE"J@!
M*U]R.XB"%="!**#L-& "*J %=A>$'D@#(@@"*A@!-J  .S@"3,!0>0B"FH[J
M+, "-I#E=+ #05@!BB\%. AQFQ?N=4#>%'GG$CYAYD9N1\?N$FZ,$G[N2X?Z
M>R6!L9&(!+ %)Q ##NB&W/CTLD]=] W"6?Z#,FB#;<"&/P@"D[_V;5B'F.B"
M)FB#/P@&9P< !$^$/$B"=6@!%]AS,R %0=   $@''0B$ X#V-AB$,GAW%,CH
MQ#<#'3@!OM^(=#@%C<Z#$["!$'\!N\[H \ ")N@!TH>#4P@"<2AJ2JCPW:;B
MS[<!G!=FC_!W_R8P>9// R;(@R>(&138Y$$ ?BFF[4 ]!5_'T$'8F"!(?130
M@290 CMP<'.X\$8  F??Z",__16(&3!G 2Q0@WWG 5)P\">G!$%@\Q=IA"/(
M 7C0\"7 &!2P R90!3L@;7FX CL^@,]__Q '" J#F(@# .!2FB@UU@!;@H*2
M#Q$&)QKDT8("Q8P:-W+L.'&#DUL=#&((.?* 28,H10) B6=D2U8L7<*DV3+E
MS9< (ABP->#G/@MB%G@L:O0HTJ1*ES)MZO0IU*A2IU*M:O4JUJQ:MW*52F06
M 8WI,N$0 @I8GB2-5*D)E$Y-,*(&/_R)A08 O$&E5)$2Q&+$DQL&I_^H >(@
M@J0D+0($*!7FE* 2:1O=D " L.&)\.2U:,&O1:D?IX))5GO#S.@VDX'5+12!
M%B4@\+ H7@=:U:DR$C-^R -G,@5*4CR=N#OWU(G=$Z=02N0  .HGG@2U&:06
MB)D\R0E8&<2&AD'4)U13M]Z(6/83F S"TYX#KX=B/9#;R( HT8(/=GC4<-,(
MF!U1\.%&"[.TL$D?$ERRA \.I/=##2> !P\M0P 3X0]8^)?%<QI),0M&76E4
M$BLP@:03B3"E"$!)++'H!"$CM:BB$PH0M>*++G:   8(@  C3"(*.>0!!F0C
M5%@$H'*D&$DNB20 2C+IY)11/MFDE55*">7_EEA.I&0W*2!!%)ABDHE*F$@D
M:4"::[89)9MBAL74 1 $.:1&!##0S3YB=!#!GONP0F:@@T99**%\&JJGHHD*
MZNBB9C2:$0&2/AJEI9%.6NFFEA*2) *U#/ I4P2 <">>J:K*E2?\L*"1.4\
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M /;(JE$B4(^X@35Q]K"J_U,(P *T9D6M4$V*%"ZR*IYDXR<_L< ,[F@DNP[
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M.IF4;'TB%.P3.TG 0'U4*0X4)+(3G*#B+9BB24W6)U8"!MB32$'59!':^U3
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M!&@'^"?L#"BE!*B"VJ9%->B7$"BJ0*A*(&C=692 1I[  < _"@F%#B@&6:C
M=0#R$( ,E.B$_F:!4LJ)<L2*VN9OFFA&O&B$ABA;18 , "6E=.A^]JB/_BB0
M!JF0#BF1%O^ID1XIDB:IDBXIDS;I1IB!3P#%3BX.*G".N@T ';#"#I*!+4#)
M]40I]\R)&=#!J(S$E4KIIIU8!/ - 9PI<D* &2@ ;%5I!'! E+ZI1IA!W[3$
M/WG.G%JI!=C5A!4D2-B";4V$&4 !A2'6D2#!2"!  @R0-[$/F1[>7_%:Z 3:
MDY0(='  H'D3!Y"HDXXJJ9:JJ6)5[@ A"(@. ]A"8U6I'WW.#*#"=]6I=*4/
M49C!Y"   ZQ9LQ3<!G: KJIJ7ID!+IVF!?P3=)E" D+ 3F7#8=&IC^1C!>QE
M1C! J&J&G)H!FA$%K$*7 2B@M0JDX;"/Y,QIM^Y$,E6 ^!  K%'_3C)U@) E
M0 6@P@[LI9$XZDZ@@HGESIB\ZT!QZJD.+,$6K,%6A1E@YD3LB=55*71D79W.
M@!E8W> -$*S)1=D][&D^TP;<@D2UZ@/NB4ALP#-1! /X)D^<6.>8@E0MK+ZJ
MA)R>+.&A @2X:[;R):Q):@)<E^&P0J1>#PE0F!DD@+!R@ S,6EB*P0!%0 *P
M;,_^+ 9,3GA$*J1" -)RZ,%FK=9N+=>&!VLBJCX*C\/J:5@ "AZ@PF'MA,N9
M0=;!P^T00*/];'H92K!@JZ).ITELP-?NA*YNP5# *KDUUI,*+)_N) ?X[3P6
MZ\L:)$J00(Y.!*0*8.<H;4; 6CY2V ;L_^Q.#-,"0*J.,0#E4H09<,#E\FC7
MGB[JIBZ00JE=V4@\;8"BTJP?95WGD !ES4G$0D<WV-7BA,IW7I>9[8-P[A0K
MD,$,'( "<!.GM.Y/W<+$MJ#*,@#+<@0#T&Y+W((,Z"JU0>_U!%9U:JCDT627
MYA5/F (BSL! $6U&C*D%3,")E426TL&A&H#YJA^@J.^K.4$VN*_IJJ[__B\
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M)1R+G!D,P 78U5/_1%0[-53_Q#,0<UD-L,D:2ET6ZTL RC- @-N^JJ&P+5'
M0[SYT:%N0+)I]<*R@J!9 *^^!"K?LKYNFI=,@0L_Z9X>P"W *4MLVI@(V5)+
M'G1Q#DW.ZCUN+A),:@?8G9_D+ "6<^BRV&+7_VD">).C\F!D7W/NJ.PZ-\[
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M1@44G:/8G.>9G1,7<+DYH:&8EMHFEU9Y!P!=+I4$$H  GWS715_% 8Q@-^P
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M@HX_#KGCDDLR!8.5/089I)>=J$BBFA.(B&42;-H9 R>0  F*FKU:=%89"."
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MNQT)B'>TVA_O5N6_]L6/ 5Q9%0$'8$ %1E!)[]N'XN!UKEC!PPD7)-UL"(
M$79 A#(00 GK4<(3BA !GCD8 D 0&1!PS@(#T$\-;7B5AGVF S&DU]@D!Y4)
M#$!]48% /18@"R(JD8A3&2(110B (0*(;YM!  !D,,,GJF^*!*CB5'9P+X@
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M0$ [P $BUA&-4*DC03G@R7[N$RH5R$8:'=K0J=1QCE#A0#<@8%&4B?$S"AA
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M%J.\L&P'YN0Q]J]U%,#_VB_I$$RS(  $3BT>XPO+D@X)+,3,9F#MX*P!M41
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MX2#-$2\3%X5-NC MGH;/K#!K%8FH UP/CK OKA@J&"VAK,8&O))O^3HKR:!
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M8_\$'# ! T$&&S9X-.8$Q@8 "S!X9O!B2-%V@]& "B #,<8!4# 0J$ "K,
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M!'(#KID*  CPE > !%XWJQ]B,1TE$G&F!?IJ&"85;S%)93FD,^S3""2T=AY
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MDM#763 ())Z("_0$Q("P-T!3B9@!YRA*774 >?"P!D,K!E*DN&*CCM&X0<$
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M?''&&S_T+CM$@H& (J[0R#3*[7#C!!@<]_SPQ!J#S(#'#'",],D*CSD"!B8
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M6S%@@ 1A\3\8>R@7BS(R*T2.F[A"V$ZAPXWY\@EB\+CN4(4K"+D]W@A_:P.
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M0 $6@ISQ_R43JH31IRA__G@$:\>]0&@-.(3"Q(Y!(A>,F1&HB&4H=FA1#Q]
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M)*$%LYC%J9KQ3(?HQJ138N.S/K=/TP' '(&9R^3@6!)^/$% P0'" 4X1DN;
M1!#1":5\.D  IQ+@J5&5:E2A2E5.'F "6T "\1# "N(E<@9FP -8MS"#[ '%
M"8M$*U/;ZM:WPC6NUE%0(G(R,!T@@A)L (87I 2/G)3@90N,0R(.@?]72B!"
M:V8XQ&0(X"!?&B45K.1)&SP$$I&((A'2C (%9@@]Q@*-%(A Q!,F@[.=S# "
M5N #WB('BM%2@JB'B,(/>O %#:E"2DPCJ)D.X+^?9.4=D9#H<80@VKR^\04X
M)-MA)(<UTQU@!'(SVQIBH,.;()$@\/# Y]2X@4'<X "KB,$1_"((/HC#*$+
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MC*#KY8Z'4:'N6$",@4^)&0 $H$(E=,!8@149B '_ N!!C%F;&&@7'>S./LB
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M)@"H*-S%*/GI5U"J2W07 -#")*@",-P)JA:H*)AJ*+FCAW'8[P@/1M[.B"&
MB17$+9AAN*$86(4;%IK!#LB"1Z9GM&9C4&9?2CZ!)[1 4QP"*<R%3 Q"7:3!
M-DFHB0#@$\ !%B0!$3Q!-V$!$:BK%I0 3:)!G)P!%@1&"WB)O99$"R2!5$1H
M$/1 )K3 7.P>!:I! #Q!80$@_\("I;W.11!0P"D@1&FRAH1E L(BPBRT0!<$
M@0T<@L"N:UE@ %)R@20D8"D  SET08@*+#N1&E,P 18X4Q%RR<4.A4($0/L1
M@!!4P2QT 1/8@' TP@FTD1"0 \("0\MVF238209DPCJ8C >@!E=0P1#"A9W
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M&+26Q*BV*HS!^J[ 7GEQ:"<L'R!"(K"6)@#S"B""+O,N&#\9)62!$O !Q-;
M$(PH,&@I4,8I,R66BK!$3R(')9C _**: /OY)Q @4FH4 AM!&N# "#R!"=1
M.W<Z 7\"<HO#/?L 4E) #7R"QQ(!=#B=N:Z GL\S=S!P%.1H%G@QWY1"T';%
MGTM!"S"3#F0ZUOZPIB?""F0Y&'>T#GPT&-MZ&)\Q P]>"^A P@[Z=W6"L91"
M#Q!!$W#I""SF"Z@!#IA=:#,G09SQ/BTI%OP&$PMP"R!"*9![2C?"#>A4&:C<
MN*N[O.LP$0#8 BA4IH,"#NR3:FQF.Q[R_^],@%G?RP%0HE&000* 0"[N(O1(
MO#7"@Q-TPRZZN))S?(ZMW.]2A4$D146H1B)<@AWX@)OD:_89015(X "Y@00Z
M8*ID0B-,X)&0@@LT[_BV@&+Z )^?@ !XP/EVQ?%Z<R9\,BCPWB6<@FI0045\
M>6S%3,D(14=$U[J>3@:  A$@ AN(PPAD>3J<0@L(\=I4)<EX/0!_7R9 K$5\
M[4@P082???T20Z:1/14 #=O'R'<]'PZP %(.)7-D@G;GP2R4%J2*@QF\0PLL
MJ22X@"<T@B P:JZW+5&M'_2]%P^W[?_0B>&#2WUG0'&: Q' P1\P?HLZ;0MT
M7=CJM-.U +82+?][?_GG$R=K;(!%S#M0;$,+C"U(LQ2G( XFA"VE2?3O X5%
M1((:*.<(= &V*@< 3(&G;+SV&/(A@]B[=8#"=_SVPQX!"$ Y6L<@SI$=^B3Y
M'P?X3PD!G&<$$(!Q'( ?MC_QI"@+8%@$V -PC:: .) ?XD6*'H!9 T0$ F@
M1*CG $!"A0L5&D28D("]A1(.L&!X,0(:"0 $++@(X""!%T$PU=OX,<(!@A\3
M.F2)4>+""!T3'H@IT]Y)@R=9NE1X$,#&>AI>_GQ8T"1* 0JG@ I4%&I4J5-?
M$K!Z%2N!#EFM;B5 %6Q8L6/)EC5[%FU:M6O9MG7[%FY<N7/I,N19EZ7_F3PM
M3H@ >Q?O1<!F#W@(XC=P8L4%&04HA6GQV@,5*%>V#,)R9<PS/$;V_!ET:-&C
M29<V?1KU6P*'SD!.C3<"@CZ#7]=>:"0&#=M1S0SP?<'W ."_@P_W7:GS;N7+
MF3=W_AQZ=.G3J5=WOJ!W<.W;N0^P\-5Z>/'CR9<W?QY]>O7.#R!PW\$] OCO
MX]>+WT$&[?7[^??W[W\#/HX@Z@ !B5+("C[60"&+,+!8(PN>-ABD!1=0,$&$
M"1OQP8%4\HA$BXTFG(6?%KKH"RH"-D",J@B,R(3$%EI@PA$V7)OJ "SXTJ"-
M/!H)43^&#EB!$A\*&;+('#XJ3 <?<CC@!42:_W@(2C9R\ "%!:-@\;\N2=L(
MS(F<8V""#A+:P)8!Z&!%!@#,2'/--A<RPPDVP?,2SSSU7.Z 0W0X0H0^_V01
MGD,R,9$2%)[PA T@3LK1!434:$20$K#H@@EQ+B$'Q(T@10'4+ YDZ0 PUKB1
M*C/XD/2)*TQ8P4:P"FN!#1J$^,,%'$8MZ@!:B*!$#296^%6-$W8% !X/B'A"
M!R8. 862)T*,X!)0V+!AD%ED' +5/;W]=JH(MK  @H3,8,64"E"90(8-T*V
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MBS1Z B+6> 9+G> ''F###\QV%&3Y20O(&H$.B$$;_WB,,@IP8X%A_'(Q)L#
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M-K*YW6W01*0S$7F+0, 3@9D\1" LL!D+/-D6@1QK=$=9S1HB'967Q4'($!%
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M'4[@61H1@LPL%<)@!3SA*0@QQ_"P,,TL,F>&'$L/+6\3-].C [8 (-^O*!
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MGTCV)+B)ZRP*<<#@P. #@&5 O)M%R %Z8(<HK("TA%O!"30A"H)N=HG>*-A
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MQG,@VC[$%5:@A27J4 OP>,%*L[Q$;J_O#Y]H0QX^@8:(1<V_257Q0$;P!"#
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M@*+Y>P@U((():\A!,S)=^1>XH 63(.V >:IO(C1"H%3C?=:)<.Z9&__X="4
M><QSE!2=IR;2K D'M*(<)X @ 3BI14VFB9/D=*8;)*C)%O(1%ISH&D1\2;%%
M'"+UA0B$ .K+B,TBT(&F(:0>"X#'#V >$0(L1(@"$'_T%Q?X9Q*7< 03$0$(
MT#01\! 5(3D7 7\400#-0$KV)W6!M'<(X3S_\8=\'OB!,<=7$I ;#.0I$. <
M?5)K<,$0TY(8F](->H4=P+01,^@:>U,#)@079[$P(-B#/OB#%5$V&W-T6Q N
MS\$9.((0>,4XD%$6/;@ 0K :=B$$2 .$5GB%PT0 IK!]7-B%72@=K' @7'$L
M9" RN7(L4E$!') -V= @N6(899,--6$?R=(41Z$R'UB#+]$N6-B'?M@U&/ A
M#.1]7=$80F@R32$+<C*"VD(GB'@<C $ "C0:)R,0- )9?YB)FKB)QM<K.X=K
MW$*"(--A(X,RW3 WVA*'RF$I ) E=L.)L!B+LDA @7@!^= !$A !AR6"O%@/
M5+$%BM% )D(M=% /_R6R)XAX6 8QB?D06'*HC+,8C=(XC173)"5V$7'2&)/H
M@MZ"A.AW34/'BIHR&!S6 8U(C>B8CNHX*DEGC B0 &3  ?%(!@D@&9 (C M0
M 0FPCQR '-V %*+1#:RPCPG0CX1A?@69D!S0CPRBD/3XBNL8D1(YD3\2-B#R
M(I>!(W3#81^C-B9&+82A<Z X&I*AAS#A<.LP"_S047&!,SYP",5W$1&0,#B3
M@_+B,"HA9?F" _5DD@DQ,$)F,#\0<:VA7C:S %]% #_@DQ39E$ZY$1BP)A>D
M&9^! (KH*1C)%1!$([>V'!EI=);!"C%(%Z*S=:(0!H70DBN0"#O#E*(S;/^<
MI1$$4 24A1(?)#7UU 95B!%0R#1)8VW<U1KU\TL0,2]]<#47^)2*N9@:H2;7
M. -"1Q@$LD%8N1S=-V()L3[)Z#8;,T$5H( FPXAU4Q<'  9E5R*)LS@X@P/P
M\CFRLP%]$#S HY0J=@!\P 1A\ (^0 'XXQ.IR8>B P>:8)LG0 7"$SN,HP3R
M(SZB8P(Y$#JTPS@;(#B$PP=!8 /<M0&%D!IA #@.(##(Z9LQ( IW!IZU4P(R
M4SX?E3E5P#F].2^Q8W^B$P,TD(MF@)P$T ;[,ST#L9378SAF\#AI<0!A$&7-
MXP=H$*"U8S^Q$SQ&8 +>LP$_0 NEL#@*VH&,F:'_&JHI D('4_DMB @!O^A
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MD @EL W/U0(MX +Q-)A8M7 5" _;H)+V$F%6$PRT4%T>  [;X&#\D%SJQ6G
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M  K%1P",T%:20%:VR]<I-5-\?0.DAWLT\%4?4'GP,'PQB=&>K8F]TFH6$2?
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M. $YCWD&ML7"(6P( PV$N9D-K (3$G 6<Y3C !;^H! :&D(:@B&*,XB@,II
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M#.<GXXAT+15_:$$ ]+UOIXG-SXEH Q^N8((V@#D"T]"+DH7PA1^D>(FG0,'
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M*:4Q<(M#N (>D *-JQH<LR9A10$X*(\K^-6HJ8%C10%E]0$^Z%6N^HULK41
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MKV__?OL#<;R%!K A#A '@.%-&STD\D(B*P0X( P9Z.!#**<<T=\!,2120@]
MY!5#"2MH 0\8*174@P\9PC.--W*L<,,&*R1R2!,8$G. AP?PX4R'@0AXQ"$X
M;&"@@D>M 0Q"1GCSPXHT!F+4"C@0<,@1++R@8P^!/)D25T,$^((/+VSE 1O
MX!!!$3]Y>8 ';ZUD4#!/'B& )$]$M1(!1?@@92 HH>'!F#YAHM:4$ACDI!'%
M\*!%!(=<L0)/1AQ1"%OP>$G "Y^PP.<"A3JB!0&T?/]"8:2T!-.3($U*D,HO
MX@RB(2V"K!K!"-A@@= (0339Z:>2! . $,6(@!^PP0H[V12Q/#8:;2N9T4>R
MP4E@SB15K90!$:1=!BT5JDF "B761I;!$%0T.^QDQ?U*[DI3^)!#<YLM>TD4
MXF202'7";9"'8%BPT4>[FLU['GH;_& /?>_%!RP/LQR,+L,-._RP9OKYT%]/
MI[3 A#AF] !'0T;DT0C&+_%!C!4K++D2/$7H$$4/-SSI#0NI6!R$M!L@> A"
MHIA  !AJN'""#8>LG&$$EY#2 B43II)'"U=0X2#+Q"S= AM<X$Q *"F-X#,3
M?Q;D00LMK$'# 40+P700XMC_5,05F!Q%,M-/'#&UEB_%?4):UX4]!' >>3VM
M&H)4V1%:9L0])SQL*?LQ*+FDPS3?&[S32+AK\65X"T_@_<'AAA.A>5JPMC5"
M+&3BP'GF"!E-1-I&M\!W!FX@PD0Q8+6 R"<P',!TM1#[_CME4X F002T%&D"
M%?Y1L8$-8)SQ74(QA'%&:C:9$4<6]:XTPB04Q""N.42<E$H<<-3[(QPBW+8!
M!0!_$(8(&YS11@Q<+  M#6:$D0,!_H7A?+TT]CR!B2(&Y\H- <]0B% 8\"4]
M,,&O-O _+.0$ 5Q@3@1^4(@%'&!@/WJ>?S3!P:&H@@+,PLO !/4#%GP0#6S+
M @MC__ \XAFA?LPIR, R: \)*,$*/U!4%D;@ ^_QKSP(V)@F"!@#@-F$%I1
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M&(U-/';@8)CC#A*0*PQF%=@OG(L6HT6O>FD CSR4X07BBU,6)+%@26#[ &$
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MP48[*H"/(FRDCN0H24&*4I6:U*,A+2DC3WJPETXRIM9,J4P[VL%PJ8((2:
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M'@PAD"S0>8,SE>&=.T$% 4CBWQK.*+Y33'$=+7 =79XFQC?<\'U?5J0O4(-
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MT KA$E@S$31L_ 8-:VB1:@#-$"JG"U1.I 9!#:+@%-R@%,[@!3QA';H@"FI
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M/5H?O E<.C@1YI1S+[)43[ %P!PGP3VKQO]5-T&M,R 1M9,VK=- B5?]C ]
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M\F0*)7XN6)AA4.R.LRH+*:'00@H+ID/[EC",L-!AP@R;*D9<F.'BR T;,@6
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M2:S$^W( VY",?SC$10R_EV S<MD")Z !F6$.FR .YM"* 1 ,F+$:98 & ,!
M=_ !@Z S6>   & .C7 # # %;D#$F/'&-R !<US'(T $Q+ :6 P Z4 *6C Q
M<+@.I8 )=DP$0+  '_ '@;   Y($C9 (#@ /?S.'B P ?^P $I .?X #D7P<
ME%P;G[B'I; "AM"*I2 .RY%&5R .F7$ >7 "9>S( : /-%#$(Z #6L "F?'#
M26#(J/P$C)P..I (/9/)-( 9&3 $?9 !.H #$O !IQ %M@&*I> %,*:'F_^P
M I[ #R[ !G#  D9 "95\ *?0!![4BIL0!@0"B@ CQ0>01R%2" !P"540 (V
M"(EPSP  #X/@!H:HS=S< I, #%[ !6V,SVE T'UP"9X0 )1P!5Q@!(C0! Y@
M!J?@ VAP !Y0(CZ0 PV- _8P(#X@"HC3S7BL&4\SATR "0= (LDQTAL0!VR,
M&4\3 "Y0T0R=TVD@TIM\TSXMTR42!2,M!*?@, ? !T=0"!%P"&E@-GT@Q?#@
M 9F@C5XD FE\ CF0#J>PA[16QT( &T]P!5G  BO$AV:]!'G#!D>=#G9@B)U
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M\HA)F$8T.J[]P)\35'%#"W-:& L>1DK1SS@ IG #B/H &.$)&B28@HA )/B
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MZ ,"0SN!4 "%&Q@!&FL!_T.B_9$$7!B])Z.9_Y^K&0V0/][KO$2IC \X,OF
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MYH?^Z#=^X:_^XR]^XR<  ,!^YO]^X^^ Y,?^#@" ;#!_]!__]6?_]!_^\P>
M%&#_^6=_"S!^&0" ^U?^_-]_X;\ @) !P,* @@,0##18$"%!@P@3_SJ$:!""
M!%D*(0"8<,'@!8H6-P[H".!C08P6+XY4*'("1XPL%<X L .F3(4#8LZDF;,@
M3IL]==)D9=,4 *$&B1H]6G3H4J5)"R)E^E1,4X-4DUZXJE(K1ZXAO7ZM&A8K
M$@ <5)8]6_!"6IL<S+J%NQ9)!"0@"[Y5:S"O0E8 $MCT"]B@7S&! 1CNBUAQ
M8L*+&2LV=5BR8\J5)T?&K' ' ,L#.%>P"7HS@!FB2Y\V;9"SZM6H2;<>, $
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MMLH5M*U-$TC ;;?0*32;=06!>RZXY!HT6SW? O"N02F4IQ"]Z-UK;[WS[CL
MO?UF4U]!],HWL,#^]HMPP0,$'*!"#3],G\,53DRQ31)$P)Z%%V.X,800$DA?
MR!*0/"&!)9M\<LDBH\RRRBRO#'/*,(M,7\PRRTQRS2W3O//-)]=LL\XYV_SR
MR#%/R'/20Z/,-,]"#ZWRS$9#'?335V/]<\A6SYRTU2%'X/*$81<- -DC?SWU
MUF('O7;//K<]]=([ ]WVUW;'K7;4>-=]M]]+=[WWTU(';C+@ADM]]MJ __L-
M-]URVZVVVV5S7;G87?==]ME:_^SUY8\_CKG@;L_]N>-$XXPZU(7[+/C>0*<\
M..>COZZW[9:?+G3>N^>N.^Z^MQZ\\*O'?G/3Q!N>]>1\,]^\\\]#'[WTTU-?
MO?778Y^]]MMSW[WWWX,?OOCCDU^^^>>CG[[ZZ[/?OOOOPQ^__//37[_]]^.?
MO_[[\]^___\#,( "'" !"VC  R(P@0I<( ,;Z, '0C""$IP@!2MHP0MB,(,:
MW" '.^C!#X(PA"(<(0E+:,(3HC"%*EPA"UOHPA?",(8RG"$-:VC#&^(PASK<
M(0][Z,,? C&(0APB$8MHQ",B,8E*7"(3F^C$)_]",8H ; $_9E'%*UHQBUCD
M!XBDZ,4O@C&,8C1?"V;1@C.6$8UG-.,:6Z"X,<(QCG*<8QR34,99),&,>)P%
M'^W81R[2,9""'"0ABYC&6:RCC(F<10 4V<9"UNP +%B Y""YO0@<P!Z4-&($
M""  %E@RE!S,8P#T. E, " =F>#C'9, R*!-P956[ (.6%!)\44@'4DH QIN
M*3UX2"*/5PP #BZAAD[DP)<B2X<:K+@.?@2!!F^L'CSR, DJ^#("&5!#"\I0
M"/JD(PU7;(0/T)!*3W0"F]0[P \*H<P(PH,/H,B"!LP'CW;Z\@!8D"4_NM $
M%@BA!F4DYS?UZ88KNJ#_">9DW@=J4 I@V.$)Q'BG]#!9 XE2]'P1& $H?%!/
M !S  V[(8A=.T$LS[+.1@L@! . A4BLV,@K)I(\^UP'3(=Q@FN4+J0MP,+.0
MNJ$%)[!!1D49R#8BL@SUA,<?_-C&:4XAJ'ILP1W8%]4RB(![$0@F&\VH!6-B
M%7I3X"8:9U$&EF8/'O+8A#A\"8]!@.(*Z@3 %-)PR!;4LJY!0.7T],D$M&[0
MI9/HPT?'%](K].%UD1Q$4,_8B"RHXA0!6"0Y'6#0-+;@L86UFQD<"@>'WJ"H
MT-L %DH!A/I%  PZT(+.@)K(S'JTLXUD9!>.(((#T,(-K\UL$SZJ3\RV()KK
M_SN ))[ 6I,=8 0CS:QMC>I<D>6Q!:^]P]A&$%V;2I=#(HO 5>MICEWVDCX$
M<(#9"$" J46@ XKKY'FW:X\NTB<" N 0,WD9W_>*UFX'^,,)LII*-7B3 !%(
M&0NF&4[[PN,4C4BL>-N[70$XN,%C(\ !!C&$N8K,O,BU, U2E@Y/_!4 ESC%
M)D(;- V;C07P)= !VKN!04339"BN&0%L:3;\XDW#[*U9)VV<X0C'=P%ABX"0
M>4P #>TXON9MFX!31N20@@((8\-QT-+KX^?-N,(XG?"*:<J'(?1ANR*-@@@B
M8(0\E.(&!_CR#5K*41_P=;L=L+$^A_#9(4C9;IU,V?^,C5Q>[;9MSTJ.,'N=
M7&/)==(>Z 6R>3, BM[2] 64( :/.7H%&@"@L\8] !@F;38CD"+$(/4 1LTP
M"!>P5LD3,N\;)=!G]0AXNP10M*P%,"%XK #5*=-GFM.1AR&(X[G/16HC4&D/
MNJ[RD+,PL!O*0-Y+N $7,(!V)-PP"0JD@9$FE4 &DM")/,RB$Y@&@!!.D<@3
M8$*?KFP$$"(0 5HDDI@.F$(FL K,  2@$<38I/72\8>P_O<)2YA%B<U<A0!,
M8J(U&ZLW6[J-270X':<P(Q."_6XU!* +@B@$,UU@B&N"N@5/4 /$MVL&< >@
MXA76;1>(0=Y4IN&L+96$&[3_D(HT=$(4GG!!$B9Q@Q'GV^69KL$Z&G&"-@QB
M'0'8!!60SD@F8#.<'I]$%CR@!GXTXI\>3H/'&\&#@>L;E)U-0@!.D(,(O-B,
M08AZ&MC@B20\]!0M8 (-TK$$1% "[L"0.]TC8 :Y-R(1#K![)):@AL [0 )"
MR$, GD")(2P#'F#@9A=\\,WX%D&<<P\V33T "L$WM!1]:,,^6R!ZE[HAWY!H
M ]&SOE":8H$-;:9/9]-\:\\WH02Q3VP$BD *'_CWT]E..0UJ#PQ'I'EKG8T$
M(@Y?3GU>':<LV,!%$>&&)T2A!M[NPP=*2XP#U, %*' ^&DB;63)G&@OG+W/F
M^VEV_QZGPMS![4.%7=#\1D0!E2A=APLH 0HM;!)N#0$DI QI&=>MT4)'H<$+
M1!G&&,$IH!OL/4$@2( ^/8$/L(#ZN0 1,,$*8-P!ZI/]D1](O< ':H&9Y0$_
MS)TTG1R^X51(1<)QT905A,%MP1CG"9LH^1&^8=4!Q, "5!,CL1(_ !HX[9(&
MO-L1CI5-14(5M  B>$( !,/@-5,0+$$ E $+'$ >&,(31*$@C  ']@ I0)PQ
M#0$/D$(CW$!].4 &<& <5,$F2-/UP ,[--Q_S5T-&$(91!812($:E *&A5,C
M( (*+ $M6=8@=*$G"%4A"$$:/ $/I($:/B(C=8(JY $17/^!'1@"TYG,6R4!
M)5!"(]("-\D>AY@!*2 3?6P3#MQ<)QQ"MH5;9#6"%'C""PX"$:! &A"!#WC@
M$S#!#PQ"$CR!79E=./%1*?1 &@3!WA$!,126K[%19J& )_A<A1'!&BQ!+V:@
M&CP!(B0!W7V W!GBX54C$31!N<V=X<T=+S8!TCU!-0Y!%K >,8Y?.E58%Z#
M^.E;N06!%RA8%KR<IGT=.KY<!%Q"&JQ4_#&!#90B$31?)]@ &$PB$U! +AHB
M$="3R!"7)@*#%YQ!9(E;?!V"&OA ":P")40!!<2 '1BDR+S8$US!*?0BT@7!
M9Y5"%NS:/L6C)^1D"7ZC(8C>;Q7_(C<5HAL<@0W4P!!\GP:B0!64 ARL $1N
MXS]Y $2BP*/] !8\@1?8@0)R)!9P($U&@0VH7R14XQ, @4MA915DG6^!@1LP
M 3"80 SD /@E'WTPI"8PX$I20 T0P1&\W &LP 3Z741I04CQ4?\9@@A&PO=Y
M0&.FY0F"F@@^02)P910X E*BP54R@1VXP5!Y@*X%VH@Q09SEH"65D1T%0%6E
M0S%@PE;M8!G9353A6RFQ&UVY02>(@'4% Q#^P22(0U3Q)CQL@QQ^5S!( %,U
M@AVT@ _DP :XTP&$0FS2 A'\7+.A@75!YP9H@F)%C\3U%WV,U5Z-XR3DFA9H
M@#D8%[^-_Y4=V=1CM:$:"((#5!/$'8 ?$!4MZ  0&%,0B,,";),@B(#$#<&X
M 4 &> *Z&>=@O95P;DTXO=]&J0$.&$',Z5PIB ,!*"@.:$ K'H(GK%0Z>$$6
MG-Q>)22#YB(DF$$:'.A&@1@5"( F %HX!>((5"@+)*0/J()"VL 'E&@L5MR#
M9H'==8(X9 #.(:DG\*@=2&1"2J2"1D$/,"D:[&C\=0+]#<(D0$(J+,%I?L"6
MWH"0RJ@ )-X,]@&'ID$3!%]G!8%#4D(6>"F P@,6S%,)# (;T, E+,%*78(=
M$"A',A:^A1LP_!L5B PMI($/D-YKS4(7H!]'6H$FZ.BB_H!#_?^E[8E,[65!
MG8)"%-C!VL$#+5#".Y;6#;!>FJ5"'C!!&)PJ2JEE/,75E^9 9UDDJV)".M@!
M$T16$-P "[3!F8J7%?R !I3;$9#>$T""2_V?3=X KOV?;^769,V"KPK!.W3"
M[)E9&B0E+;#F&9TF1WI (ZG@W*4;5[[C($1"3AU"1[7!"@3>AZI!4F)!)+1;
M28KB$V2!/0B /41 "80!"]BJ)GA #+Y.9[D !::F#II1OF':!IQ!5JF2'[E2
ME^72<LT"4X)3LVG =0+@5JEA5/WF5F&G)!#!QYJL%S33.I3"OF6:!R8!NS%<
M@9("(N7DRX$4']R=(18B(A3BW6D!*''_Y+]=7GV)@'&6 B?&8QJL0S (+<R5
M0AC\ "T20PGB@ .\FQM HQEXX"P\EA"0@LSA* X X99V&'V,K9#Q9] .0C&<
M+3@I*7V80X7>7"GTJ$0" (Y^XQ(D@2"48'V*3((%00Z,@(AB[=J6F[A)P,F1
MW66*0,K\73J- "2B0-X)@@<"G\B8 R4(0@ALE XD0BKL:@[8W5_5E2"([E])
MZ'#VZ0I (B+P[0F()!6L&2C<P.02Z%;-8T/E44*Y$TR^@%U5'LZ^FPZ80 WX
M:I)NG#91PDFRF1%4P=Z&(X*NF4I2@-2&0AX(E]D4@0Y$02'P@0YLXKRB)GUL
MP"$L00M *ND]_Q1H[62:$8 '4,(NTAT 7&@4;*6XI4,-I),9[&H8\,%C\AHQ
M$, +Z  B<!T*-%\SYD$DL,$2& (39,$^%9U,_13ZVE$PKD I!(+D/=JJ]EWW
M.L-'%?"GAB07H(&I!<%I?=HI7,%$J@$;_&']AF5TN<"E@51A:H$0P!BFG1P3
M$*Q$D1NKJD*>^G >4((4--818!IU<F(7-.1HIEK-F%_F+FPHK1$6XBQ]&&<I
MI1%4<2PLN4$PR"8%DNP-B*R F>P-F*P9KW$J#,) _5PF8-\@-,*> AAYC9W7
MFA@ ?, ?-%)9M5$+_*:'_9M_C55_;>$D<&(0[",*"*3(,)PY71P.>/\L>4D"
M)?@G*=0Q$?AG&HPGCFJ!?>9!,;25V8CRX4K4%AYHRM25-PF9YQ%#0I:!*(!R
M5M&")\3C/B:"!WC"U8I,F'Z"#8PM>9%JZ"KDY:$4QLGG,BV!V>GM(_<RDP9?
MX6;N,7OI:28D@9YN*'PI)FQS(=15%*R +DNS*MA!*=! G4)>+&Y<2$W",BRN
M!YY1$PPD8%Y!#31O\"7H$E""#JQ4DI[ -XV #IQDGG)!YCW!&NRC"<19G2&H
M_^8EE#4!:04!_8FE#X1 ) G4%3B"05]J5")?'Z/=(*09LRIP%(B#-IW"$>1O
M'_AOQ746-KAJ*4 "7CZK!^@ &U0!6N[CE$;_;R&B@ F(PP&\@!-"ZD.+)1LX
M@DINI5JFE@XTP:KN%0&L+7+1@L8**D:930):'JD" 5 U5^>I9="$5)HM7C1%
M0+D!<6&>%@B'@?9*$UO;0(AF,,$2@0Q_J0T4[!1W7F#R\Q47TG7]Y@$HP0_\
MP(0$DQ>O0Q&FTBYM<2J-L028 Q&4004>9]VIP2:DFQTC:1X;9R/ 00R@ <D&
M0G&UVQI?%1I800P4PKN=;&1+SSA^@G_5UVMOPQ X A$(GAF$P4R!4]BBTE95
MJ((.](/>;G^R $=E@1!00A:*&'T6*(G-U11X@KWEHIIMJ2#JP"J>'"7B7(@*
M BJ9PR\[@&\7@G%C_\+I_H#VBH.$YH"G0L*!L=0&4$ R%72@@M,I8$,.).G5
M^K8-I"CIYL$)H.]?,6MSV\%9[:@(=/."YT"#GVXL M\&J +IIG,?;%4Q$$/I
M1F=VMX$H4$'O*21?)2GP99X/;#'UQ:P]ZZI:)V BH"1.C9@@H,$!A &-<B2;
M?>(*N(%,V2^:W;0'X%D$',(IV+3)F-DIE-/]_H C# $P+*7"T=12MALM%,/7
MB5YJ/1KI1=/^RG0-M*KWK1E4JY84?&E1(W8JB/E=(G8)B$(?L !#CMM:U\ 5
M@/,I",(/N'7O=7EIT=\*/-I'18#\4GE+'8)<^O!%:8'DK98$2-P!TI0.__\4
MJ85UGV> #AQ!9Y+3AVJZ64(UJ#$!')P! 03430Z"ZK(J7TMZ?(&:GG(D/@FV
M(*W1'0. .312;JK2';E1VUR5L)+G9.\7!S)>?495'FKQ!^1!"UR!,;[ W%%
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M@;-:- +B((*9&DE:,,G1<%"2+BB(X+CDZ81! .E.S0JR9 @-"0C-##+4D@8
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MC* #!W[ET]F^(L# GE0)* ';0%<5@ !##S!7T0BB7=?6:]VM1X"^PJUWN@X
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M\YDN'?]V0*!\$'6 %ZSA!AM0$1"8= 4*U. $-A"  U22DX/T4"<+,0,63K#
MY: @/"=4XA);.(@R[ HD0:! &$3!!0>8PW!^2L<)?M ']07*#&OHP\72P00*
MG&$%09& &9(3J"F<X",&],034("")CS+89)@ @TV,HD^"&$);2)&&T[1P4L4
MZ6)3*%(0@[.$1%PL O(X0FZ8"#F5N*".46CCH8K@R#;4H!%-* $?$L2'*TCA
M"IB0X1$6N %3+G A'QC#%712FU%4KI*YU&4L3[&$,@@0(6^$XO_NH $SQ,&*
M/T0F"V@1A!@XY2K(=, &?B"*&##R*CW@ C/_HX&A"/,NDKC_X :HL($PQ$""
M,3B#NJZB3A:,@ TWL$(/EF$N<\9 $Z&(01\(  \_Q/%T&P0"?:R9 PQ2\0QX
M5 @MUL"%_C2"&",8@@G"H(E#Z$ 0FC "(J(0@VUNT 3J5-<!"KJ 0W9P Q1H
MCUUVZ;@4?@E'5O#H @Y0S3-H FE]NL08?'"(4W3A"*K@:2&LL +9],$*-3#C
M&6Q H#-0X"4$D"D7%M!#3!S "A18 0Q;VE5=PD,34XC%,.\B5F".(!CI6(,7
M[!# ="PA"GGP@8I Y8 41N$4.!A!"Z)@AQ,(T RGB*L@L$"$)NADBSHQQQ/?
M-P(B<%2P-< !&@++ SL(HDE2X%\-_P0A G,\%A%,\,(2@/"!7^#O=%-0@P]^
MH D6'" F)2%&!CPQBTF@-H1K@,,@$*$#'ZR #2N@!!SRX 8+'B(J+;"@$6K;
M GTD0@#&D:T1EH #"T4J,5Y=W :4RH4?V(, M%"#X%A;@Y*,T$]FF&4/TD")
M*_1@#!6J0:1:\@/S"NX$89CO+(!J@Q&00G""^ $I-;&6L%%.NPE>HC![- 7.
M!8 ?3\0B+8QD6DQ0>(U9R, )T"H!2=S!,:-PQ!/-H @C2H)'!_A%#]@01' "
M8 2Q@ $61R"(=QKI */(P0CN(($/G,$()\!"(/REXQJC@1;[,0,E3Y<FCJQ#
M'\0H@@Z ,/]!0;S MSF(P)]X<@5* ",/5S@%9BE!#,P08P$9H$0BVI '08!A
MS6V.0@^6D(42Y.$(+T!$(L# 04*R5,%ZT\[8HB#4*!3" VL !H*H(#$_46<-
M2[C":%$ 0Y6L 06=(9 -$@T'+##!!B^$@R..8 .& L,1)Q#J$4K@@7@&&M;C
MF\(O%[)%*"X B]O &7=N, @>2206:"6 ),(3R24$P\>C,*(';I E27CA$[!,
M1RQ$,!1S=-8<=T K"R1A"'[PM]?$(&,4:C#02-X@ VX]!5446KHI\&^*A: %
M&VB@EB  %\W3&H0G&I&%%2 B"8(X!"*T8(53/'(*>]Y 'DYPB#7_<Y<)U>D0
M+42+B":\@ U]6(IT8HTWE; !#C<]A!VTX"&X2@&FCWY!)IX0A9$;8BY#9 ,*
MHH ),_ A"IQF C#XD$,/<-0.2C*"':* RAOB0 ,C0 $N.]YT[;TX(5#_7S &
M@8,?M$$3$9#$0.'Q@PV_(!@1&,24EH("^'U $3# D3S(O@I'!,'%1[B1UN'7
M6!QPF[4"^($&)#&?FAJ!"35H-CQ6087WS=T(DF5GZC*@@_G<903%H(+63P#<
M/I"5(5IRPR8TPA$M##P+J5A#!T4XP1.P5PMMKGS&^<Z$'N@@$0R]P44$T6ZG
M"RT=-8"I$$;1! T< @5>X"DP^;0<4C1"_PMF:0$K/\X9$?00T;K%8?2]((4F
ML" 4<"6B4*__PB3>'OR&"N^W[]<[LQ+P*1$P:T( .((3:. #Q1!'C5GPQE"<
M .RX1GHZ%+$"9'] V9[B\/CO$*(-(1(K @ZA&)HMVX3MR,Q@%&B@QCSC" X!
MLSJ+_^;O#KCM@HY,"8P%==0,A':"?UZOI\"#^/C$-B*()_KMD!(!D%SB!>^L
MX?;L ,9,%2"#O7IJ";0@^XZ@!WR#R<)/:+BK,P[B1W9N$,R(I[")3\P"0HJ#
M"'P #60($5" #;A "1SA"C1!SSSM!-K U3P-Y&K AK@P1=A@T>:&"-O07LR!
M),J/=X0I_H##4_\>C!\:X0;0"K9<@ BT0"D&H20&Y ]: -E@JP6(  BPR,<4
M(8B6(A&)X1):+)C4 &>DY" :ZPX< +:(@ @280&6PA,AX0-.(1+LP!.)(4T"
MR S^P 7<Q Q^01SH)W$:#PAB!2]:(@<R8 VN(U!HZ^[@(0_H[8/N#!2TH!C'
M[/6R0/4*H4KV:(,2(6[4P 74 -#<,&BT Z8\) \"H!1NH V&+U!RKQ.H !YH
MX1C7R ZNP!'<(*@&P>?4,-5"#8;&8QT8Y"T<R BJ(!$1(2FP$2 9@@!&0&8:
M81:AIUP2HAZV!3OJ(0458E4><E#VQ5J :55 \%A")B%H$7((8&06)57_(N C
M^<0CU>< ,"\@C<8C26=8:.J+&"("6  C$8( '(TC4S+0:F,@Y! G>](G;^<F
M?U(H:=(<^&$J[' HDU(IEY(I:T<M!N*VFE(JIY(JJ_)Q(L <+,4@@](JN](K
MOQ(L V4!1D!P>#(LSQ(MTU(M%T(MXO ?UQ(NXU(N?7(@$>AIHL9L!B)2ONTN
M.6\N_Q(P [.KVM)O1L)O=JTP2:(%A@"6!-,Q'Q,RNZ<V.N=O^J9O:*9O-J$Q
M(Y,S.],SF8< IB .3* '1K,TO: &9(:O>L +8B .6K,'3  E/W-H*,$N;Y,O
M<7,6[C(,#&4)J.8NPP9JA!,XAY,W:1, @$$W_^]R-Y<3:GC@:\H&.'=3.IT&
M-Z$3.<EG,DOB+1>"*[-341#!, >"/,O3/,ES%I3 4,1S%E@B,=U3*@YS('X
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MDVE(52'25!60TP3BE$GY)@ P]4_ AE(%A4KO%%2Q1T^Y$WD\) U\2")\8 $
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M62'4^X4OE;YW=<-@8,-VQ:QD]A3$#;;N@!$+7)PD8&CS#\9P@!8ZJQ0]880
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M98X@:.(%GX!!0J80A#"H8@5#,"Y/S!$,PTWA! V6R*-%8 8JI*,8M4O>I#.
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M.3#E!J6 "3SF:/&7EWP@9P" B@20F*4@"OJ6BY? !@7Y"S8P!N*XD_6$ PN
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M1^9 "?W*:OP'D,BX ML8CK5&KW2Y?4FHI"O !)@P!8I@ R/@ VB0:HZ @5J
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MTI.?!&4H13E*4I;2E*=$)25?@PESW.&2#4F'&KJ B-^PL2)_J4@@TX <]'W
M!&@HH1'2P(0;I$D(=KC"X\P !SYE0 HH0,$:BIE*:E;3FM?$9C8[-!,TF*$/
M 93(%)A @3.L8 A'\T@K&SF1*5RAG*8BH"1.8!V#7,*=\!$'DK)@(A&TS%$
MV( J*+ ")A!.FP=%:$(5NM ]PL,/63E &#2P@3@0,@)FB$,6T+"!,%" "K3J
M 70 ^@-1G &89HB!'!2!B0-080,D-:D$4!J&RH1J21&0!* V$ .1 I2G(=PI
M=%YZB"RP(!0F95$,SI"5"!S@_Z<1]6A?A) %"3CN (-80AE851!:$,,!\%A%
M?22U@5&D#A'S1%\$/%!4AK;5K6^%:UP_A%-B+& *)TC%$KQ0 QQ<@A(FJ,$)
M7M "-MP@5$L [%E&T @>E"P5.O#"*38! SLUX@K4"<4:>)"&3=!S"D?PU64$
MD=>]^LT[?$V%'7C UQ<\X0JG<.T2!#$"U_+51:K% @Y>X 8V4+4@&\!"$[Y:
M""/(T2$SH4)7O[H*+O1A5=>QE%RE.UWJ5M>Z%,G "30@B4#00D?P^$4,##N3
M%Y3A@7]: 'A9*0@8?& -CKA#5:L4#!9IP QKL(,6)# 3S]I(32=8@7[!"R8<
M$,"I ?_NR2CDQ,H3H"$=@C#15T=!A1%H(2]$DI)!)@8*"X=J3P[!J0^VFXCT
MAK55C_.39*Z[8A:WV,7:_, OYC$&&_PD /QHQ T.88<DE.(%8>S33[#5"# 9
M235+  *)T*"2G1QI%$O(Q9&^X-D36&8$V,B#M6:18TG4M4^26 >U9LF3[,[H
M"#]>;A:$O(XQ%S)4:T G=C)7$#^9RD]>A0=] "!G@@3FFR\&=* %/>A*XM01
MGZ@)#H;2!DDP@0KD!3).<? 533C **-( S'&,PI,F$5D[DT*B5A%'*;:9!!0
MD<IV Y%>L 1%"84(TZAF)%B>P>,47.A*(301H@>: 3]@[4/_FO@WYS[1X@@&
M-<=9-F!BQQ'DLP8E=+2E/6UJ8W$$GF@2BXZD S4 00(C&$(/@(RR*G^@&.)H
MY0+<RR,69& ((E!)$7B"I"Z)Z4?.KG($,E",>;"H$#&NDXWLV:49$2D8EL8*
M_UXPIY6RJ)L&%P\M!!&"2RABA7LF'0$$0#Y[XNX21T##QZTS;#7AP!Y]4L("
M;%EMEK?<Y2\7R0= <;2)+4T+E]"!)Y@P!,08<&(,6S5+F.(TH'VBTR+2$5/0
M@ 4BS,VS:@A  !HAEI:!3 /P6!D1@%#U+H3L+$; RA0@_(2E45T20&O"8\0S
M,;>QSL,BF (;Q/'E)/!''WW :=,A_]&7YU[F+ 0<Q31A/GC"%][P$[E;YC9@
MF0-LU2&+)P@+SP<_7\M$$<1N".1_Z[X01J2 !D'@0RK(P@A, W<.\>#A5;]Z
MUK<^+5@8MX521 $SKKQ>!UC&*UV_>][WON5"6*J& @D,0MK>]\='?O*5OWSF
M-]_YSX=^]*4_?>I7W_K7QW[VM;]][G??^]\'?_C%/W[RE]_\YT=_^M6_?O:W
MW_WOAW_\Y3]_^M??_O?'?_[UOW_^]]___P?  !3  23  C3  T3 !%3 !63
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M@4<FAL[SJ\L2!%48@R?O<N8J@5-(!,/X,R3A 3Y@@@:5@L8: @I @<8:WPQ
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M/2) $I* T%H@ '#@$M2@$^[/$SH!AA#C 'X@!-(A#3I!<MP#'C0A^PK"?,I
M N?##.R@%/H@*IZ" NW!H^#! T"A8N#E%-:A#*A@3"9+$QY'"7"0308A"&Y
M/F[P<8H %)K <>;B "0A $JO!9A  Y&F'C0!^N0BA#+!!W:F,M2@])J0>UQ
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M$WY$#0(2!ZB&AV:A"\@0)F101:/$# 8A 4^@#0;!#32T!Q"A%&C -I,@ (*
M+/$O$I*C$6)4%)< $1JQ%( A_YHP/4,P8>+R!3BQ"WR@$"0!2B>A+FW4#IX
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M!3ZSN:-@!5 S4A6SK0>!#;@@PH'U!4 A'NVBPK4Y4J'[!DK@!V!@OFW@$'1
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M%.PO&8C@#B2@ (G "XC '"]:* #"31E, "2I>8("Q1IBD@QI67!@VR9,$@
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ML !M$ <H6HVQ2:$B^C'IL 8WA0.7H ,F4 -$D0%,4"E T!ENA0/<EP%78"A
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M!E] S32?JO;))<!406RQ]!2@!8>+<T8P"CQ@X,=FHI!P27' [:'] WG-)4!
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M. 6@"!!>N#@P%XP HR3\6K2X<<B.FU*8/OQIY(,%HUFS6C0" @! .E(5'8S
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M@,5IH':)\<()$B.Z0MA'<]OE;G>[R[F]U$X"(SB!!LR@ S44; 1#P(0DM&#
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ML5+_.J/0)MT'O]@P]_354W']&-E3O_UT)]ATP"#S(8(("H@LL<85.5 T1<'
MS&F.((,8LLXLC4!"<@U)E!)&'HWX  V22,+L\+> BF0 !SH: V$*E $?'$*!
MR\.0AC@D"4C$9!2:4$4-W+ )<;@H#RV8Q3I:0(P#PJQ \!C$&;#@!A*V !&"
MJ$$?'#"X+!C!!RMPQ E0)"G2 3&(0O1)*% @A2CPP#!QPE(BMA2'943@!TV:
MA!>B0 4WG2H&6((#%6A!BED$H M-. P /A"#&WA&5DM(W_G0AX(K<&$U9G#$
M%>!7",P!0PI?7 ?C<F %/JAA$L!P!!&NH!A2!"",/CB,_QG^UP1[% &188Q"
M#TC1@C!2(@H:F48,#L,T-S"A#ZGH011B@ EX:/%/BXH!)Q*F!B)H 4Q3BA<8
MO-$&7AFA"NL(XQ$. Z8H8 &)UZ( '$0!+5ZATI:DI  0.C6GD1R"DD"( +="
M\0=^S*(+5\!$1<P JP@4(1-,0,BQ,,&T;0[Q2 >@A2>(P 1SON!$BSJ$-TJP
M@I>53!4(*8(W6!!-9B:MGCW P0%6 !LC/"<D0A@#Z$Q#$AVL 1&4Z&&L5C!-
M(8R" AI!J#UCI80PO."B)@,:$Z2PJ) " *,V0*D0OF #_$@@%:/@)M,P9@5-
M4,BB25,$#%Z @YW"(!0:284BY/] T!&\+!7/\6D$/+ 2C')S),DS1R/2$[@[
M))  (P@& "ZAB!<$HT/!((!786"1!(H5<XH0X$K,,%.+\ YOXI!$( " -QOD
M 1&Z2R=?^QJ:"$PA%MZ"AR3R$TK9T 8;@\#!#P2@"0<<<'?!6(#P@%,&#01V
M.+]I#0N8$U+"$J.,IU@",21 (DR8 P@2:*HC/H$&UIX $Q&0A!2$,ULI'$$G
MS/$(/'YP!E6((@RJ^&T8SL""%@F"C #( #@&X8,?*$$3+!@!'#DBCI8,0K%1
M@*YT&:1 !W$A@2Q(('[0<( +94@G%>G1 DCD""9PH:4Y,)$=MON#[B+P0_!8
MQ1E68(+_+FFB+WP@A@U7P84/2&$-%!@#:7_HUP=#^",9>--(XI"&*#@"#H5
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M,,T=;;ANCCLL('58GQH5@./ (:Q@K/\C&$(./$"# YHCX109@1K0OEQ/W($
M?U>9.11X&HG;1,(XZ$LAED<%25PN T,PG 9&H,/D+N_GK#F!.&1C@P1V9_$2
M1&]N/R*_0EP"?2D*&PW2<805" (3)+I3!J[0>7B-X$7]X4/@?%"E+VQI$,I"
M7!\BH(3$.SWYI)O"%[(@ 0N-P6%:NL055/RF);[ 4D*00@RB($HM"8$'D$B%
MF;+4AS@]TZ[ N)-IS""1]TP!6VR*DPG"G(.%(B(*XA#"E.8O)DG%'Q>0BRIX
M0:C4DAS$0:_$P2A< 3& B3=X1I*UWJX RI7P7Q.D2J^ @0Z\B!EX02R1$C
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M@".H06$6P@N\DAH8PA# H*#!S"DT9MM]1&2N"3%8RPW00OYQ&KI82R*(R*W
M0:8=P BT3J^@BP:$0AY0IN:-!!:T0",P@0TT)W5J0I)1 48XRQ-FHZP<@:V4
MC T(3+35P]:9(<88#0K0  ;@R+#542-Z@-:$5$%I0;MXYTB 08X<2;N\X4\
MS=<8 6'>  ',9\+$2D[MAQ&\%4EH 49Q 5,QZ$I)!X/FP L<1P;T4G0FJ"#@
MAT]IE6L=@LLI L?_3!,M,($J'$<$=8AK(152?LTE9&(9_4$9E, I.!M^&('6
M0)Q7H</+;%S-+1>/OHP97 $,;)4$I,/76<0(7):&@H=T+*DJK($-[$8$2-=5
M:NF1$,!Q@<1J'8"7?D0$K((XY&5HP$-3<$@]O,<!.$4'T,D1)!YB583K'0:)
M\%:9 E&8?@0!"$ $<(@ M*E#%EX).*1H8-E'L&E%P,.H?>E(P%A(', ")&J8
MYLL!0-:6:NKH)(1E4,0&: )_/%&F@00!..J81@ !J.G($$"B]M4!K&J72DH$
M=("8$D 'G"E(P.I[J.KS\<JJCFFM?@1=4-R?)2JEJJI#IFJB JI/L("K_P(
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M*[NC_\<Z@/_XLD/[: RUBH/Y!O\ $?Q   ]P#"!"&T"[F4/Y'9=0LD=[N5.
MC[LZ:,!YLY=[NX^I_>RY </WKV.P%"#"Z"XP"U""%]"[JAM[FH\0N;N[LH?!
MLY.&*ES2+,CZP"M[/U/[+'#PM:/Y!5, MD<["HS0Q(_&J L\PZNZ*,0Y+M-Y
MNGO\K-NZ/N>ZO)=POS/P30H !A, (O  RZ?ZD@_Z=(=[R4=[P2L\+F-Q "R\
MSH>Z1_-Y"X Z! L E!^] E?\#RR]JH-[J6_\"$F]T,\Z!>AX7.MYT%L]HA/
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M8T:-&SE2), O89*.(TD::L&/ $G_E2L!M"$2AF7,D3TH_9!Y$V?.@3QFM:!
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MWKR@I%'NB.,AY8[AY>]>AVV+V65G5W,*1(YKOE5 $(\<-#<!*#-6.O82W1D
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M:]3F-\<93G)VLYS@U.96Q!E.=[X3GO&4YSSI"4]R)J:>^=3G/OG93W_^\YZ
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MP+EI/>YK9WO;"7@U CHC;R>X>R#ECO:NTRUO:AL@)=AFA;8%XF]W^QO@!$&
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M5\  SF? #"( @N7SO?#.QX 8(G" LG>; QR81@+ +N9L#&  @0= "M"O<8&
M( 470#_Z'7[^^0\ X!)(@ 4NP JSL#_].B/^\ __,D# _N;O]=9/_N:OV/3O
M_*0- "8 _4!@1B1P (J-("!@ -'O EY/ BR0 0E  @S@ =%.%M!O[23@! >
MUQ0. #E0_79@ =&O!4WA_.@@W79@ "[ % 1"!UGPYA  !-$O!F<0"*_M_'8
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M'H+O6A'RZG '*@ BNZ$2$A !Z. VA5$6\&!_C-$6%" !=XX$+( .O(W6U.\
M., "^-$ ?//U)H_6F#,MD6!&TG "EI$$"<'A$* 6)B >#4 6_I :G4 6XA$5
M@O,-3><85Q'J0( .]F$'8NX='W$6#>#NIH$.4F#X:&__$#&".V7 / =.\RH
M#_*- \@ \C  %?*0^1!@"Q)@!NK!"2K!Z\[SZZIOX!QN\HYSY[Z.$$% #+;Q
M]1#@%K9Q[.CN !P. RI4#(PQ17> 1 4" TC 0CMC\L8N\#  1-FQ'B"R_!Z2
M&'&4#%(4"I)4 AC@2,%1 MXQ\ K1.4D 'E%TYRI@"UXO A2/'0MQ!K8 'S?
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M.;>-)/O5 @Q98FO1H_N5:OFNA6_8GA? /+=8&&\Q',_8C8.;BIDT8H^4 )S
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M8O,P-B(B0.<0AI*K]2&X'0YC[N)ELT_AL"#<!3(L S(>'HDBXN$;22TQ&?U
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M&\P5("0 &$BP( (ZK#H8L"7+B<-L%NC,Z%"0X 8G"F0<<+(#@D4GA&0,C(#
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MT*QO:1(!PC1 X[:#1\XU<D079, N32'-! B(B^ DF99&,X"7Y45^ T!,SP8
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MSJKT1\*"F# WO$+6KS(%EV'%QX7(8B]U1TSB$JL%E1RX!4E8,1T$H(>LDC3
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MT2,@4/F<R5 !2HZ6#$VRZBG)\%N7RSOD.Q#0RE?>DXLD!98(KT16O&GT9'+
M"::@.0 6@(J;WU+E4B<# W:@P#-+X #+>[?:R=(][I;S2^>5-6OJ=*8TN=U[
MY2Q-!""P3CG)[T_T@Y!G]&1 Y.R$?]BQ+YWPBZ:_W*_P$/3O@LV6M<GK3]NQ
MLF!/IDT0#?[W;"JE2'7VD?E57;#"N>*+8'BUJLL J\,M-!^R$KSVVML^>R#@
M  @4QP$IV_O&!B#N(T72XZA, "%K-84IP"L5CE0@ ;*$- +D+62'"=( 0NH
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M)HD6))&+,79*=80K(."!=B1C>T<" ?_G+WKA.*ZR#W>6<B])!X1 9+YH<P-
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M0)@##!0$43/F (4O!^S#%]/  @ )L@T@0=2G3)HQ$[0<",+"SI@*)4R(&71
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M6"!%7@"U:.R'&^.!RB2F\K7(( ..RN  'PVS$UBAY!N+@0Q/-@"SZM$3;UF
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M1.#9*0;@@,&C@Z6SHM4+1:(XPD@)Q5!,.U+D  \C S^T,_0P-3L!C T Q4H
M'@8@)T>,%M?KPHA(E4@:$7!$-A,)-NJ+$(41B7X9&-^8A74\MA98MH^(&,#0
M))Q@/XO9"8S9DHVQ&!!(I0$0 ^[AHJG(I9*YBBL)% GPBIUIF2\YR E2B_^P
MJ1FVF!')6$BZ>,B?L1E@,K=]:"TJ"9MJXB4)RK=F2@L)D)J@D";(T(K-&$&W
M"(W&& WS.HVPN8M_XY'8X)+/6"&B0">G@Q!+28.XP2&(V(YB\!MIR0!2:(*/
M X 7O"&$N)1$0 ,/6(-263D+08!::#K=2!8+H*DKJB)N^BBW,P@&R 9+8 4G
MT+D4H .T4\+@@2PO DIW>JB-@+JLE#!42,4\FS.J0@*E !Y9N,L.D(\:PYU?
MG %4,(!&,P D$$,@([) K!RWZ[,T\BML63JX6CVE(@,#V(%%_,M:5(K.N4L"
M((##7$S"W('%-(709$0< P$KHTP&",;88\W%E '_5&"%6^@ U<, *" K6H3-
MOV2 6Q!,E'("$HN 'D/,%- Y"$"%"E  QL2# VBRV:P<MO*Z]'#"Z$2%W>2/
M:9@)Y*O+B)B"&/"".' 5]O2"&NB7%KB"]@2&. "&&( #&#!'"+F><,2^D B
M[ O0=S0MA$"M\^LJ@4 AJJBM&RD_2O&>U,*1J""3^+F8]PLG'P&2,($1 _K'
MY/*?+@D@YPJ4R=@N/"$F"M0@+KFWF(B@H,FN 9R1&9' #]*@!BJOV#))*$&O
M$5(O$Q*? 3@;\@A(M'$A#+$.Z=!"[@ BXE"5)L#!@?B 00B"&"2Y06 "5; #
M@L(7+#*%"*,6D&H(U]$P_S12@"OT(K.L#I49C)C(P@+!G<N2(SI 3B5D #$
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M\169&8&?>0/1^V6NAYB &:F_ K*3@TU1@8"_Y<K1Z^+(9XI ."$;@5A11\G
M''6F$-H_/"FABF39N2@G$SQ2"S&#06B$*^ !$_ "+S !+E@ W8D 2: $K)1!
M4F"#%XX#.U"# $B<AKB$/&B!7-$7,HTRWD$SL1P 63 JF4J "NC"9*D$9G$6
MX9$(X*D$-?7"#[,6;+$ L%V(__%8EF:)0PI+NC[-,4)JSNV-#]/(CY7['(B
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..^K?_^\?__-?_00\( #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g101602bgi002.gif
<DESCRIPTION>G101602BGI002.GIF
<TEXT>
begin 644 g101602bgi002.gif
M1TE&.#=AIP.Y!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
M#*  !TC  AKP@ A,H (7R, &.O"!$(R@!"=(P0I:\((8S* &-\C!#GKP@R ,
MH0A'2,(2FO"$*$RA"E?(PA:Z\(4PC*$,9TC#&MKPACC,H0YWR,,>^O"'0 RB
M$/^'2,0B&O&(2$RB$I?(Q"8Z\8E0C*(4ITC%*EKQBEC,HA:WR,4N>O&+8 RC
M&,=(QC*:\8QH3*,:U\C&-KKQC7",HQSG2,<ZVO&.>,RC'O?(QS[Z\8^ #*0@
M!TG(0AKRD(A,I"(7R<A&.O*1D(RD)"=)R4I:\I*8S*0F-\G)3GKRDZ ,I2A'
M2<I2FO*4J$RE*E?)RE:Z\I6PC*4L9TG+6MKREKC,I2YWR<M>^O*7P RF,(=)
MS&(:\YC(3*8RE\G,9CKSF=",IC2G2<UJ6O.:V,RF-K?)S6YZ\YO@#*<XQTG.
M<IKSG.A,ISK7R<YVNO.=\(RG/.=)SWK:\Y[XS*<^]\G_SW[Z\Y\ #:A !TK0
M@AKTH A-J$(7RM"&.O2A$(VH1"=*T8JV+AY1"( \_*%1CFX4#.6@H@+0L=&.
M=K0!&F!#3TZA@P\$X*4P#< 1,#"0;;1@!S^PAT=9(0  Q ,8,7@  $X1 5<P
MP 3^4(0,#@" 'T! I2Z(0#D((!"G0E6J5"6!5!D C)D"0 ) *,$/(I /G0["
M 57M! \(P  UE   "##!!Q3A PS$ PH?\,=&S^I3,1RA @!H*P<.$-<(:, '
M0\"K/?(1@$'\(0(E'<0.3G&'!G3" CN@:E^/<(+ 2L(?+9@"59W* \ *A )1
M^,!B&_L'M1)  FZMPATBFP2J_YZB$4*H@1'J&@\Q=&$.JF4L"P"!B,@^UAZ*
MH(,/*B "*G# KF+PP0H0L5H6F"$*$="K/P:1 LTBX!!WT  '.BL"ZFI@'G4]
M+2'RJM$6 "((C+4'"_2 !BS0%  B"()> \""0N17'D:P !::6U<&,&&\"O!#
M>-U W@,_  $AZ$$5@M!1%@A!LP+)KT[EX8$=)!@1XNC!#N"*A"4P%0 3D(0\
M.K&!0F 8OTS@+(E-/! %_ $(XG##B"? A!X\V 1="(, 5D#A#G3WM#30 4<7
M*PX./( !(;"! R0@B0 L5A'$8*H$UA  %M^@ G" 0GQ'T 4FR$,<1>C"#L)<
M4E D@?\"T\UQ"@# 9G&@0,T"D0 3,$N",I1T!/H@PG/A' 1Q6" %<(CR#B@0
MB#Z,F"")3NH&OASIC2J" WTN*1@XD.@./)H"$P[Q#HXJY>^^ SX#Z?2(X6 "
M3PN !$180@@"H(%W+.&^@0V!/<0QCRZD(!2ZUJL&>N"(>S3 HP'H@ ,2#(,=
MA.(7+^V$KT-A@G?L8,B-&+$ :F!L87< $.\(0X)1@ 4IQ'?83(VK/\Z+9P'D
M-P#O*(2[[Q%?6@<W .+XJPBJ'.^XYOL $P"&(EHA$ 000AX0V, ,A.IN?A?"
MX(R5-A8F<(_]BJ,#APBJ %(< !2X.,$LF(*[U:!2 ( \!"'_'WG))5"+DC8
MXRP0\@\Z(00:E-4?XO# B15@<YU>_!"*F )^2?Y5)D3@'2(7P0+",)"-A\ ?
M%J9J@B,@CKH*@ :K#4 ,#F&/ *19J *Y^H:U?@ :* *J<? %$'B*7S\C.P8
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MG7"%2!=V-?] 7!=H!"'V -3&AEO&8AO0!RZ&8B'0"480 2S  Q.P!IA(!+Y
MBMG'!VY #YU(?KZV D#PAQV0!(G&8DYH T)6 T  "C=0!9 X#WW@"T30 Q4
MBQ>("+86 DJE "10!*B6:B9P@1$P HC5BIFX!&3P!'30!IW0![TH"8HP50VW
MB&M(!B%@ 0X0"GYP:DVW;W1( -2F""5@8XV !2;P@G=P:2<65QI0!$; !^]
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M;D")$09V=*R\!W8%7/\6E";0!WK@Q,1)$ E0 T5P T]K:W_ !):X!D6P!)1
M#V W 1(X@T.LR"2YQ)3@JR< ;!; BCHKQ[.* 0(0"D_@!N9H R>0:)C% $_
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M#U1 SW&EV@V@")[:KDR58!"0S*K-V%3UM)O';"I@ CK7@N3F!RRP!BB !E1
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M0XT-,TP@BM##D1HWQ3*<& ! HD07:]XM<7BJD8P# !BHX7!E#H<'$B>,Q*"
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M (TGD$( .F&,%?FA!2%@QP[>$  61&DBT?O1>K:8.3(E"6Q160\+N.BE&.S
M#W(L!PD !8 :Y( '-5 "%Y$T1P"$(@II_&1/WN"$%BKB,UXR):LBX$=#*4):
M7M(3#>2AB"C]P!_B\  !:!"MJ+0*45Y20I04$(46',*5_-$&+Y<5#W3(45K,
M@F8TI7DL%Y3_X0A\XU?%VA617AFJ!8%"@"1&X(M#1.!'(6.!+Z#0@FSIJSH2
MB  O8@6 >*CA" P0PP=8$9%3(.(=:$##.<"V#78B  H!0X 8%-&%<AX!*A0P
MAP=P,I%XB,&<$8G''"# @4,@0D()^QH SK6!+@3T!*=P#B""P,ZVQ0,*YL3
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MT!3-T23-TC3-TT3-U%3-U63-UG3-UX1-;BR V9Q-B:!-VK3-VQ0  +C-V4P
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M(X=RGH2*!7AIO;N"]\V -H@ PC89(PA'04ME*B"#"H  >9!U7Z$##1AL?TP
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M;7M8@&0Y 7D!!(FX9'M8 HF8_W_WQPV @.8$B OS(F0 8!  &2,! AA( ,!
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M>$ -?O^' E#"! G #Q3A#O"$ -" $WY@^[V!T"R$/\##)XR'"  !O<F#.)0
M _K$#3*"#E($#QIA3L2@9^A; _  !OR #ICA=\ !%,3 %!C$#[2!!SSA3D3A
M'71 $E#A^H5@ ,3 #@Q!!A#"18AA>#  %-B#(MQ !22 " 1!! S"#HPA%&I#
M!!S!"VX$!NX$ BCB%4A!!'1 "JA !F  #^:@=S#A'<1 "AA$*(3"&>H$('J
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M@0^80$30X@K<@3]H  <$C@"@(@<<0D2,(P\R@A_8)5[J)0U$ "-@  6@X@Q
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M*Q@$5XJ#&S@F* ) / ##"&RJ(1[!3=($ P"#./#"-"(C,E; A1Z!K(9 !)3
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M'=OQSMZ*?GY 8MKB$%R!&/AQ%7C&T+B,)E+ _@9.UA(H5?(!_VKK5DKP#I#
M'#HE(\(M0<KMWQ[A,ABRRY3H%%!PCPYD$?[H=G) %:#I(2]$"^"P/.J@ #+!
M0B@")@+N82:P04!K"_@"*S= RYBHYT[0NDX0Z>HA(M"NFP:A&DEG9RX$&,B
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ML ( XC$';6J@!*%4C!MCD(*\#>$$K<O6,H+0@D(8!G]W8 $5\=<&#<B@ C5
M1 <<@*T6#D.>!NH>$#IP1@V2X X1)>5%,8HN<@9 'D<(6SQ4*3<!+*Z!@J&
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M@J'#6P8U#H(C+5A' "!@RXW1+L:!3LFH&SM0]H"ZU)%^P:4;%!$1__@ **9
M40V\@PH1& $'7IQJO6>TE4<@@3V8^UP-&",!Y&3!%%!X!W&T8K,H19\  / &
MSSH0I;8&\!<>X+P <.  SA.'*Y(;@,-O4/'E4("V(2EMP^!TBG  @A+*X4 :
MW&$1>0< 3@NL07(B\##XE-Z\/9#0"7-X!.4X !PD\7EYFR,"BFBG!))_5&K?
M4@%1X,.)G0<!! K@>4K/+)G)Z8%#(.((%8@"!)8P!^T[D,D[H( )R+]T#MO
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M5.\+1;*&6DG7_JX%R*"8IN"Y1B#2 F,;3NF66+' =FV'S+ %<DXPUJ<%EL
M#. 0'BE]!J,/=ZL36\ !<&H0A.\PO,@?Q$<0U0#V9&\B;8^ *+$2:2\D Z/?
MS(8!HB]LL(N7S(K#3@R[1,RL=J\"IF^SK"_=_&H"D$ "&^#QDBP0@>\*_R0!
M!@HMGL[O^:A@!+J '@S R71* JA  [J@)YT,DM(HGLP*@FYM]FS1K$IP&.<
M]NSH?)8R, :P&.6&@_Z)@P8!"PC G01@ IPL,E;LD^SGSA)!^$;G#PS)[(R0
MHBPJ(S7 !@3S#ZB@!6Y '<.(Z>@Q!)4 ![^+"7R3 %HKHCCK(KEG!6*('D)
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M9^!=ZW5OA#,GM\X1UB R0&$?,_5HJ68\T0D8&F-XB-6HP!*EN&%:K8<2YW
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M2!$X( .J@ D*D >#P*)22!%\X +X.  Z,*Y@X,OBBGWYU(20J<INC8.*UIT
M^)>'!IP"@!'DA@+0 =Z(!P'_CMD@&B/WU!-[7&$^B=FYKL@?$J(!8L_7HJ@Q
M?NB:OHB9[_B6;"Q!Q:U1!04.3X!8/^!#/* >W3&E*C%?#T-4']96=0 >(LE_
MGG4L*TS>5I3%.$SIQL@BY $,\$KINE4<YJ'=F(U_(,A&P>EQ!_ #_(C[U@\
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MM/# <"*$BB\& [@P\5(UA%K!4?;XB'&4W*0GHP8+W*'E4!X4Y&H4XI23G@1
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M+?$X^'D2+:5+!=HAKQ('^*D AU"A$T@ <+ &/K&5),$::J"G$$.)-!%2?7H
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M+&LR"%4D955298QRGCJP)FAV%*?<RC4S!^V37,M#2U30!E@R<>>)+$OV'RE
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M@H59J(/Q^:@]SA\_ZER2<+RV#@0,&@'"T*+Q6((1K9F^(Q>J6P.=BDP2]5;
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M#0*>"L ?D (("K1%NJ) BIAO R#H%J90#>67EF'-D3OHA>[ $FZ3((BJM?8
MS-5B.&&G#+M@HI/,-O,/ /\7$$E-@.G*47F9(#PX0376'* AAQ)"+'6S[PZ2
M@(D1"HD'\2%JN^&EXH[.IP%[G%O<O3"GHV_Q#I(XZ)0@8B#C01E&5N 0D/T!
M@SZ%2$"$ RLD6",&T3\#BHPG($A=H01(#\">RP,01ST!3##R  $"2>\$#P,4
MX(7T*E >Q!%]J& %1!JP8 UNK>B0CP [+X.#/W) I),>'%D#E,J.3IH%?9@(
MR9^0!KF!2>P#P?0"__6 2*Q"TB"$H),5J$%<I>()2/PACP=&$(+R& &($,(
M$Z! " 1@0 @,*#4Y24(<1= '(KQ@)TW% 2<=')4 V/.EAB@J3VD2F B8( X4
ME+#_ P910 V.$H!PG0!/C0J5 T.BB!DX(@Z)$(H 5E"&.@VL3@SI8*4$]D0+
M/.!4 ER=(LHA  E  07T",'10A* ?=V& E4H@P3=.$%Q%$PG-8C#.^@!!0@8
MX1VGZP0;7!@"<71B 4$P5X\ZP0%8M8(AKXJC Q;2H7UIJ0,.F  4 M )"+1"
M:@MY501VV"\2\.$(_U$$M!05 79\*@$DZ(0K-MDP6,92EK.D)2T1  P-$,T^
MP(#'IY8RB":^ 2I3LZ0]R((;8+!@#;E<R#)T$(.N$',$0A!!&:"I$V%F9F)3
M^ I6+(:(0?"0$BGH9EC&,@4"U*!D(T/(,L[2E:#-16I?_X' !G?2M9S$0U1K
MJ)3*# ,[W*BA!2E@3E)T\IJ92,!N.R# :TJ  "A4S3,N*)WHXB$YE8W-/9#I
M6@78Y -V H VPO&, 'YPEAWTYC>]D2A\/.#(<04!!NA\4@8Z1)T#:#0%D$&$
M&U00A=UL,@%78,S9PD0"-8"(7"S(D4E[^E,GS"U,#0S 1T(R& 68P'<*RL$,
MK*<$Z7UT"%JECUA^-($UP&"#77(#ASR4H(2,B -58$(#\D-7%3$!%#2T'2AR
M=Y[T8$ Z1JK (1!$)"-]2Q'$D)"/!)B0/456LI--@,I82)='@>* %PR!KFPX
M11&]X+ (2-(!F6,#&D)VB"A<F?\)%"$# MC0 BAT82",(X0J>(J%FQ58D3B0
M$U-AZ@&*\M1"!/"H4I:T!E!T0)$V]"HO$F!69/A%'U\)G;Y0-K)]JFQAEFL!
M,H3 'N)(A J6Q08M:8 #! A5062( CJ\@[4B\@,?/JF3">BA$ * KBN -RR(
MK(D/,:"M.ID8"BATHF+^ MBG$""%/M92PA.F<(4M7)@HB$.1"K%*. \2SW(
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M"V@XKJ78! B%5VQ6"2B#I+B-'^"84W "!\C2APB5 *"@<DB C%@&N_/;BF"
M1I@"PET("5 AMR6U.QB!'KP+Q'6($1LHV7@+OQE!%TH"K? "+#F(91#=RSU4
M&:(UV1 (,IB /A#!;V0 6775AY#=R6& %)B V8TAEJD .'@$@!)3%X("@:3=
MAH #)( KAV"9*T""WV*9N54(YG5>X[4E)!A#C/] @.NM7HRX@"O(@#^X4HFX
M3?&=B)KSA-3JT]0"TP6=@/6MB 00 ?2UB/9]7^!Q7__\&8R(7QCHTEA"/W$8
MA/K\C"20DQ;PWTZ5@%I("8%Y@Y"1@&ZY"-H -:)B 88Z7858!G888(.1 $]X
MC\03@]C@)#% C!+.CHSX"@V8FWNBF<2; V(@  GP@J)C@',X ;754['H@M$5
MJ2>0 =?%@AR.I5!XW1P.A7Y( 01XA'.X@D?PCWI<XAEX  9XXB&^, IX@0V
MW8H(!230SX80U#XX 3TH!G3I@M:LBT 88T<HAAN]L%#X@PC1".V=8X7I(?2]
MWE)5 !& K8IXDCZ(.07_J()&@- $C=]&*+H1E5]#]E 12.04[3J5J %V:#7X
MK8$8L.0518!2*)Q=>5R5T& $YE0&B(-A*A4QL(>,D=X!, \Q:>7$BP-]"QI7
M&-(*Q<9;[A< <P$8<  %0%*=&%LG1=$]80!/Z&&O4(,1GM'&I8 Y$((/Y.(%
M-8T*O=R@D8F7>)H/4#$!F+&#,.;^<P$O8%PCI5%LK(#&A5$5-6=F9&>=R&5<
M7F=@;M'&;9YS4+\GF '7U0]B=N<,I>9Y5F?SB"Q7KE )>&(^26>*R*HN<&(>
M0&>%_K!\WC,T>&@&E= L=6>,CHB-QF7CNF4*T ,D2&-=CFBO0(("T5!SI@ D
M_T#C$T2"/C!D)XSI@]@5>3;I"/7G6_;GONL' 4H P]%IPF7FOM,#)@KH(P5F
M"J@'(E#-#>$3R")F +A<=I;0&NB# 8Y?3T AGO9H71[F8?YJ7([<?XYJ:I9?
MP(,LLXUG[,( $? "#FX(H*ZAQ<5ESYV 1#:I5()JN_92PA6 4]AKLJ:XL"[K
M<W8(%NW'B/GF. CEH.!KL:Y4,%*#-6 $TW !-=B+4^A?$5 FP^07MC&4$4[F
M+!.(OSF%,K K>UHN"B*:DO2'02B$9< ](!IM;#P9T1X $3""-:CM 3"Q * #
M)Q!1^Q!AW0:"?&B!'A,#/L"?!O"'(ZB"'* "_GN+ /^8IGPY@K^1@$8HA'3V
MX#4X L(8L2 X@@?X@3*PAW 9 BC0@9MXY#7 @08 $7$FJ"#PA_XH4S)3FIWB
M%4G(S<EQ@4:@@\L D7J,WZ+\'"J@;D#KEQJX W\((NXF\/F&'J(3,4_0C[;[
M;X&D#3YX/S#Y0)LP@D[8 -#3;JV4A AXG0J0 !NDO2Y@C!%('(;@E3GPAQ&0
M'N:(\+%<M]SD #@@ CKHG@N?C7P^ 098 P&2 ") @RY8 A,H W$P OCJ'J/*
M$D(H@PZDA$>@ D20!QM( EDSS+T\"#AX D0H<!S^%G]0+W.+:56-P]_-00P!
M P$Z<R- F;E-@$=QG3BD 2W_QQ%L?+B%_ X&0(,$40 D. <5>((\;P"BDZ%\
M.(Y N(=+0H%S^ -+KT+G'0!%1P/_D0<(@ 'Z.+DVMX$3$%0C"(),)6[(8O,&
MF*E0@,C02 $I^( @VB1!77!YF"D .+D/B*-?H_4.* 83P'7C1!<O]QZ"(@*2
M0)?RY?,0B' 4X TD2(0#F&E-!T,4:(2C4*MH.79Q^!)T@0!$,((^2(0K@((_
MS ?/D\Y@1RWQU  4"&3H$(%:D(=GZ1!<%XVX^@-S_SLM8;\=NDUS[_4D,'A$
M@ $L\ ,=R%3"J*1\<#XM<6\]824ZV$4AF(![:( (ZY=78;]8&3@6H -[**5H
M$<81_R)0;(2#.6B%/:D!NZ,!][:[":B%,$0O$JCY806C6C#,<CB%3E@#P26
M@>-YH4(P=S^""JB!H6^ ->-WH/<7#:@^(?@!]S:H4(EP#PBIOLC;2>>FG\<!
M5KB@GX>R4U "HM< _S(I]V8J4FX$1W "PB !-PB!(PCL!]@*[2:!%M@!%W!
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M2#9,8=OC@I]./$8G4MSC0*A '!P35L[<QA ]\RG4@]5B2QS2B0_ V?  "8V
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M[%H$.E#A'?DUCE8Z\60J% $+_9A/KP)1B*@((4 O)$P"J2 ._E"HC7J0 T;
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M==P+G3C%)_ZM)."J"AX80A08(0)>NB#;[2R$"\KPCB4XP@FE.]P$SI%@>L?
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M @R+2<S=<1#*% QC% Z>*TG6'P2!!I0 +%Y2'"1!#91!!RR!AH3!QQV T,
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M5*4N)4(NOM+L?((A(1+H/$'4 0@090<ID8T!E!$O>1+_$0C!"@ 1D'!I*!C
M#OQC=G3 (:Q3ER8!YH61LLU$U!T,T[31"M 2IUV2&DS!SCG1V4#I*XE #M!!
M*["*,GF:.QU3 E@38?2#*XW,)W (0=G//CZJ O0#W"&C23AJ#*C,&OH-#7##
M)*G<,B2*2V(, O3#6(3E8A'4X3RJKK ! W0#K@D 1OD3JAX'1DT!#2P"QE#
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M!!#$*($ !>II!Q#3HK <GKQ(H4,!!>A0) \'6E'"C%S4;L 81UHF+ TU8A
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M"D9B$D *;N):,4%C6]7.V&5B>$"!,*F4-+^"1SK%B> D@' 9)=8( (P2"!"
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MZN.&*Z#P!XRL&>A#-[S@8%\$2:)O)*^9GC!B:ASXR01" #\.G$  )%@>"VX
MF04&#PXA&%X/'@"1.P2 @02 C-HR6!#$S. 099 '*-PE$/09 7,]^$D$1_>
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MH,!#,$$?3.R#":#!!PH(A#Z6L( @^T&+@>"Q"!Y!/2,[D@@,!40)'+D!.#(
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M5'H\X*CEH+IW>%KVE#E$)3M81E%[U!P2>  F(O /"6+0F'@03>[$(D$LA_"
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M*HX %J8L*\1&0D$/)&@$"F$"A((I7O\O] @@*)BO0F@ C5@' LZ&=HH"/-Z
M ]9R3^3J""A!$Y\ , 7S!AZ)"E@GP;Q/ ^?@ UA@"4Z@+<""'AYA-:$$Q\0B
M%.9@"2*S&(K+* I0+.+!$W[05(;D_3PA ;GB]ZC "%BG#(Y@_P;"!<+"!VLG
MO>9@!D@@PAP/2E: "N:!=7+ #2C!! =@C"*@$\RG1QZ!#MR )81D!J[  ?'S
MN*J3#@)+#\;3+-:$3,X""4( M\[B#[K 61*H"W9S#?%@":X@$.K360:4E CP
M!B%B 1:T6C9,M>!3A12 $.!3@*I@#;Z2#G(@N5XI/ME" 6B #Q1!O&($RV3
M5O1$:&[P9@#_P1=2U'*HH(\X P.&L QH=#D60 C 0P2(S%#64<DT8PX1 0(
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M2 SR'6: $NC!;R-E?BPD_,9/+(2DOP3,_\Z"!#9@!E[6 )J).QL).33O?(B
M"5SW<\=/Q=J/!(K %]2V&/Q@NUZW'S)T"!^A#Y"@#P"!?4+L*A*H#QPA!=,K
M#(>@#^A 0,.P:NA"-W(4$!C4:AAT(Y[@#A9G(R3H'?3 >^EA=(MA -H7$=Z!
M);9#@A;'@SCC %[@'+*SHA@#(M  "=;@08FV&!#-9GHC<=YA ;H@ 3ET"1)C
M"2OE!$P@![I #P !%!/C@["G?!.M+=1D  JX@F< >T+ #6BW&! $D>X !;J
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M3N&M:9 ,3/  0J' "$T?+ !U!1L(O4+(.'@!+/]D"#61#!P"QV)P3R9@ 8A
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M\ ;E&*U@ O;:U1#9T]ZQ:]CM'97#-N1MCZ>-.?)M"1Q!$N 2,S8+DTS "QY
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M*(FP@4U'C<U(!#YP!="8&@L$C2F 21QPC.\P VFT0(\@8.;1 T-@ HG A%1
MCV@00R;0!^FX 3- *[Y18.? ?"@P U6@#^:EB^L8 N]P XX0!-7X!ZT8" @S
M 312CRP@!)1 !#W ?.Q%8J%P"$607>:%23T0(N<!!X#0 U78"3EHD<08"#U0
M 229 O,X!!99")!V?S[YD[A4%HPP;"WP+0P@--IP3(51#BY0E,12#.[5,$WY
M+58E;1Y %F)0#J61@<#S.8XA%@_P X/T&N=0@JG1.]ED&"*@!.%QE$GP _^1
M0BT&$B1J( 0SN!6[51P*\3NNJ&72EHAS8"(_5HFO059PB1 40!X3 !UPN7)W
M*#Z-*1V*V0C=D1EA^ A+\ 1^2 -+$ )GH@"4<#=DE1E+< "$8'-"42P%8ESZ
M@ C=^ ,V]P-+\  T< ,3A@#C%9;LQ1"$X%]RB&7PR'84!QW280(ST)&VPCL9
M("8,= -#\ CZQ3O%(";\TR#BB '5^9R;V05T.'8_ F!=('0L YYZ0 0\, #S
M(R0UPD 2MFI=H =]P#("$ AJ  .VH0"/< [>!2)(@ 9D\ BV,78^D![Z8(F9
M)!W]^9^V00'060'&V4HNL  \@"JKI*#$$U7B86#_B,<#X@&=&5 H$[  F7(M
M?4 /A4*AYY !-'D Q=<<J;)[2"!@#*19$Z /70 (R88MQ4"3#U J,?0'#H9*
M0$H&@3 R"? '<D"D8$$!N4:D&\.2R?8'F!D(R58#"$,)N@:46KJEFY1_1V!<
MLQ43A? &G1!\&M<*R^ $#J :<* '!_=,%Z@HP%8"9$H'&1<!6LD62".%=P$
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M5A%T"N@&!F"QF(Z4&>'\",5P ,VM-I%Z(LW4 .^@!MO^ V08031P!XGE#^+
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M(T),=&%GY/OV<T)]XUA\M$8GS $FKD/$+Q0B8,_P8_S)$U310_R;=G7 7Q1
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M00<?A#!""2>DL$(++\0P0PTWY+!##S\$,4011R2Q1!-/1#%%%5=DL47:*$K
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M  ]$H 88;+D&'W!AQAJP1=,9#MHEV)<XP!VQ&%RA%KI3$\H0@3^YG([$[JK
M#^RA"#X,PA']N@(P N />>! 2@FH000\(!@1:C<&#^!IB5TW$#@ PV(). 4?
M%G& A/<+ PQXJ3@&\8 ?W,$?'&,4$,1'D!]\P'P"B4<M6! &"=QCY(D=@3%4
M@P!T?&#0,XB9R\0!97L03/\$$6 !(.Y049?9PQZ+F, =.K& .PPB##^(@ 4
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M]<HU"CC_A#CH@C)) 1+( =H:B'A SR0(!4DQL^N\ =2QS&60/^LZA;Q(@0O
M#,.!@2EH%*RA #]0 A_ B^Z# SWP@0WLJ .TFQN@@.M<0 O%4 X0E:&D@T<Q
MG!;@@2I@ AM@N1DE [GA@5P2B%P!A;^1I/-A@,,I!_OL%%&)L;R!%8<0@;S
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M "B!*F&]_:*)L%L$AW@?%*A"<SF%._"7@(* !7B9.GF?>2@"TCL"--$=SJJ
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MF6I*XP#H/A)055?3/R880PX8URD86&>9(/[LI6-4QHC10#B>ARKD_]=Y(;4
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M L[^_?&3O_SF/S_ZTZ_^];.__>Y_/_SC+__YT[_^]K\__O.O__WSO__^_S\
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MH@8 PHQ@ "?)QRG(T !(P*B ) "HB"=^HAJ( P_<U'[ HQK$P &\X2+\G:Q
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MB27%P!4DB3[< >$9$QE5 2+$@ K,0024E";Z]3MTR2*X&P;9LP8@45)%]HP
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MGEH C0@E!L1[[@A1C <2$/D+H(A']^\#D.Y>],"](CI4Y!V! \S\LO(FOB-
M@#=(FJ"\$\1K80<"5F- C!BL< &114Z@0 P8P(I@.D0B. (#E20(@K'&2OA0
M B!B.$$ $A IL3N2*(@B@AAV "!$&EG<\+<KU/A@/1\^1$H ! )!) "F)@@"
M1T2@8B* (TX0,I0_[@A '!^2]. $!N9HH1 $YJ!1 DEB2(("$YP0X@=$./B0
MA!R(0&20)/]L)+,O]]QX8,U.B@CBMT,0Z>$!"J1(DT$ $ @!AKY^  )* 7Z
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M(9");WPR"%(!K0<B1!S!"@ @P1U<M$ >#&$.'Y@3 %R (K PZ7\^$( $D!6
M$?  /B"2Q,%"T D9@ M*)YS.^'Q@O3$!L4!*<E674L"E,MTH!3%:%(LX0!\:
MY$ ?1O! 2B3 A!BD@#1W&".D:#B^&?B!314252$.!:8Q F!-@EI1#I*(E!I0
MX510JL$(H_0F#CB+<6G<P RBI"HFS"I1L&)"!VA% BIPX _5ZE1;.#"!-0!,
M+SFXP:$$$ I 6<E7(0!81I1P Y3IJFRFW!<AB,6@B)Q$7%3H0@:*(H2R9$L
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MX**9S&QN D#P'%5%H 8/A(UYC77L8R$;6=MH)QW,.8 "GE.<LB'G -IK#@6
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MH$88@)5)P*7L1E*%A!!FH(RSO-L?>!F&!P"$F(A1Z@U<VP#(P "2(+IKY ?
M>[XORQ$P.GU410W88$ >CU >#T1@H#@$0/\*KL:UR8 >*('&*X<&CN /9A$
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M__CBCT]^^>:?CW[ZZJ_/?OONOP]__/+/3W_]]M^/?_[Z[\]___[_#\  "G"
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3B<QD*G.9S&RF,Y\)S6C2+B  .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
